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Promoter DNA methylation, which is carried by members of the DNA methyltransferase 
(DNMT) family, negatively regulates genes transcription. In most cancers, silencing of tumor 
suppressor genes by aberrant promoter DNA methylation is considered the initiating event to 
uncontrolled cell growth and tumorigenesis. Currently, the approved hypomethylating 
protocols are based on two drugs: Azacytidine (AC) and Decitabine (DAC). Unfortunately, 
cytotoxic and global non-specific demethylation effects limit their clinical application. 
The identification of thousands of noncoding RNAs (ncRNAs), for long time deemed as merely 
“transcriptional noise”, has provided an additional layer of control to many biological 
processes.  The ncRNA revolution has not only impacted our understanding on gene regulation 
but has laid the foundations for a new “RNA-based” therapeutics era.  
Short activating RNAs (saRNAs) are small noncoding RNAs able to trigger an RNA activation 
mechanism. They can be endogenously expressed or artificially designed to recognize targeted 
sequences and promote gene-specific activation upon ectopic delivery. Thus, saRNAs might 
represent a novel strategy to selectively induce gene expression with profound implications for 
basic research and clinical applications. Yet, their mechanism of action remains elusive. 
Our group has previously identified a novel class of functional RNAs, named DNMT1-
interacting RNAs (DiRs), able to inhibit the DNMT1 activity and to prevent DNA methylation 
in a locus specific manner. On the example of the CEBPA locus, we showed that a specific 
DiR, the extra-coding CEBPA (ecCEBPA), prevented downstream CEBPA methylation by 
forming complexes with DNMT1. Expression of ecCEBPA in cells in which CEBPA is 
methylated resulted in promoter demethylation and gene activation. Collectively, our data 




Provided their gene-specific mode of action, we investigated whether saRNAs could function 
as DiR-mimicking molecules, thereby modifying DNA methylation and restoring expression 
of silenced gene loci. We modeled our study on two genes, frequently undergoing aberrant 
DNA methylation in lung cancer and/or hematopoietic malignancies: CEBPA and P15, 
respectively. The former is a critical transcription factor that controls tissue-specific gene 
expression and proliferation arrest, the latter is a cell cycle regulator and tumor suppressor 
gene.  
By using number of cell lines displaying varied CEBPA or P15 expression levels, from 
undetectable to low, paralleled by similar promoter DNA methylation profiles, from fully- to 
hemi-methylated, we showed that transcriptional activation by saRNAs promotes, to different 
extent, DNA methylation changes of the targeted loci.  Thus, saRNAs may represent the first 
demethylating tool to correct DNA methylation in a gene-specific fashion.  
In conclusion, this study delineates a new mechanistic action of saRNAs  and suggest a novel 
RNA-based therapeutic strategy, aiming at reestablishing proper expression of genes aberrantly 













La metilazione del promotore, meccanismo catalizzato dalla famiglia di enzimi chiamati DNA 
metiltrasferasi (DNMT), è associata ad una ridotta trascrizione genica. Nella maggior parte dei 
tumori, il silenziamento di soppressori tumorali a motivo di una metilazione aberrante del 
promotore è considerato il meccanismo iniziale che porta a crescita cellulare incontrollata ed a 
tumorigenesi. Attualmente, i protocolli ipometilanti si basano sull’utilizzo di due farmaci: 
Azacitidina (AC) e Decitabina (DAC). Purtroppo, la loro citotossicità e l’effetto ipometilante 
non specifico limitano il loro uso clinico.  
Il riconoscimento di migliaia di RNA non codificanti, per molto tempo considerati 
semplicemente come “rumore trascrizionale di fondo”, ha offerto un ulteriore livello di 
controllo in molti processi biologici. La rivoluzione degli RNA non codificanti non solo ha 
cambiato la nostra comprensione della regolazione genica ma ha anche posto le fondamenta 
per un’era terapeutica basata sull’RNA. Gli short activating RNA (saRNAs) sono piccoli RNA 
non codificanti capaci di attivare meccanismi trascrizionali. Possono essere endogeni oppure 
disegnati artificialmente al fine di riconoscere sequenze target e favorire l’attivazione specifica 
di geni in seguito alla loro trasfezione. Tuttavia, il loro meccanismo di azione rimane non del 
tutto compreso. Il nostro gruppo ha identificato una nuova classe di RNA funzionali, definiti 
DNMT1-interacting RNAs (DiRs), in grado di inibire l’attività di DNMT1 e prevenire la 
metilazione del DNA tramite un meccanismo locus specifico. Usando il locus di CEBPA come 
esempio, abbiamo dimostrato che uno specifico DiR, l’extra-coding CEBPA (ecCEBPA), è in 
grado di prevenire la metilazione del gene CEBPA grazie alla formazione di un complesso con 
DNMT1. L’espressione di ecCEBPA nelle cellule in cui CEBPA è metilato risulta in una 
demetilazione del promotore ed attivazione genica. Globalmente, i nostri dati suggeriscono che 




Considerando il loro meccanismo di azione gene-specifico, abbiamo valutato se gli saRNAs 
potessero agire in maniera simile ai DiRs, modificando la metilazione del DNA e ristabilendo 
l’espressione di geni non trascritti. Abbiamo condotto la nostra ricerca su due geni che spesso 
sono caratterizzati da metilazione aberrante nel tumore al polmone e/o in malattie 
ematopoietiche: CEBPA e P15, rispettivamente. CEBPA è un fattore di trascrizione chiave che 
controlla l’espressione genica tessuto-specifica ed arresta la proliferazione cellulare, P15 
invece è un regolatore del ciclo cellulare ed anche un soppressore tumorale.  
Usando linee cellulari con diversa espressione di CEBPA e P15, da non rilevabile a bassa, 
insieme anche ai profili di metilazione, da completamente a parzialmente metilato, abbiamo 
dimostrato che l’attivazione trascrizionale tramite saRNAs favorisce, in misura diversa, 
cambiamenti nel profilo di metilazione dei geni target. Di conseguenza, gli saRNAs possono 
rappresentare il primo approccio demetilante per correggere difetti di metilazione in maniera 
gene-specifica. 
In conclusione, tale studio identifica un nuovo meccanismo di azione degli saRNAs e 
suggerisce una nuova strategia terapeutica basata sull’RNA, al fine di ristabilire una corretta 








1  Epigenetics  
The term epigenetics was originally coined in the 17th century by the physician and physiologist 
William Harvey to indicate the gradual development of the embryo from a homogeneous to a 
heterogeneous material, referred to as “epigenesis” [1]. Later on, in the 1940s, Conrad 
Waddington used the term “epigenetics” to explain the relationship between the genotype, 
defined as the whole genetic system of an organism, and the phenotype, indicating the entire set 
of characteristics that an organism develops over time [2]. Waddington established the first causal 
relationship between genes and their outcomes by introducing the concept of the “epigenetic 
landscape” as “the various developmental pathways that undifferentiated cells (sharing identical 
genotype) might take toward differentiation” (Figure 1) [3]. In other words, he described how 
the static information written in the form of nucleotide sequences is dynamically translated into 
tissues and organs, thus driving cell fate decisions [4]. In the last two decades, the definition of 
epigenetics has evolved from “the study of mitotically and/or meiotically heritable changes in 
gene function that cannot be explained by changes in DNA sequence” [5] to “the structural 
adaptation of chromosomal regions so as to register, signal or perpetuate altered activity states”, 
which is inclusive of all the stable or transient chromosomal markers arising in response to 
different stimuli [6].  
 
Figure 1. An outline depicting cell-fate plasticity according to the Waddington’s epigenetic landscape 





2  DNA methylation 
DNA methylation is a key epigenetic signature implicated in regulation of gene expression that 
occurs predominantly within CpG dinucleotides. DNA methylation can also regulate other 
mechanisms, such as DNA binding of transcription factors, nucleosome positioning, i.e. 
limiting the access of protein complexes to DNA regulatory regions, and gene splicing [7]. 
CpG dinucleotides are under-represented in the mammalian genome (1%), but tend to cluster 
in CpG-rich regions called CpG islands (CGIs), located in the proximity of the transcription 
start sites (TSSs) of the majority (70%) of human protein-coding genes [8, 9]. CGIs are 
stretches of DNA sequences of 200 nucleotides or greater [10], with the GC ratio 
observed/expected to be greater than 0.6. Although the bulk of genome is methylated at 70–
80% of its CpGs, CGIs are mostly unmethylated in somatic cells [10, 11].  
DNA methylation is mediated by members of the DNA methyltransferase (DNMT) family that 
can covalently transfer a methyl group (CH3) from the universal donor S-adenosyl-L-
methionine (SAM) to the carbon 5-position of the cytosine ring. Conventionally, DNMTs are 
classified as de novo (DNMT3a and DNMT3b) or maintenance (DNMT1) enzymes (Figure 2) 
[12, 13]. 
Figure 2. De novo and maintenance DNA methylation schema. De novo DNA methyltransferases 
(DNMTs) DNMT3A and DNMT3B establish DNA methylation in germ line and developing embryos, 
(the black circles represent methylated CpG dinucleotides and the grey circles represent unmethylated 
CpG dinucleotides), whereas DNMT1, which has a preference for hemimethylated DNA, maintains the 
methylation pattern throughout replication (Jones and Liang, 2009) [13]. 
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 Of note, DNMT2, a member of the methyltransferase family, catalyzes methylation of RNA 
at position 38 in tRNAAsp GUC [14-16] (Figure 3). DNMT3-like (DNMT3L) is a DNMT3-
associated protein lacking an enzymatic domain and interacting with DNMT3a/3b to modulate 
its activity [17, 18]. In mice, Dnmt1 and Dnmt3b are essential for embryonic development, as 
DNA methylation changes dramatically. An overall demethylation after fertilization is 
followed by de novo methylation of discrete regions upon implantation [19]. Dnmt1 knockout  
Figure 3. Schematic representation of the methylation reaction catalyzed by the DNA 
methyltransferases (DNMTs) (adapted from [14]). Shown are the mechanisms proposed for methylation 
of cytosine by DNMT1, 3a and 3b on DNA (upper left panel) or by DNMT2 on RNA (lower left panel). 
Briefly, a thiol group (SH) from the binding site of the enzyme provides the nucleophilic attack to 
position 6 of the cytosine heterocycle, to activate position 5 towards one-carbon transfer (I). The methyl 
group on position 5 is donated by the coenzyme AdoMet (II). A proton in position 5 of the 5,6-
dihydropyrimidine is then removed (II–III), and a consequent β-elimination generate 5-methylcitosyne 
and free enzyme (IV). 
mice show early lethality at embryonic day (E) 9.5, whereas Dnmt3b depletion induces death 
at E 14.5–18.5, due to developmental impairment. On the contrary, Dnmt3a knockout mice do 
not display defects in embryonic development, but they do die at 4 weeks of age. Although this 
binary classification is convenient, the function of the de novo and maintenance DNMTs 
overlaps in many instances [13, 20, 21]. 
A number of studies have shown that DNA methylation is not randomly distributed across the 
genome, but displays regional specificity [22]. Methyl groups promote conformational changes 
in the major groove of DNA, thus altering protein-DNA binding [23] and, as a result, gene 
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expression. Most studies have initially focused on the effect of CGI methylation within the 
promoter and TSS of protein-coding genes. Recently [24], however, more comprehensive 
genome-wide methylation analyses have started elucidating the role of DNA methylation at 
CpG clusters within exons, introns, and intergenic sequences, expanding on the previous 
knowledge of CGIs and leading to the identification of CG shores (regions up to 2 kb from 
CGI), shelves (regions from 2 to 4 kb from CGI), and open sea (the rest of the genome) regions 
[25-27]. 
Hence, DNA methylation needs to be framed in the context of the genomic location. As a proof 
of concept, methylation of TSS-associated CGIs negatively correlates with gene expression, 
leading to long-term gene silencing [8], whilst gene-body methylation positively correlates to 
gene expression [28-31]. Another interesting finding emerging from bulk methylome studies 
is that non-CGI-CpGs are mostly methylated and therefore less stable than CGIs, due to the 
tendency of 5-methylcytosine (5mC) to undergo spontaneous or enzymatic deamination to T 
[32]. The C-to-T transition causes germ-line or somatic mutations, resulting in the depletion of 
CpGs dinucleotides in the human genome. Methylation at other genomic regions, such as 
enhancers and insulators, does not follow a specific pattern and may vary in different settings. 
Enhancers and insulators are long-range regulatory elements able to alter gene expression or 
protect gene promoters from inappropriate signals, respectively [33, 34]. Aran et al. have 
shown that distal methylation sites in estrogen receptor (ER)-positive breast tumors associates 
with breast cancer-related gene expression better than promoter methylation [35]. Moreover, 
Tatetsu et al. demonstrated that aberrant methylation of the 17-kb 5′ upstream enhancer of 
PU.1 is required for myeloma cell growth [36]. Insulators are bifunctional instead, acting either 
as a blocking enhancer, by preventing enhancer-mediated transcription, or as barriers, by 
limiting the advance of nearby heterochromatin that would otherwise silence expression [37]. 
CCCTC-binding factor (CTCF), an enhancer-blocking protein, does not bind to its DNA 
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consensus sequence if methylated, as demonstrated for the imprinted IGF2-H19 locus and 
CD45 gene [38]. It follows that DNA methylation can regulate gene expression indirectly by 
controlling access of enhancers to gene promoters [39]. Finally, CGI shores, with a lower CpG 
density, have recently emerged as critical regulatory elements affecting gene expression 
depending on their DNA methylation profile [40]. 
3  Non coding RNAs 
The genome sequencing project revealed that complex organisms have a lower number of 
protein coding genes than expected. Differences between individuals and species cannot 
account for variation in protein-coding sequences, but rather for variation in gene expression 
regulated by a control architecture [41]. In this regard, perhaps one of the biggest surprise of 
the post-genome era is indeed the great number and diversity of transcripts arising from the 
previously assumed wastelands of non-coding regions. The first efforts in mapping 
transcriptional events to the genome led to the identification of thousands of long noncoding 
RNA (lncRNA) transcripts resulting in potential novel RNA regulatory elements [42]. Later 
on, other classes of regulatory noncoding RNAs were discovered, whose biological functions 
are still largely unknown. Thus, the growing number and increasing pace of discovery of new 
noncoding RNAs are followed by the challenge of their definition and annotation [43]. 
Noncoding RNAs (ncRNAs) can be classified either by function, as housekeeping (ribosomal 
RNA and transfer RNA) or regulatory RNAs, either by length, as lncRNAs or small RNAs 
(snRNAs). 
3.1  Long noncoding RNAs (lncRNAs) 
The general term long noncoding RNAs (lncRNA) defines a highly heterogeneous and poorly 
conserved group of transcripts >200 nucleotides (nt) in length that do not contain protein-
coding sequences. The size threshold represents an arbitrary but convenient cutoff that excludes 
other classes of small infrastructural and regulatory RNAs [43, 44]. Some annotated lncRNAs 
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are not functional and do not confer any fitness advantage to the cell, e.g., spurious RNAs 
produced during transcription and showing tissue-specificity due to variations in chromatin 
states within different cellular contexts [45]. Despite the idea that the majority of lncRNAs are 
not functional, there exists a percentage of functional polyadenylated and non-polyadenylated 
lncRNAs, including sense or antisense, intronic, intergenic or enhancer, and overlapping 
transcripts with respect to protein-coding loci. They have been proposed to accomplish a 
variety of functions, such as gene regulation. lncRNAs indeed can be categorized into 
transcripts that regulate chromatin structure and gene expression in cis versus those that, by 
leaving the site of transcription, act in trans [46]. Cis-acting lncRNAs can regulate gene 
expression through three potential different mechanisms: (a) the lncRNA itself regulates the 
expression of neighboring genes by recruiting activating or repressing factors, (b) 
transcriptional or splicing events of the lncRNA acquire a gene-regulation functionality that is 
independent of the sequence of the transcripts, or (c) the recruitment of DNA elements within 
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the lncRNA’s promoter is eventually responsible for the neighbor gene’s regulation and is 
lncRNA’s sequence independent (Figure 4). 
 
Figure 4. LncRNA’s function in local gene regulation . lncRNAs can control the expression of nearby 
genes in cis (A) by sequence-specific functions of the mature lncRNA transcript, (B) by mechanisms 
of  transcription or splicing of an RNA, but the lncRNA itself is not functional or (C) by DNA elements 
within the lncRNA promoter or gene body that function independently of the transcribed RNA . Pol II, 
RNA polymerase II; TF, transcription factor (Kopp and Mendell, 2018) [46].  
 
(a) The most known and well-studied example of cis-acting lncRNA is the X-inactive-specific-
transcript (Xist) that orchestrates X chromosome inactivation. In female mammals, during early 
embryonic development, one of the two X chromosomes is transcriptionally silenced for 
dosage compensation. The silencing process depends upon transcription of Xist, that is 
transcribed from only one X chromosome, which will be later inactivated. Despite aspects of 
the Xist-silencing mechanism are still elusive, recent development of focused and innovative 
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methods able to capture RNA-binding proteins (RBPs) has allowed a step forward in 
understanding Xist’s interactors as well as in re-evaluating previously proposed mechanisms 
[47]. Therefore, studies have demonstrated that Xist directly recruits SMART/histone 
deacetylase 1 (HDAC1)-associated repressor protein (SHARP or SPEN). This further leads to 
the recruitment of the SHARP/SPEN-interacting protein silencing mediator for retinoid and 
thyroid hormone receptors (SMRT) and its interactor histone deacetylase 3 (HDAC3), 
ultimately inducing histone deacetylation, one of the earliest event in X inactivation [48]. Chen 
et colleagues also demonstrated that Xist entails remodeling of the three-dimensional (3D) 
structure of the X chromosome by recruiting it to the nuclear lamina and, by doing so, Xist is 
able to spread to actively transcribed genes across the X [49]. 
 (b) In contrast with the activity of Xist, where sequence recognition plays a key role in 
recruiting protein interactors, Engreitz et colleagues demonstrated that other cis-acting 
lncRNAs exert local effects on neighboring genes without sequence-specific function [50]. By 
analyzing 12 lncRNA loci in mouse embryonic stem cells (mES cells), 5 of these 12 lncRNA 
loci influence the expression of adjacent genes, by ultimately acting in cis. As one example, 
the linc1536, also called Bendr (Bend4-regulating effects not dependent on the RNA), regulates 
expression of the adjacent Bend4 gene by DNA regulatory elements within the 750 bp 
promoter-proximal region. Thus, knocking-out the Bendr promoter reduces the expression of 
the neighboring gene by 57%, whereas introducing polyadenylating signals (pAS) into the first 
intron of the locus does not exert any effect.  
The process of transcription and the 5’ splice in the Blustr locus (bivalent locus (Sfmbt2) is 
upregulated by the splicing and transcription of an RNA, also known as linc1319) are both 
necessary for regulating the neighboring gene Sfmbt2, located 5 kb upstream. Hence, Blustr is 
essential for Sfmb2 activation, but the entire process does not require precise RNA sequence 
beyond the initial splice signals. 
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(c) As for the Bendr locus, in most of lncRNA loci, effects on adjacent genes are mediated by 
enhancer-like function of DNA elements located within promoters and functioning 
independently of the production or sequence of the transcript [50]. lincRNA-p21 is a nuclear 
intergenic noncoding RNA that neighbors the CDKN1A in human and mouse. An initial study 
defines lincRNA-p21 as a p53-dependent trans-acting lncRNA, able to mediates apoptosis upon 
p53 signal. However, more recent studies suggest a cis-acting regulatory function. Indeed, even 
in tissues with no detectable lincRNA-p21 transcript, deletion of the locus dramatically affects 
the expression of neighboring genes, as Cdkn1a. Further analysis has defined DNA enhancer 
elements within promoter of the locus, which are responsible of its regulatory activity. 
Therefore, the lincRNA-p21 locus can exert an RNA-independent function on gene expression 
[51].  
lncRNAs can also act in trans therefore regulating the expression of genes located at distant 
regions from their transcriptional start site (TSS), influencing chromatin structure and, 
interacting with proteins and other RNAs. Cis and trans lncRNA’s activity are not mutually 
exclusive. The Xist has indeed the ability to shape X chromosome structure during X 
chromosome inactivation process, in addition to cis-acting gene silencing mechanism [49, 52]. 
Firre, a lncRNA transcribed from the active X chromosome and escaping X chromosome 
inactivation, has been detected, in addition to its transcriptional site, at other autosomal loci 
using RNA antisense purification (RAP) and RNA fluorescent in situ hybridization (FISH) in 
murine embryonic stem cells. Moreover, Firre expression is essential to maintaining the Xi 
structure and its epigenetic features [53]. 
3.2.1  DNMT1-interacting RNAs (DiRs) 
Previous work has shown the existence of noncoding RNAs able to regulate methylation 
patterns of their respective coding transcripts [54]. These novel class of noncoding RNAs, 
namely DNMT1-interacting RNAs (DiRs), interact with and inhibit DNMT1, hence preventing 
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DNA methylation. Using as example the CEBPA locus, Di Ruscio et al. demonstrated the 
existence of an overlapping, sense-orientated transcript, the extra coding CEBPA (ecCEBPA), 




Figure 5. Schematic of DNMT1 sequestration. Top panel, DNMT1 can access transcriptionally inactive 
hemi-methylated sequences. Bottom panel, DNMT1 cannot access transcriptionally active hemi-
methylated sequences. (Di Ruscio et al, 2013) [54]. 
 
Characterization of ecCEBPA demonstrated that DiRs were non-polyadenylated, enriched in 
the nuclear fraction, and overlapped the gene in the sense orientation. From genome-wide 
analysis, they found that, besides CEBPA, DiRs regulated other loci and were associated with 
hypomethylated regions. The discovery of DiRs provided a new mechanism showing how 
genes can be regulated by noncoding transcripts arising around a gene body.. 
3.3  Small noncoding RNAs (sncRNAs) 
All noncoding RNA species smaller than 200 nt can be classified as small noncoding RNAs. 
However, what defines eukaryotic small noncoding RNAs in the RNA silencing pathway is 
their limited size (20-30 nt) and their association with Ago-family proteins [55]. At least three 
classes of snRNAs can be identified, based on their mechanism of biogenesis and the type of 
Ago-protein they are associated with: microRNAs (miRNAs), endogenous short interfering 
20 
 
RNAs (endo-siRNA) and piwi-interacting RNAs (piRNAs). An additional subgroup, the short 
activating RNAs (saRNAs), that positively regulate gene expression, will be also described. 
3.3.1  MicroRNAs (miRNAs) 
MicroRNAs (miRNAs or miRs) are short noncoding RNAs able to control expression by 
targeting specific messenger RNAs (mRNAs). Canonically, miRNAs are encoded by intronic 
regions of noncoding and coding transcripts, however, some miRNAs can also be encoded by 
exons. miRNAs are transcribed by RNA Pol II as poly- or mono-cistronic primary miRNAs, 
also named pri-miRNAs, and containing an m7G cap at 5’ end in addition to a poly(A) tail at 
3’ untranslated region (3’UTR) [56]; alternatively, some miRNAs requires Pol III, e.g. in the 
case of the human chromosome 19 miRNA cluster (C19MC) [57]. The miRNA precursors can 
be several thousand base pairs in length and are 
processed in the nucleus by the Drosha/DGCR8 
complex to produce 70 bp stem-loops (pre-miRNAs). 
The small hairpin-shape is then exported to the 
cytoplasm by means of the nuclear export receptor 
exportin5 and cleaved by Dicer. Dicer’s cleavage 
results in an RNA duplex of about 21 nt in length. 
Once the RNA duplex is unwound, it is loaded onto 
an Argonaute protein complex, named RNA-induced 
silencing complex (miRNP/RISC complex), which 
identifies the sense and passenger strands in the RNA 
duplex and guides mature miRNA (single-stranded) 
to its target mRNA (Figure 6) [58, 59]. miRNAs 
recognize their target mRNAs by Watson-Crick base 
pairing: they contain a seed region, centered on  
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Figure 6. miRNAs’ mediated expression regulation. Primary miRNA transcripts are processed to 
miRNA precursors in the nucleus by Drosha. The pre-miRNA is then exported to the cytoplasm by 
means of the nuclear export receptor exportin5 and cleaved by Dicer in 21-nt RNA duplex. The RNA 
duplex is resolved and loaded onto miRNP/RISC complex. Mature miRNAs bind to Ago proteins, 
which mediate translational repression or cleavage of target mRNAs. Other sources of long dsRNA in 
the cytoplasm of a cell are processed by Dicer into 21–23 nucleotide dsRNA intermediates. Following 
unwinding of the dsRNA (mediated by Armitage and R2D2) the single-stranded siRNA-containing 
RISC is formed. ADARs and exonuclease ERI-1 can regulate dsRNA stability during processing 
(Meister and Tuschl, 2004) [58]. 
 
nucleotides 2-7, that binds within the 3’ UTR of the targeted RNA. However, miRNAs 
responsive elements (MREs) can be found  
within 5’ UTR sequences as well as coding regions of the target mRNAs. In addition, non-
canonical seed pairing can also drive miRNA-mRNA recognition and annealing [60]. The 
degree of miRNA-mRNA complementarity has been considered a pivotal element of the 
regulatory mechanism. While perfect complementarity is responsible for Ago-catalyzed 
cleavage of the targeted mRNA, central mismatches prevent cleavage of the mRNA and 
promote translational repression of the transcript [61]. The canonical function of miRNAs is 
that these small RNA molecules repress gene expression by targeting the 3’UTR of targeted 
mRNAs, thus inducing mRNA’s cleavage and/or transcriptional gene silencing in the 
cytoplasm. However, since the discovery of the first miRNA, lin-4, in the 1993 [62], more 
recent studies have demonstrated that miRNAs can localize into the nucleus and are able to 
regulate transcription [63-65]. MiRNAs nuclear localization is strictly dependent on tissue, cell 
line and condition analyzed. The regulation can be either repression or activation and the 
miRNA’s modus operandi can be affected by the presence of TATA box motif, CpG island 
region and the epigenetic status of the promoter [66]. However, whether miRNAs function 
depends on DNA methylation status of the target sequence or whether miRNAs can determine 
changes in DNA methylation profile is still a matter of debate [67, 68].  
22 
 
3.3.2  Short interfering RNAs (siRNAs) 
Short interfering RNAs partake, together with miRNAs, in the RNA interference mechanism 
[69]. Initially, siRNAs were thought to be primarily exogenous, that is directly derived from 
the virus, transposon or transgene trigger. Subsequently, they were identified upon transgene- 
and virus-induced silencing in plants, persistent with a natural role in genome defense. Further 
studies of small-RNA profiling in mice reveal the presence of various types of endogenous 
siRNAs (endo-siRNAs) in oocytes and, to a lesser extent, in embryonic stem (ES) cells [70]. 
Endo-siRNAs are slightly shorter than miRNAs: they are 21 nt in length and derive from 
different sources of double stranded RNAs (dsRNAs), such as  transposable elements (TEs), 
cis-natural antisense transcripts (cis-NATs), transNATs and hairpin RNA transcripts [55]. 
Some siRNAs originate from expressed pseudogenes, suggesting that pseudogenes can 
regulate levels of the founding mRNA by means of the RNAi machinery [71]. Long dsRNA 
precursors are processed by Dicer into discrete siRNAs duplex whose guide strand will direct 
the RNA interference (RNAi) complex at the targeted mRNA. During the canonical RNAi, a 
perfectly complementary mRNA to the siRNA’s guide strand is recognized and the targeted 
mRNA is cleaved at a single site within the duplex siRNA-mRNA. After cleavage, the mRNA 
fragments are further degraded. In some cases, siRNAs can also recognize targets with 
imperfect complementarity therefore acting as miRNA-like molecules. Finally, in plants, 
siRNAs can activate or engage DNA methyltransferases (DNMTs), leading to an increase in 
DNA methylation and heterochromatin formation [61, 72, 73]. Therefore, siRNAs mediate 
gene specific silencing resulting in an exquisitely specific mRNA suppression. As a 
consequence, synthetic siRNAs can be used as a powerful tool for regulating exogenous and 
endogenous gene expression, as well as innovative therapeutic approach [74]. Conventional 
synthetic siRNAs consists of 19-21 nt with two nucleotide overhangs at 3’ end, usually TT or 
UU [75]. siRNAs longer than 21 nt require Dicer cleavage to obtain shorter and active 
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noncoding transcripts. Increasing the length of siRNAs has been demonstrated to potentiate 
siRNAs’ silencing effect. However, dsRNAs longer than 30 nt can activate the interferon (IFN) 
response, and should be avoided for therapeutic applications [76, 77]. 
3.3.3  PIWI-interacting RNAs (piRNAs) 
PIWI-interacting RNAs (piRNAs) are a class of animal-specific small single-stranded RNAs 
that associate with PIWI proteins. Piwi proteins are a clade within the larger family of 
Argonaute proteins and are mainly expressed in the germline. In general, Argonaute proteins 
silence their target RNAs through RNA degradation, inhibition of translation or chromatin 
modification [78]. Biogenesis, as well as function, differentiate piRNAs from miRNAs and 
siRNAs. PiRNAs originate from long single-stranded RNAs independently from RNase III 
enzymes, whose role is essential in miRNAs and siRNAs expression. Single-stranded 
precursors are then processed into discrete piRNAs’ units. PiRNAs precursors arise from 
genomic loci known as piRNAs clusters, from which long and single-stranded RNAs are 
produced. They usually consist of more than 100.000 bases and include transposable DNA 
elements. The majority of them have an antisense orientation to transposons, thus inducing 
their silencing. Loss-of-function mutations in piRNAs and PIWI proteins activate transposons 
that are able to randomly relocate or insert copies within the genome: these events can often 
impair gonadal development and lead to infertility [79, 80]. Indeed, the ancestral function 
attributed to piRNAs relates to transposon-induced genomic instability in the germline, where 
piRNAs repress transposable elements thus preventing transposons mobilization. However, 
some piRNAs correspond to unique genomic sequences unrelated to transposons. Therefore, 
there exist evidence suggesting that these piRNAs might regulate expression of host mRNAs 
[81, 82]. In addition, it has been demonstrated that piRNAs are not only expressed in the 
germline but, to a lesser extent, can also be detected in somatic tissues where regulate gene 
expression [83]. Indeed, disruption of piRNAs involved in transposable elements silencing 
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might results in genomic instability, transposons mobilization and hence, contribute to 
tumorigenesis. Besides being involved in silencing of transposable elements, piRNAs can also 
modulate DNA methylation. In this regard, genome-wide methylation profile revealed changes 
in DNA methylation in Farage and MCF7 cell lines upon transfection with single copy piRNAs. 
The study showed that genomic regions close to differentially methylated CpG sequences were 
enriched for sequences recognized by the transfected synthetic piRNA. In conclusion, piRNAs 
could induce DNA methylation of non-transposable elements loci by means of directly binding 
to genomic DNA or nascent mRNA [84].  
3.3.4  Short activating RNAs (saRNAs) 
Small double-stranded RNAs (dsRNAs) molecules, such as miRNAs, siRNAs and piRNAs, 
have been originally identified as the trigger for RNA silencing, where dsRNAs inhibit 
translation or degrade complementary target mRNA sequences. However, if RNAi is 
considered a mechanism to regulate gene expression, it is reasonable to suggest that RNA-
mediated gene regulation can also positively control target sequences [85]. RNA activation 
(RNAa) is indeed a mechanism of enhancing gene expression at transcriptional level by means 
of short dsRNAs and is triggered by both endogenous and artificially designed small RNAs. 
dsRNAs usually target gene promoter [86, 87], however, there are examples of short activating 
RNAs (saRNAs) recognizing sequences within coding regions of target genes, e.g. the  
intronless gene CEBPA [88]. Therefore, saRNAs offer a new method to promote gene 
overexpression and represent a powerful laboratory tool to enhance transcription by a more 
natural approach. Moreover, RNAa can also be a new option for gene therapies: the ability to 
specifically upregulate transcription in the absence of exogenous DNA can have profound 
impacts either in basic research and therapeutics [87]. RNAa has been recently identified in 
mammals as endogenous mechanism for upregulating transcription. For example, Kuwabara et 
al identified a small double-stranded noncoding RNA able to induce transcription of genes 
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containing NRSE/RE1 sequences and to promote neuronal differentiation in adult stem cells 
[89]. Moreover, in the liver, mir-122 facilitates replication of hepatitis C viral RNAs by 
interacting with 5’ noncoding region of the viral genome; hence, it may represent a new target 
for antiviral therapies [90]. To further study the role of dsRNA in RNAa, synthetic dsRNAs 
can be designed and tested in vitro. Based on empirical observations, a set of rules for saRNAs 
design has been generated in order to improve the chance to identify functional saRNAs targets, 
including (i) RNA duplex size of about 19 nt, (ii) 2-nt overhangs on the 3’ ends of both RNA 
strands, (iii) GC content between 40-60 % and (iv) thermodynamic stability in base pairing 
within the 5’ end, whose modification can interfere with Ago2 processing [91]. In regards to 
target location, saRNAs are usually designed between -100 to -1000 bp relative to the TSS, 
with the most responsive site usually occurring within -200 and -500 bp region of the promoter. 
Moreover, avoidance of GC islands, lack of repeat elements (Alu sequences) or inverted 
sequences are also considered during the design [87]. Due to their nuclear nature, high 
concentrations of saRNAs are required in order to compensate for the potential nuclear 
exclusion of duplex RNAs [92]. Therefore, concentrations between 10 to 100 nM can be tested 
for initial studies to identify optimal conditions for gene activation.  
As RNai, RNAa depends on argonaute proteins but with a different kinetics. During RNAa, 
gene activation is delayed by about 48 hours and, even though the underlying reason is not 
entirely known yet, it might depend on cell division and accessibility of the nuclear membrane. 
Moreover, since duplex RNAs are loaded by Ago2 in the cytoplasm before entering the 
nucleus, it is possible that this process is a passive mechanism that occurs during cell division. 
Therefore, gene expression analysis should be performed between 48 and 96 hours post 
transfection in order to validate saRNAs activity. However, saRNA-mediated gene activation 




Thus far, the mechanism responsible for RNAa describes Ago2 protein loading the guide strand 
(antisense to the sense target gene) of the duplex saRNAs and forming an active saRNA-Ago2 
complex. The complex binds to promoter of target genes and induces open chromatin structure 
and transcription by recruiting CTR9 and RHA proteins. Activation of transcription is also 
associated with phosphorylation at serine 2 of RNA polymerase II (RNAP II) and 
monoubiquitination of H2B (H2Bub1) (Figure 7) [93]. 
 
Figure 7. Accepted working model of the molecular mechanisms of saRNA-induced gene activation. 
The saRNA:AGO2 complex enters the nucleus, binds at promoter of target genes and induces open 
chromatin structure. AGO2 recruits CTR9, RHA and promotes transcript initiation associating with 
phosphorylation of RNAP II on Ser2 and H2Bub1 (Yoon and Rossi, 2018) [93]. 
 
Even though there is a sound understanding of the saRNAs mechanism, there exist some 
unresolved areas regarding RNAa effect on DNA methylation and whether both saRNAs 
strands might function in transcriptional activation.  
4  CEBPA 
The CCAAT/enhancer-binding protein alfa (CEBPA) is a decisive transcription factor that 
regulates tissue-specific gene expression by coupling lineage commitment to terminal 
differentiation and cell cycle arrest [94]. CEBPA is a member of the bZIP family and 
consists of N-terminal transactivating domains, a basic region necessary for specific DNA 
sequence binding, and a leucine-zipper region necessary for dimerization at the C-terminal 
end [95]. Moreover, evidences demonstrated that it acts as tumor suppressor, supporting the 
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general view that disruption of normal differentiation and its uncoupling with cell cycle 
arrest are key features for tumor development [96]. The intronless CEBPA gene localizes on 
chromosome 19q13.11 and its mRNA is transcribed into different protein isoforms generated 
from two different but consecutive in-frame AUGs within the CEBPA mRNA. The shorter 
isoform, namely p30, lacks the amino-terminal 117 amino acids whereas retains the same 
carboxyl terminus as the full-length form, known as p42. Differences in the N-terminal 
sequences confer distinct functions to the two isoform in the regulation of differentiation and 
proliferation. The p30 isoform maintains the DNA-binding domain but miss the N-terminal 
transactivation domain and is a dominant-negative regulator of the full-length p42 isoform. 
Since p30 fails to induce differentiation and promote proliferation of myeloid progenitors, the 
ratio p30/p40 is critical for granulopoiesis [97]. An additional CEBPA protein isoform, named 
extended-CEBPA, have been identified. This isoform, translated from an alternative non-AUG 
initiation codon and having an extended N-terminal sequence, occupies the ribosomal DNA 
promoter in the nucleoli and stimulates rRNA synthesis [98]. 
4.1  CEBPA in normal hematopoiesis 
Fine mechanisms of differentiation regulate formation of terminally differentiated 
hematopoietic cells from hematopoietic stem cells (HSCs). HSCs maintain the ability to self-
renew throughout the entire life of an organism and also to generate all types of mature blood 
cells [99, 100]. The interplay between tissue-specific transcription factors is a decisive element 
driving the expression of genes defining a precise cell type. As examples, CEBPA 
synergistically cooperates with PU.1, c-Myb, and RUNX1 to regulate transcription of genes 
such as myeloperoxidase, neutrophil elastase, lysozyme, lactoferrin, granulocyte colony 
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stimulating factor receptor (G-CSFr), macrophage colony stimulating factor receptor (M-
CSFr), and granulocyte-macrophage colony stimulating factor receptor (GM-CSFr) (Figure 8).  
 
Figure 8. Development of granulocytes and monocytes/macrophages cells from hematopoietic stem 
cell (HSC). CEBPA drives differentiation towards granulocytic and mononcytic/macrophagic 
population. MPP, multipotent progenitor; LMPP, lymphoid-primed multipotent progenitor; CMP, 
common myeloid progenitor; GMP, granulocyte–macrophage progenitor (adapted from Imperato et al, 
2015) [101].   
 
CEBPA is largely expressed in several cell lineages, including adipocytes, hepatocytes, and 
type II pneumocytes. Within hematopoiesis, CEBPA is primarily expressed in granulocyte, 
monocyte, and eosinophil as compared to the lymphoid or megakaryocyte/erythroid lineages 
[102]. Reducing CEBPA expression promotes monopoiesis by forming heterodimers with AP-
1 proteins, as c-Jun or c-Fos. On the contrary, formation of active CEBPA homodimers is 
essential for granulopoiesis. Indeed CEBPA induces transcription of various proteins 
indispensable for subsequent lineage maturation, as CEBPE, Gfi-1 and KLF5 [103]. Moreover, 
CEBPA induces mir-223 transcription that leads to NFI-A mRNA degradation thus enhancing 
granulopoiesis. CEBPA-deficient mice have normal numbers of common myeloid progenitors 
(CMPs) but lack granulocyte-monocyte progenitors (GMPs) and all subsequent granulocytic 
stages [104]. Conditional CEBPA knockout in GMPs allows for normal granulopoiesis in vitro, 
indicating that CEBPA is not necessary for differentiation towards granulocytes beyond the 
GMP stage [96].                 
In hematopoietic malignancies CEBPA expression can be altered by promoter 
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hypermethylation. Methylation of the core promoter, located -600 bp from the ATG, was found 
to be an infrequent event in AML [105], whereas methylation of the distal promoter (-1600 to 
-600 from ATG), also known as upstream promoter, occurs with higher frequency in AML 
patients [106, 107]. Surprisingly, Hackanson et al demonstrated that, while treatment with 
DAC of AML cell lines induced upregulation of CEBPA mRNA in vitro, the CEBPA protein 
levels decreased. Further investigation proved that mir124a, often silenced by epigenetic 
mechanism and targeting CEBPA transcript, was upregulated upon epigenetic treatment and 
responsible for CEBPA degradation [106] 
4.2  CEBPA in lung development 
CEBPA is expressed in a number of epithelial tissues, including  the respiratory epithelium, 
breast, colon, and prostate [108]. In the respiratory epithelium, CEBPA is involved in lung 
development and airway epithelial cells differentiation. CEBPA, indeed, regulates the 
expression of several genes during lung differentiation, as surfactant B and uteroglobin [109]. 
Since CEBPA abnormalities were originally observed in CEBPA (-/-) knockout mice, where 
aberrant proliferation of type II pneumocytes was detected,  it has been demonstrated that 
CEBPA plays also a critical role in lung cancer development. CEBPA has growth inhibition 
properties, therefore its downregulation in lung cancer leads to uncontrolled cell proliferation, 
whereas its induction promotes growth arrest, morphological changes characteristic of 
differentiation, and apoptosis [110]. Reduced expression of CEBPA in lung cancer might occur 
because of promoter hypermethylation. As in AML, methylation of the upstream promoter is a 




5  P15  
5.1  P15: a cell-cycle regulator 
P15INK4b, also known as P15, CDKN2B or MTS2, and its functional homologue P16INK4a (P16 
and CDKN2A) are genes located in close proximity within a small 25 kb fragment on 
chromosome 9p21 and they are both transcribed in the centromere to telomere direction. The 
P16 locus, in addition to P16, encodes for the alternative transcript P14ARF (p19ARF in mice). 
P16 and P14ARF share common exons 2 and 3, but have different first exons, 1a for P16 and 
1b for P14 [112]. The three genes are tandemly linked to each other within 42 Kb of genomic 
locus on the 9p21 chromosome. The 9p21 locus also contains the Antisense RNA in the INK4 
Locus (ANRIL), a long-noncoding antisense transcript that overlaps the entire P15 gene body 
and shares a bidirectional promoter with P16 (Figure 9 ) [113, 114].  
Figure 9. Schematic of the 9p21 locus. Red rectangles indicate P15, striped-pattern rectangles indicate 
P14 and squared-pattern rectangles indicate P16 transcripts. P15, P14 and P16 mRNAs are transcribed 
in the direction telomere to centromere. Black rectangles depict ANRIL transcript, whose transcription 
follows centromere to telomere direction. 
   
P15 and P16 encode for cyclin-dependent kinase inhibitors (CDKIs) that negatively regulate 
the cell cycle by inhibition of cyclin-dependent kinases (CDKs) 4 and 6, which control G1 to 
S phase progression through regulation of the Rb pathway [115, 116]. Once the cell pass the 
G1/S phase checkpoint, it is irreversibly committed to the next cell division. CDKs are a family 
of multifunctional enzymes able to phosphorylate target proteins involved in the cell cycle and 
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require the presence of cyclins to be activated. There exist multiple cyclins acting during 
specific stage of the cell cycle; in this respect, CDK4 and 6 only partner D-type cyclins which 
regulate the early G1 phase. P15 and P16, acting as negative regulators of cell-cycle 
progression, directly bind CDKs thus inducing allosteric changes that propagate to the cyclin 
binding site. Since interaction with cyclins is essential for CDK’s activation, conformational 
changes within cyclins’ binding site prevent cyclins from binding hence causing CDK’s 
inhibition [117]. P15 and P16 genes share 90% homology at coding exon 2, and isoform 1 of 
either proteins show 83 % identity. Therefore, the high degree of structural identity explains 
the high degree of functional homology. However, despite their similarity, in a variety of 
tumors, genetic alterations of sole P16 expression due to deletions and/or mutations are 
observed. On the contrary, deletions of P15 in lymphomas, carcinomas and sarcomas, occurred 
in conjunction with P16 and P14ARF loci [118].  
5.2  P15: a tumor suppressor gene 
P15 is important during differentiation of early hematopoietic progenitors: it indeed drives 
normal CD34+ towards granulocytic and megakaryocytic commitment. P15 mediates 
antimitotic signals and it is the effector of transforming growth factor β1 (TGF-β1), which 
induces arrest at G1 phase [119]. Aberrant P15 methylation is a major gene silencing 
mechanism in hematological malignancies, whereas P16 and P14 methylation more often 
occurs in solid tumors as well as in leukemias and lymphomas [120]. P15 promoter 
hypermethylation occurs at high frequency in acute myeloid leukemia (AML) and 
myelodysplastic syndrome (MDS), 80 and 50 % respectively [121, 122]. Aberrant methylation 
of the P15 locus is associated with poor prognosis in AML and with increased risk of 
progression to AML in MDS patients [118]. P15 aberrant methylation has also been reported 
in up to 60 % of chronic myelomonocytic leukemia (CMML) cases and is associated with a 
higher degree of disease’s severity [123]. Due to its important role in hematopoietic 
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differentiation, P15 has been suggested to be a tumor suppressor. To assess whether 
inactivation of P15 is a critical event for premalignant myeloid disorder and development of 
leukemia, a p15 (-/-) mouse model, in which the second coding exon of the gene was eliminated 
by homologous recombination, was developed [124]. The p15 knockout mouse did not show a 
correlation between loss of p15 and AML outcome, even though the p15 (-/-) mice have a 
competitive advantage over wild-type cells in myeloid cell formation, therefore suggesting an 
important role in common myeloid progenitors’ (CMPs) differentiation [125]. A more 
informative mouse model generated to define the role of p15 as tumor suppressor is a 
conditional one, the p15Ink4bfl/flLysMcre mouse, where P15 was silenced specifically in 
myeloid cells. Even though the p15Ink4bfl/flLysMcre mice did not develop acute myeloid 
leukemia, inactivation of the p15 locus increased susceptibility when additional oncogenic hits 
were provided. Moreover, the mice developed non-reactive monocytosis in the peripheral 
blood and expansion of myeloid blast progenitors in the bone marrow (BM), either symptoms 
resembling CMML in human patients [123]. These data demonstrate that loss of P15 contribute 
to preleukemic conditions and can be defined as tumor suppressor gene for AML [118, 126]. 
As in AML, P15 is not expressed in acute promyelocytic leukemias (APL), hence favoring 
blasts expansion, but it is progressively upregulated by all-trans retinoic acid (ATRA) 
treatment, able to drive differentiation [121]. Restoring normal methylation is therefore a 
rational therapeutic approach when aberrant methylation occurs. 
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5-azaytidine (5AC, trade name; Vidaza®, Azadine) and 5-aza-2’-deoxycytidine (5-aza-CdR; 
DAC; also known as Decitabine, trade name; Dacogen®) are nucleoside analogs of cytidine 
used as demethylating agents (Figure 10) [127].  
 
Figure 10. Chemical structures of cytidine nucleoside (a) and azanucleoside (b, c). Sugar moieties are 
indicated in grey whereas chemical changes between cytidine nucleoside and azanucleosides are 
highlighted in red (Diesch et al, 2016) [128]  
 
Later, they both were approved for the treatment of MDS and AML. 5AC and DAC act 
differently within the cell: 5AC is mainly incorporated into the RNA (80-90%) and a small 
percentage into DNA; DAC, instead, incorporate into DNA only. 5AC and DAC are cell-cycle 
dependent drugs able to exert their activity during S phase, when irreversibly and covalently 
trap DNMTs at C-6 position [129]. DNMTs’ inhibition has disparate consequences: it can 
induce mutagenesis within CpG dinucleotides, inhibit methylation during the following DNA 
replication, and cause cytotoxic effects when additional drug molecules do not bind any further 
DNMTs. Moreover, 5AC and DAC can trigger genomic instability resulting from 
demethylation of repetitive sequences. It has long been debated whether 5AC and DAC’s 
anticancer effect depends on their cytotoxicity or on the analog itself once incorporated into 
nucleic acids [129]. However, it is emerging that low doses of analogs inhibit DNMTs, whereas 
high doses induce cell-cycle arrest because of cytotoxic effects. Besides their efficacy, 
epigenetic therapies induce off-target effects that limit their clinical use. Moreover, little 
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success has been achieved thus far in treatment of solid tumors [130]. Therefore, these 
evidences suggest the need for more specific therapies to treat hematological malignancies, 
where aberrant methylation occurs.    
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Aims of the thesis 
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CEBPA and P15 are genes frequently silenced by aberrant promoter DNA methylation  in 
hematological malignancies and/or lung cancer.  
These past years, our laboratory has been testing a double stranded RNA platform, the short 
activating RNAs (saRNAs) to reactivate expression of aberrantly methylated genes. SaRNAs 
are double stranded RNAs shown to upregulate transcription in a gene-specific manner, yet the 
mechanism behind this activation remains elusive.  
This study is built on the  hypothesis  that saRNAs may promote gene expression by acting as 
DiR mimicking molecules and changing DNA promoter methylation. 
In collaboration with the U.K. biotech firm MiNA Therapeutics [131, 132], saRNAs targeting 
CEBPA and P15 gene loci were tested.  
The CEBPA saRNA AW1-51, developed by Voutila et al. [88] and currently under evaluation 
in patients with advanced liver cancer in a phase 1/2a trial (ClinicalTrials.gov: NCT02716012), 
was delivered by nucleofection in the AML cell line K562 and by lipid-based transfection in 
the lung cancer cell line A549, which have low-to-medium CEBPA expression and fully- to- 
hemi methylated promoter profile, respectively.   
For the P15 locus three saRNAs targeting: the promoter (saP15-PR313); the first exon (saP15-
PR11) or the intron (saP15-PR56) were designed. All three saRNAs were delivered by 
nucleofection into the AML cell lines KG1a and Raji, which display low-to- medium P15 
expression and fully- to-hemi-methylated promoter profile, respectively.  
The effects of RNA-mediated activation was assayed by qRT-PCR and strand-specific qRT-
PCR analyses. RNA sequencing was performed to account for potential off-target effects and 
activation of specific pathways correlated to P15 and CEBPA re-expression. DNA methylation 
changes, upon gene reactivation, were assessed for the respective loci by Bisulfite sequencing 
PCR and comprehensive genome-scale (in progress), to exclude additional off-target effects, 
by the Infinium EPIC arrays platform which covers 850k CpG sites across the genome.  
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Material and methods 
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1. Cell culture 
KG1a, K562, Raji, U937 and A549 cell lines were growth in RPMI  medium supplemented 
with 10% fetal bovine serum (FBS). HEK293 cell line was cultured in DMEM High glucose 
medium supplemented with 10% FBS. All cell lines were purchased from ATCC and grown at 
37°C, 5% CO2 in the absence of antibiotics. For all cell lines, media was replaced every 2/3 
days; KG1a, K562, Raji and U937 were passaged 1:3/1:4, whereas A549 and HEK293 were 
passaged 1:5/1:7 every 48/72 hours.  
In contrast to the parental KG1, the KG1a population, a male-derived acute myelogenous 
leukemia cell line, is mainly composed of undifferentiated promyeloblasts, thus being 
morphologically, cytochemically and functionally less mature. The KG-1a cell is insensitive to 
colony stimulating factor (CSF) and does not spontaneously differentiate to granulocyte and 
macrophage like cells.  
K562 is a highly undifferentiated population and has been classified as human erythroleukemia 
line. K562 blasts are able to spontaneously differentiate into progenitors of the erythrocytic, 
granulocytic and monocytic series. K562 cells are positive for BCR-ABL fusion gene whose 
oncoprotein leads to transcriptional inhibition of the granulocyte colony–stimulating factor 
receptor (G-CSF-R), through down-regulation of  CEBPA [133].  
U937 was derived from histiocytic lymphoma and can be differentiated into macrophages or 
myeloid lineages dendritic cells (DC) by supernatants from human mixed lymphocyte cultures. 
The Raji cell line was derived from B-lymphocytes of a Burkitt’s lymphoma and holds the 
t(8;14) translocation, which results in the juxtaposition of the MYC gene to the IGH enhancers, 
which leads to its activation and oncogenic transformation [134, 135]. KG1a, K562 and Raji 
are suspension cell lines. A549 is an epithelial-like cell line derived from a lung carcinomatous 
tissue from a Caucasian male. HEK293 is a human embryonic kidney cell line. Either A549 




2. RNA isolation 
Total RNA was isolated by phenol chloroform purification using the commercially available 
Trizol (Invitrogen) according to manufacturer’s instructions. Briefly, cells are harvested by 
centrifugation and supernatant is carefully removed, leaving just a drop of liquid. Cells are 
briefly vortexed and Trizol is added to the cells solution. Chloroform is added to Trizol (1:5 
v:v, respectively) and tube is inverted several times. Follows centrifugation at 13200 rpm, 15 
minutes at 4°C. The suspension is now a lower red phenol-chloroform phase (organic), an 
interphase and a colorless upper phase (aqueous). RNA is exclusively in the aqueous phase. 
The aqueous solution is pipetted out and isopropyl alcohol is added (ratio 1:1 v:v). Sample is 
incubated at -20°C O/N (low amount) or 2 hours (high amount). The sample is centrifuged at 
13200 rpm, 4°C and pellet is resuspended in 178 μl of RNase free water. DNase I (Roche) is 
added to sample in the presence of RNase inhibitors (Promega) and solution is incubated 1 
hour at 37°C. EDTA 0.5 M and NaCl 5 M are added to sample at the end of incubation to stop 
DNase I reaction and precipitate RNA, respectively. Cold phenol solution saturated with 0.1M 
citrate buffer, pH 4.3 (Sigma) is added to sample and tube is centrifuged at 13200 rpm 15 min 
at 4°C. The supernatant is moved to a new tube and 2.5 volumes of cold 100% ethanol is added. 
Sample is incubated at -20°C, O/N (low amount) or 2-3hrs (high amount). Pellet is recovered 
by centrifugation, 13200 rpm at 4°C for >20 minutes. Supernatant is carefully removed and 
pellet is resuspended in 30-40 μl of RNase free water. 
For one-step quantitative reverse transcription PCR (qRT-PCR) using Taqman probes, 50 ng 
of total RNA was used per 14 μl reaction (Affymetrix USB; HotStart-IT Probe One-Step qRT-
PCR Master Mix Kit). GAPDH was used as normalization control (Applied Biosystems). 
Taqman qRT-PCR conditions were: 50°C for 10 minutes (to generate cDNA), 95°C for 2 
minutes (to inactivate the reverse transcriptase and activate the Hot Start DNA polymerase), 
followed by 40 cycles at 95°C (denaturation) for 15 seconds and 60°C (annealing and 
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elongation) for 1 minute with fluorescence acquisition during the final step. qRT-PCR was 
performed using a StepOnePlus Real-Time PCR System (Applied Biosystems) using the 
standard run protocol. For relative expression by qRT-PCR, target gene amplification was 
calculated using the formula 2^-∆∆DDCt as described by Livak et al [136].  
To accurately assess expression and re-expression of low level transcripts, we verified 
transcript levels using strand specific qRT-PCR (ssqRT-PCR). For ssqRT-PCR 250 or 1000 ng 
of total RNA were retrotranscribed using SuperScript IV RT, according to the manufactuer’s 
instructions (Invitrogen). In place of random hexamers, specific primers were used for P15 
(KG1a and Raji) and ecCEBPA (K562) detection. cDNA was purified using the High Pure PCR 
Product Purification Kit (Roche) and 60 ng of purified cDNA was used for 14 μl reaction. For 
P15, iTaq Universal SYBR Green Supermix (BioRad) was used; for ecCEBPA, One-Step qRT-
PCR Master Mix Kit was used and conditions of reaction were modified (95°C for 2 minutes, 
followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute). SYBR Green conditions 
were: 95°C for 5 minutes (to activate Taq polymerase), followed by 40 cycles at 95 °C for 15 
seconds (denaturation) and 60 °C for 1 minutes (elongation and annealing). To measure number 
of copy of P15 transcript per each sample, we used a reference standard with known number 
of copies. The standard curve was generated by serial dilutions of a reference plasmid, pGEM-
T easy vector (Promega), containing the amplified PCR product. SsqRT-PCR was performed 
using a StepOnePlus Real-Time PCR System (Applied Biosystems) using the standard curve 
protocol. qRT-PCR primer set for the CEBPA mRNA is located in the coding region and after 
the poly(A) signal for ecCEBPA (Fig1f and g). qRT-PCR primer set for P15 is located across 
exon-exon junctions, as depicted in Fig3d and 4d. 
Primer sequences are as the following: 
Human CEBPA: 
Forward 5’- TCG GTG GAC AAG AAC AG-3’;  
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Reverse 5’-GCA GGC GGT CAT TG -3’;  
TaqMan Probe 5’-ACA AGG CCA AGC AGC GC-3’ 
Human ecCEBPA: 
Forward 5’-GGT TGT CTG TGG GCC AGG TCA-3’;  
Reverse 5’-AGA GCT CAT GAA AGT CAG GAT TG-3’;  
TaqMan Probe 5’-AAT AAT ACA GCA TTT TCC CTG GCG G-3’ 
Human P15: 
Forward 5’-CGG GGA CTA GTG GAG AAG G-3’ 
Reverse 5’-GTG AGA GTG GCA GGG TCT G-3’ 
P15 specific primer for RT reaction: 
Reverse 5’-CCT GTG AAC CTT TAA CAT TTC TCA-3’ 
ecCEBPA specific primer for RT reaction: 
Reverse 5’-GGT AGG GTG TAG CCA CAT GGT CTA-3’ 
3. DNA isolation 
DNA was isolated by phenol:chloroform:isoamyl alcohol (25:24:1) purification. Briefly, cells 
were resuspended in lysis buffer (0.5% SDS, 25 mM EDTA pH 8, 10 mM TRIS pH 8, 200 mM 
NaCl) and treated with RNAse A (Roche) for 20 minutes at 37°C. The cell lysate was digested 
with proteinase K (Roche) at 65˚C overnight. Phenol solution (pH 8) was added to cell lysate 
(v:v 1:1) and sample centrifuged 15 minutes at 13200 rpm. The aqueous phase was recovered 
with a cut tip and transferred to a new tube. Isopropyl alcohol 1:1 v:v was added and sample 
incubated at -20°C for 20 minutes (high amount) or O/N (low amount). Pellet was recovered 
by centrifugation and resuspended in TE (pH8). 
4. Sodium bisulfite conversion 
Bisulfite genomic sequencing is defined as the gold-standard for detection of DNA methylation 
at single base-pair resolution. This method was first developed by Frommer et al and it is based 
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on the finding that the amination reactions of cytosine and 5-methylcytosine (5mC) proceeds 
with very different consequences after the treatment of sodium bisulfite [137]. Therefore, 
cytosines will be converted into uracil residues and recognized as thymine in subsequent PCR 
amplification and sequencing, whereas 5mCs are immune to this conversion and remain as 
cytosines allowing 5mCs to be distinguished from unmethylated cytosines. A subsequent PCR 
process is performed to define the methylation status of the loci of interest [138]. From 200 to 
1000 ng of genomic DNA were bisulfite converted according to manufacturer’s instructions 
(EZ DNA Methylation kit, Zymo Research) and eluted in 20 µl of warm RNase free water. The 
conversion was performed as follows: 98˚C for 8 minutes, 64˚C for 7.5 hour, 4˚C storage. 
5. Combined Bisulfite Restriction Analysis (COBRA)  
Combine Bisulfite Restriction Analysis (COBRA) is a qualitative approach to detect the 
methylation status of CpG-containing regions. Sodium bisulfite treatment introduces 
methylation-dependent sequence modifications and new restriction enzyme (RE) sites can be 
generated or pre-existing ones can be lost or retained depending on the methylation status 
[139]. As an example, the BstUI enzyme recognizes the CGCG sequence, which can be altered 
upon bisulfite conversion depending on the methylation status of the Cs. This property can be 
exploited to study DNA methylation in a qualitative way, by digesting the PCR amplicon with 
different REs and looking at the resulting digestion patterns, that is the basic principle of 
Combined Bisulfite Restriction Analysis (COBRA). 
4 µl of bisulfite converted DNA were used in 50 µl of PCR reaction (FastStart Taq DNA 
Polymerase, Roche). The PCR reaction was performed as follows: 95°C for 6 minutes, 
followed by 35 cycles at 95°C for 30 seconds, 53-57°C for 1 minute, 72°C for 1 minute, and a 
final step at 72°C for 7 minutes. PCR product was gel-purified (QIAEXII Gel Extraction Kit, 
Qiagen) in a 2% TAE agarose gel. After gel purification, about 400 ng of gel-purified product 
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were digested at 60°C for 2 hours with 10 units of BstUI enzyme (NEB). Digested and 
undigested product were run on a 3% TAE agarose gel. Primer sequences are as the following: 
CEBPA upstream promoter, -1.4 kb from the TSS: 
Forward 5’-GGT GTT TTT AGT TGT GTT TTT TT- 3’ 
Reverse 5’-AAA CCC TAA AAC CCC TTA-3’ 
CEBPA upstream promoter, -1.1 kb from the TSS: 
Forward 5’-TAT TTA AGG GGT TTT AGG- 3’ 
Reverse 5’-AAA AAC AAA CTT AAC TCT AA- 3’ 
CEBPA upstream promoter, -0.8 kb from the TSS: 
Forward 5’-TAG TTT YGT TAG TTT GGG GGG TTT- 3’ 
Reverse 5’-AGG TTA AGG YGG TTG TGG GTT TTA- 3’ 
P15 promoter: 
Forward 5’-GAT ATT TAG YGA GTA GTG TAG TTA GTA TTT TTG G- 3’ 
Reverse 5’-CCT YGC TCT AAC AAA ATA AAA AAC CAA- 3’ 
6. Bisulfite Sequencing PCR (BSP) 
After bisulfite treatment of genomic DNA and PCR amplification of the CEBPA upstream 
promoter or P15 promoter, the PCR product was gel purified as previously described. The 
amplicon was cloned into the pGEM-T Easy Vector (Promega) as manufacturer’s instructions. 
E.coli competent cells (bacterial strain JM109, Promega) were transformed with 3 µl of ligase 
and plated on LB agar plates containing ampicillin (Sigma Aldrich), IPTG (Sigma Aldrich) 
and X-Gal (Sigma Aldrich) for blue/white screening and standard selection. White positive 
colonies were amplified and extracted using Pure yield plasmid Miniprep system Kit 
(Promega). Plasmid DNA was sent for sequencing (Quintara Biosciences, Boston, MA) and 
results analyzed by QUMA software (http://quma.cdb.riken.jp/). Clones with percentage of 
unconverted CpGs higher than 95 and with percentage of identity lower than 90 were excluded 
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from the final analysis. For DNA methylation analysis of the CEBPA upstream promoter, 42 
nt, preceding the reverse primer 5’-AAAAACAAACTTAACTCTAA-3’ and containing 6 
CpGs dinucleotides, were excluded from the analysis. The 6 CpGs were unmethylated both in 
the CEBPA-saRNA treated samples and in the NC-treated control. Moreover, the region where 
the primer was designed is the only one without CpGs, whose presence within primer sequence 
can affect primers’ efficiency.  
7. DNA Fluorescence in Situ Hybridization (DNA-FISH) 
DNA Fluorescence In Situ Hybridization (DNA-FISH) takes advantage of fluorophore labeled 
Bacterial Artificial Chromosome (BAC) probes to visualize the presence or absence of 
genomic DNA fragments on interphase DNA. BAC probes (Empire Genomics) covering 
selected areas of the P16/P15 locus were used to assess the presence of the locus. The 
manufacturer’s recommended hybridization protocol was followed with minor modifications. 
Briefly, cells were fixed with methanol acetic acid (3:1 ratio) for more than 2 hours at -20°C, 
dropped onto uncharged glass slides, and then left for at least 20 minutes at 45°C. To increase 
accessibility of the chromatin to the BAC probe, dried slides were then washed for 1 minute in 
2X SSC (Cold Spring Harbor Protocols) and digested with 1 μg/ml proteinase K (Roche) in 
proteinase K buffer (Cold Spring Harbor Protocols) for 3 minutes at room temperature. Slides 
were then washed twice in 70% ethanol, 85% ethanol, 100% ethanol, and then allowed to dry. 
Hybridization was carried out with 1 uL of probe and 9 μL of hybridization buffer for at least 
16 hours in a humidified Hybrite chamber: 85°C for 3 minutes, followed by 37°C for at least 
16 hours. The following day, excess probe was removed in Wash 1 (0.4X SSC/ 0.3% NP-40 
warmed to 73°C), 2 minutes; Wash 2 (2X SSC/ 0.1% NP-40 at room temperature), 1 minute; 
and dried in the dark. Prolong Gold antifade with DAPI (Thermo Fisher Scientific) was used 
to counterstain and cover the slide. A chromosome 9 control probe (9q21) was used as 
hybridization control. BAC probe coverage is depicted in Figure 3b. 
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8. RNA Fluorescence In Situ Hybridization (RNA-FISH) 
Single molecule RNA FISH is a methodology for detecting and localizing particular RNA. 
Stellaris RNA FISH technology is based on the use of fluorescently labeled tiling 
oligonucleotides complementary to a sequence of interest. Unlike DNA FISH, RNA FISH is 
strand-specific, enabling the visualization of sense and antisense RNA strands. The use of tiling 
probes also has the added benefit of increasing the chance of hybridization success within the 
oligo pool and reducing the effect of nonspecific hybridization as multiple co-localizing probe 
signals are needed to visualize a single RNA molecule. The P15 probe set was designed against 
nucleotides 1-516, 517-1650, 1651-2198 of NM_004936.3 covering the coding sequences 
only, and detects both P15 variants, P15 NM_004936.3 and NM_078487.2 
(www.biosearchtech.com). Visualization of RNAs was carried out following the Modified 
Fluorescent In Situ Hybridization protocol (Stellaris, BioSearch Technologies). Briefly, 
1x10^6 cells/100 mL were cytospun onto glass slides and fixed using 3:1 methanol-acetic acid 
for 10 minutes at room temperature. Slides were first rinsed twice with freshly prepared Wash 
Buffer A. Hybridization was carried out with 250 nM (2 ml of the 1.25 mM stock) of Ready 
Designed P15 probe set in 10% formamide (Sigma) for 4 hours at 37°C in a humidified 
chamber. Next, slides were incubated with Wash Buffer A twice, 30 minutes each wash, to 
remove unbound probe. Hoechst counterstain solution was added at 1:1000 concentration in 
the second wash. Finally, slides were rinsed and then incubated for 5 minutes at room 
temperature with Wash Buffer B and mounted with Vectashield H-1000 Mounting Medium 
(Vectashield). The Ready Designed Xist probe set was used for control of nuclear 
permeabilization and compartment-specific hybridization. All solutions were supplemented 
with vanadyl complex RNAse inhibitor (New England Biolabs). RNA FISH images are 
generated from a composite of z-stack images. Raw images were acquired on a Leica DM 
5500B Microscope with a 100W high-pressure mercury lamp. Autofluorescence was checked 
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for by simultaneous acquisition of images in the opposite filter channel. Images were taken 
with a Leica DFC 350 FX camera (CCD with a Peltier cooling system). 10 μM of z-stack 
images were acquired in 0.3 mM steps. Images were assembled and contrast-enhanced using 
FIJI (FIJI is Just Image J; https://fiji.sc/) as per manufacturer’s recommendations. 
9. Cell synchronization 
During synchronization, cells representing different phases of the cell cycle are brought to the 
same stage, resulting in a synchronous population. Cell cycle consists of the synthesis of 
genetic materials (S-phase) and the further distribution of the genetic materials, together with 
other cellular components, onto daughter cells (M-phase). Progression from S- to M-phase is 
intermitted by two gap phases, G1 and G2, that establish the cell cycle. An additional phase, 
named G0, defines quiescent cells that is cells that have stopped dividing and have left the cell 
cycle [140].  
Thymidine is a chemical method used for reversely perturbating cell cycle progression and 
synchronizing cells in G1/early S-phase [141]. As Xeros et al previously demonstrated, excess 
of thymidine prevents DNA synthesis by inhibiting the formation of deoxycytidine 
triphosphate (dCTP) from cytidine-5’-phosphate [142]. The reduced size of dCTP pool 
compared to other deoxynucleosides triphosphates might have a regulatory function in the rate 
of DNA synthesis [143]. To obtain a population of cells uniformly arrested in G1/early S-phase, 
cells were treated with various concentrations of thymidine, according to the cell line used. 
Thymidine (Sigma) was dissolved in cell culture-grade water at 50 mM concentration and 
aliquots stored at -20°C. KG1a cells were seeded at 1*10^6 cells/ml in complete RPMI medium 
(Corning) in the presence of 2.5 mM thymidine for 18 hours (first block). Following the first 
block, thymidine was removed and cells were washed twice with fresh medium and grown in 
thymidine-free medium for 8 hours to release cells from the block. Eight-hours release was 
followed by a second thymidine block by the addition of 2.5 mM thymidine for 18 hours.  
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K562 cells were seeded at 0.5*10^6 cells/ml in complete RPMI medium and grown in the 
presence of 2.5 mM thymidine for 18 hours. As for KG-1a cells, K562 cell line was washed 
twice with fresh medium and incubated with thymidine-free medium for 8 hours. A second 18-
hours thymidine block (2.5 mM) followed the 8-hours release.  
Raji cells were seeded at 0.75*10^6 cells/ml and incubated with 3 mM thymidine for 18 hours. 
As for KG-1a and K562 cell lines, the first block was followed by 8 hours incubation in fresh 
medium to release cells from the block and by a second thymidine-block for the same duration 
as the first block. 
 A549 cell line was seeded at 0.07*10^6 cells/ml 24 hours before incubation with thymidine. 
After 24 hours cultivation in fresh medium, cells were incubated with 3.5 mM thymidine for 
11 hours. A one-thymidine block was sufficient for synchronizing the cells. After thymidine 
incubation, cell cycle was assessed by flow cytometry prior transfection.  
10.  Cell cycle analysis 
The simultaneous detection of RNA and DNA molecules can be determined by the means of 
Pyronin Y staining dye (PY) and double-stranded DNA staining, respectively. PY is indeed 
able to distinguish quiescent cells (cells in G0 phase) from active cycling cells through their 
RNA content: cells in G0 phase have a lower content of RNA, thus resulting in a lower PY 
signal. On the contrary, a double-stranded DNA staining, as Vybrant DyeCycle Violet dye is 
(VV, Invitrogen), allows to reconstruct cells’ cycle according to their amount of DNA. Cell-
cycle analysis on thymidine and non-thymidine treated cells was performed as follows. Cells 
were harvested and washed once with phosphate buffer saline (PBS). Cell pellet was 
resuspended in phosphate-citrate buffer solution (see recipe below) and incubated 20 minutes 
at room temperature (RT). Four ml PBS was added to the cell solution followed by a second 
wash with 1 ml PBS. Cell pellet was washed once with 1 ml PY (1.5 mg/ml in PBS, Sigma) 
and resuspended with 400 μl of staining solution (PY 1.5 mg/ml and 5 μM VV). PY is able to 
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stain RNA molecules whereas VV is a cell permeable double-stranded DNA staining. Samples 
were incubated 15/30 minutes at 37 °C in the dark prior analysis by flow cytometry. CytoFLEX 
LX (Beckman Coulter) instrument was used for detecting PY and VV signal. PY was detected 
by the 488 nm laser (Blue) and B610-ECD filter; VV signal was detected by the 405 nm laser 
(Violet) and V450-PB filter.  
For 100 ml of phosphate-citrate buffer solution:  
Prepare phosphate buffer stock solution by dissolving 8.903 g of Na2HPO4 in 250 ml of H2O 
(A). Prepare the citric acid buffer stock solution by dissolving 2.11 g of citric acid in 100 ml 
of H2O (B). To 35 ml of A add B until pH 4.8; then add 0.87 g NaCl, 0.5 g bovine serum 
albumin (BSA), 0.02 g saponin and 1 ml 500 mM sodium EDTA. Adjust volume to 100 ml 
with H2O.   
11.  Short-activating RNAs (saRNAs) 
The short-activating RNAs (saRNAs) targeting the P15 and the CEBPA locus were designed 
by MiNa Therapeutics and purchased from Sigma and IDT. saRNAs were reconstituted at 100 
μM stock with cell culture-grade water and diluted to ready-to-use concentration of 50 μM. 
Either 100 μM stock and diluted aliquots were kept at -20 °C. The saRNA’s sequences were 
selected among bioinformatically identified hotspots at the gene of interest. Hits against the 
P15 gene include: saP15-PR11 (targeting the first exon), saP15-PR56 (targeting the intron) and 
saP15-PR313 (targeting the promoter). In addition, a scramble control against the firefly 
luciferase, named FLUC, were designed as negative control. Since the P15-saRNAs had never 
been previously tested, in order to assess their transfection efficiency as well as their 
localization within cellular compartments, the 3’ end of either strands was labeled with 
different fluorophores to distinguish sense and antisense strand. The guide, or sense, strand was 
labeled with Alexa Fluor 488 dye, whereas the passenger, or antisense, strand was labeled with 
ATTO590 dye. Transfection efficiency and cellular localization were assessed by flow 
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cytometry and fluorescent microscopy, respectively. The CEBPA-saRNA, the AW1-51 saRNA 
targeting the coding region of the gene, was chosen according to published data [88, 144]. In 
parallel to AW1-51 saRNA, a negative control, NC, was used in each transfection.  
12.  saRNAs delivery 
  12.1 Nucleofection 
Nucleofection is an electroporation-based methods that, by combining cell-specific 
nucleofector solution and electrical pulses, enables DNA and/or RNA molecules to directly 
access the nucleus. Therefore, in contrast with other transfection methods, nucleofection does 
not depend on cell division.  
KG1a cells were transfected with Amaxa Nucleofector Device II, Kit L, program V-001, 
according to manufacturer’s instructions (Lonza). More specifically, 1*10^6 cells were 
nucleofected in the presence of 4.5 μl saRNA (50 μM stock). After nucleofection, cells were 
diluted into 4.5 ml fresh medium and distributed into 3 wells in a 12-well plate, 1.5 ml per well. 
Two μg of a pmax green fluorescent protein plasmid (pmaxGFP, provided by the manufacturer) 
was used as transfection-efficiency control and detected either by fluorescent microscopy or 
flow cytometry. Raji and K562 cells were also transfected with Amaxa Nucleofector II, Kit V, 
program M-013 and T-016, respectively, according to manufacturer’s instructions and the 
protocol previously described for KG1a cell line. For all cell lines, 1*10^6 cells per cuvette 
were used. Seventy-two hours post nucleofection, cells were re-transfected with saRNAs with 
lipofectamine2000 (L2000, Invitrogen), a cationic liposome based reagent. 0.33*10^6 cells 
were plated in 1.3 ml fresh medium (12-well plate). The complex lipofectamine-RNA was 
prepared as follows: 




2) 1.5 μl saRNA (50 μM stock) was added to 100 μl optimem and the mix incubated 5 minutes 
at RT (mix-B); 
3) mix-A was added to mix-B and incubated 20 minutes at RT (mix-C); 
4) mix-C (200 μl) was distributed to each well (1.3 ml cell suspension) dropwise; 
The ratio saRNA:L2000 was the following: per 1.5 μl saRNA (50 μM stock), 4 μl L2000 were 
used. In addition to saRNAs, pmaxGFP (2 μg) was used to monitor the transfection efficiency. 
Cells were collected 24 hours post lipofectamine transfection.    
 12.2 Lipid-based transfection 
The CEBPA-saRNA was delivered into A549 cells by DharmaFECT 1 (DF1, Horizon 
Discovery), a lipid-based transfection reagent. Two consecutive transfections were performed: 
1) a reverse transfection followed by a 2) forward transfection. The first reverse transfection 
was prepared as follows: 10 μl DF1 were added to 490 μl optimem; 1 μl saRNA (50 μM stock) 
was added to the mix. The complex DF1-optimem-saRNA was transferred into wells (12-well 
plate) and incubated 30 minutes at RT. Meanwhile, synchronized A549 were diluted to 
0.13*10^6 cells/0.5 ml and 0.5 ml was added, per well, to the complex DF1-optimem-saRNA 
at the end of incubation. Twenty-four hours post transfection, a second transfection (forward) 
was performed as follows:  
1) 1 ul saRNA (50 μM stock) was added to 99 μl optimem and the mix incubated 5 minutes at 
RT (mix-A); 
2) 5 μl DF1 were added to 95 μl optimem and the complex incubated 5 minutes at RT (mix-
B); 
3) mix-A was added to mix-B and incubated 20 minutes at RT (mix-C);  
4) Medium was removed from wells and replaced with 800 μl of fresh medium; 
5) mix-C was distributed to wells dropwise; 
Medium was changed 48 hours after forward transfection.  
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13.  saRNAs transfection efficiency 
Labelled P15-saRNAs were transfected into KG1a and Raji cell lines and fluorescence 
intensity was determined by flow cytometry. Twenty-four, forty-eight and seventy-two hours 
post nucleofection, samples were collected and washed once with PBS. Finally, cell pellet was 
resuspended in 400 μl PBS and DAPI was added to each sample in order to exclude dead cells 
during analysis. CytoFLEX LX was used for assessing fluorescence intensity. Alexa Fluor 488 
dye (green) was detected by the 488 nm laser (Blue) and B-525 filter; ATTO590 dye (red) 
intensity was assessed by the 561 nm laser (Yellow Green) and Y-610 filter. Dapi was 
measured by the 375 nm laser (Near UV) and 450 filter. Forward and side scatter, FSC and 
SSC respectively, were used to identify the cell population and exclude doublets. Dapi positive 
cells, whose cut-off was first defined in the non-transfected control, were excluded from the 
analysis. By plotting B-525 (green) against Y-610 (red) and tracking a quadrant gate, 4 sub-
populations were identified: a) green negative and red negative, b) green positive and red 
negative, c) green positive and red positive and d) green negative and red positive.  
14.  Fluorescent microscopy 
P15-saRNAs localization was assessed by fluorescent microscopy in KG1a and Raji cell lines. 
Images were acquired with LSM 880 Inverted Live-cell Laser Scanning confocal microscope 
(Zeiss) and either live and fixed cells were analyzed. Samples were collected 30 minutes, 1 
hour, 1.5 hour, 24 hours and 48 hours post transfection. For live-cell imaging, about 0.05*10^6 
cells were re-suspended in 150 μl fresh and complete RPMI and transferred into a multi-
chamber. Hoechst 33342 was added to cells 10 minutes before acquisition. Whilst live-cell 
imaging did not require any processing of the sample, confocal microscopy imaging did. 
Hence, about 0.06*10^6 cells were collected, washed twice with cold PBS and re-suspended 
in 200 μl PBS. Samples were cyto-spun at 400 rpm for 5 minutes onto microscope slides and 
incubated 20 minutes at -20 °C in 100% methanol. Slides were washed twice with PBS, 5 
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minutes each wash, and incubated 5 minute at RT with DAPI to visualize cell nuclei. Following 
DAPI incubation, a PBS wash and a final rinse with water were performed. Excess of liquid 
was removed from the sample by gently tapping the edge of the slide on a wipe. A single drop 
of mounting medium (ProLong Glass Antifade Mountant, Invitrogen) was applied to each cell 
spot and a coverslip was lowered onto the mountant avoiding trapping any air bubbles. Images 
were acquired after curing of the mountant.  
15. Western blotting 
Cultured cells were washed with PBS and lysed with reduced 2x sample buffer (0.1 M TRIS 
pH 6.8, 4% SDS, 5% glycerol, 0.2 M DTT and 4% β-mercaptoethanol), 1:1 ratio PBS: reduced 
2x sample buffer. Samples were boiled 5 minutes at 95°C. Equivalent amounts of protein were 
resolved on a NuPage 4-12% bis-tris gel (Invitrogen) with MES buffer (Invitrogen) at 130 V, 
and transferred to polyvinylidene difluoride (PVDF, 0.45 μM) membrane at constant voltage 
(12 V) on ice. The resulting blot was blocked 1 hour at RT with 5% nonfat dry milk in 0.1% 
TBS-T. CEBPA protein was detected by overnight incubation at 4°C with the appropriate 
antibody (1:500, 5% nonfat dry milk in 0.1% TBS-T) (Abcam) followed by enhance 
chemiluminescence detection (Thermo Scientific). CEBPA protein signal was normalized to 








CEBPA-saRNA AW1-51 induced re-expression of CEBPA and ecCEBPA mRNA 
in myeloid and lung cancer cell lines 
 
Previous evidence revealed the efficacy of CEBPA-saRNAs for treatment of hepatocellular 
carcinoma [88, 144]. Voutila et al, by means of bioinformatically directed nucleotide walk 
around the CEBPA locus, identified the CEBPA-saRNA AW1-51 as the one able to upregulate 
CEBPA mRNA in HepG2 cells and in patients with advanced liver cancer in a phase 1/2a trial 
(ClinicalTrials.gov: NCT02716012) [88, 144] (Fig.1a). To investigate whether CEBPA-
saRNA could also upregulate expression of CEBPA in myeloid and lung cancer cells, we tested 
CEBPA-saRNA AW1-51 in two cell lines, A549 and K562, expressing CEBPA mRNA at low 
and low-to-undetectable levels, respectively [111, 145, 146]. Prior to treatment with 50 nM 
CEBPA-saRNA, cells were synchronized in G1/early S phase, when the synthesis phase of the 
cell cycle starts and DNMT1’s activity peaks [54, 147] (Fig.1b and d). Synchronization, indeed, 
allowed to enhance potential direct and/or indirect interactions between CEBPA-saRNA and 
DNMT1 at S phase [54]. The CEBPA-saRNA reduced proliferation in both cell lines (Fig.1c 
and e), data consistent with an antiproliferative and differentiating role of CEBPA in myeloid 
lineages and lung cells [108, 110, 111]. Twenty-four hours post transfection, cell-growth arrest 
was detected in NC-treated samples as well, indicative of an initial cellular toxicity of the 
transfection reagent, which was more significant upon lipid-based transfection method 
(Fig1.c). Commonly, the extent of cellular toxicity caused by different transfection techniques 
is influenced by the reagent and also by the nature of the cells, as we observed.   
Data from the published literature show that gene activation by means of saRNAs is delayed 
by about 48 hours. Since saRNAs exert their activity in the nucleus, the effect on gene 
activation depends on cell division and accessibility of the nuclear membrane, resulting in a 
cell-cycle dependent mechanism. Moreover, as duplex RNAs are loaded by Ago2 in the 
cytoplasm before entering the nucleus, it is possible that this process is a passive mechanism 
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that occurs during mitosis [86]. Therefore, gene expression analysis should be performed 
between 48 and 96 hours post transfection in order to validate saRNAs activity.  
Standard qRT-PCR analysis demonstrated upregulation of CEBPA in A549 and K562 since 48 
hours post transfection, with peak of expression (up to 4- and 2-fold in A549 and K562, 
respectively) 72 hours post treatment (Fig.2a and b, left panel).  
Gene expression can be affected by noncoding RNAs arising from the promoter and 
downstream region of the corresponding gene [47, 148, 149]. The extra-coding CEBPA 
(ecCEBPA) is an overlapping, sense-orientated noncoding transcript arising from the CEBPA 
locus, whose transcription controls the expression of the corresponding coding mRNA CEBPA. 
ecCEBPA is able to interact with DNMT1 and prevent DNA methylation of the CEBPA gene 
[54]. To assess whether CEBPA-saRNA promotes transcription of noncoding transcripts, we 
evaluated expression of ecCEBPA upon treatment. While in A549 the highest ecCEBPA re-
expression was detected at 72 hours, in K562 peak of ecCEBPA activation was observed 48 
hours post transfection. 
The delayed re-expression of ecCEBPA in A549 might account for a different detection 
method. While in A549 the expression of ecCEBPA was evaluated by standard qRT-PCR, in 
K562 it was necessary to perform strand specific qRT-PCR (ssqRT-PCR) as a result of low 
basal levels of expression (Fig.2a and b, right panel). Therefore, since ssqRT-PCR is a more 
sensitive methods compared to standard qRT-PCR, the different approach might explain the 
delay in the re-expression of ecCEBPA in A549 cell line. 
We also evaluated CEBPA protein expression in A549 upon treatment with saRNA (Fig.2c). 
CEBPA expression increased 48 and 72 hours post transfection in saRNA-treated samples 
compared to the negative control (Fig.2c, upper panel). The expression of CEBPA was 
normalized to Beta Actin and an increment of 2 fold was observed 72 hours post treatment 
(Fig.2c, bottom panel). On the contrary, in K562 cells, CEBPA protein expression, either 
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before and post treatment, was undetectable (data not shown). K562 cell line expresses the 
oncogenic fusion protein BCR-ABL, which downregulates CEBPA protein by inducing 
hnRNP E2, responsible for inhibiting CEBPA mRNA translation [133]. 
Re-expression of CEBPA protein in A549 led to morphological changes, as axonal growth 
(Fig.2d, left panel, red arrows), 120 hours post transfection. This result confirmed previous 
data showing that ectopic expression of CEBPA induced differentiation in lung cancer cell 
lines, as Calu-I, squamous cancer cells, and H358, adenocarcinoma bronchoalveolar type cells 
[110].  
Collectively, these data demonstrate that CEBPA-saRNA upregulates CEBPA and ecCEBPA 
transcripts in synchronized myeloid and lung cancer cells and re-expression of CEBPA protein 
induces morphological changes, suggestive of differentiation.  
 
Figure 1 Schematic of CEBPA-saRNA delivery in A549 and K562 cell lines. a, Schematic of 
CEBPA-saRNA (AW1-51) targeting the CEBPA coding region. b, Schematic of saRNA’s delivery to 
A549 cells. Top panel, A549 cells are seeded 24 hours prior synchronization and then synchronized in 
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G1 phase by one-thymidine block (11 hours, 3.5 mM). Bottom panel, synchronized cells are reverse-
transfected with 50 nM CEBPA-saRNA or 50 nM NC and, after 24 hours, forward-transfected with 
CEBPA-saRNA or NC at 50 nM final concentration. DNA, RNA and proteins are collected from 24 to 
72 hours post forward-transfection. c, A549 cell-growth curve upon 50 nM CEBPA-saRNA treatment, 
from 0 to 72 hours post forward-transfection. d, Schematic of saRNA’s delivery to K562 cells. K562 
cells are synchronized in G1 phase by double-thymidine block (2.5 mM); after synchronization cells 
are electroporated by Amaxa nucleofection with 50 nM CEBPA-saRNA or NC. DNA, RNA and 
proteins are collected from 48 to 72 hours post nucleofection. e, K562 cell growth curve upon 50 nM 
CEBPA-saRNA treatment, from 0 to 72 hours post nucleofection. 
 
Figure 2 CEBPA-saRNA reactivates transcription of CEBPA mRNA in A549 and K562 
cell lines. a, Top panel, diagram of CEBPA locus and corresponding qRT.PCR primers (black arrows). 
CEBPA (bottom left panel) and ecCEBPA (bottom right panel) re-expression upon 50 nM CEBPA-
saRNA (AW1-51) treatment, from 48 to 72 hours post transfection, in A549 cells (n=2). b, Top panel, 
diagram of CEBPA locus and corresponding qRT.PCR primers (black arrows). CEBPA (bottom left 
panel) and ecCEBPA (bottom right panel) re-expression upon 50 nM CEBPA-saRNA, from 24 to 72 
hours post transfection, in K562 cells (n=2). c, Upper panel indicates CEBPA protein re-expression 
upon CEBPA-saRNA, at 48 and 72 hours, in A549 cells; bottom panel shows densitometric analysis of 
CEBPA protein relative to B ACT signal. d, A549 morphological changes upon CEBPA-saRNA 
treatment 120 hours post nucleofection. 20x magnification. NC: negative control; ecCEBPA: extra-





The CEBPA-saRNA induced, to different extent, demethylation of the CEBPA 
upstream promoter in A549 and K562 cell lines  
DNA methylation is a key epigenetic signature that is not randomly distributed across the 
genome, but exhibits regional specificity. Evidences demonstrated that methylation of 
promoter associated CGIs negatively correlates with gene expression, and this mechanism 
often occurs in cancer [8, 9].  
CEBPA expression can be altered by promoter hypermethylation, as in AML and lung cancer. 
A 2883 bp long CGI, with 281 CpG dinucleotides and coordinates chr19:33792062-33794944 
(hg19), extends throughout the promoter and part of the coding region of the CEBPA gene. In 
the literature, the mentioned CGI was arbitrarily divided into two sequences, the upstream or 
distal promoter (-1.6 to -0.6 kb from the ATG), which is the one often altered in AML and lung 
cancer, and the core promoter (-0.6 and 0 kb from the ATG). A schematic of the CGI is shown 
in Figure 3a. In order to evaluate the methylation profile of A549 and K562 within the CEBPA 
upstream promoter, COBRA was performed on bisulfite treated DNA and two regions were 
analyzed (from -1.4 to -1.1 kb and from -0.8 to -0.55 kb from the TSS) (Fig.3b). Aware that 
COBRA is not a quantitative method, we used this technique only as preliminary approach. As 
COBRA demonstrated, A549 displayed high methylation level (fully digested) within the 
sequence located at -1.4 kb from the TSS, whereas displayed a non-methylated sequence (fully 
undigested) at -0.8 kb from the TSS. On the contrary, the K562 cell line displayed a hemi-
methylated region (partially digested) at -0.8 kb from TSS and high methylation profile (fully 
digested) at -1.4 kb from the TSS. Therefore, since we wanted to assess potential DNA 
methylation changes upon CEBPA-saRNA treatment, we decided to analyze further the 
following regions: in A549 cells the sequence located -1.4 kb from the TSS, whereas in the 
K562 cells the sequence located -0.8 kb from the TSS. Indeed, previous studies demonstrated 
that the upstream promoter region located between -0.8 and -0.55 kb from the TSS was the 
most responsive in terms of demethylation in K562 cells [54]. Another region, located between 
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-1.1 and -0.8 kb, was analyzed in A549 according to the study of Tada et al where the 
methylation profile of the CEBPA promoter was evaluated in lung cancer cells [111]. The 
methylation profile of saRNA-treated A549 cells was analyzed by bisulfite sequencing 
(Fig.3c). The genomic sequence located between -1.4 and -0.8 kb from the TSS is shown in 
Figure 3c, upper panel (double pointed black arrow), and comprises 45 CpGs. The middle panel 
shows the methylation trend, plotted as ratio of methylated versus unmethylated CpGs relative 
to the respective NC, from 24 to 72 hours post transfection. A demethylation effect was 
detected at 48 hours post transfection (10%) and became more significant 72 hours post 
treatment, with a decrease in methylation of about 30% compared to the control. The lollipop 
representation is shown in the bottom panel, where an increase in demethylated CpGs (white 
dots) can be easily observed 72 hours post transfection. Bisulfite sequencing analysis was also 
performed in CEBPA-saRNA treated K562 (Fig.3d). The region between -0.8 and -0.55 kb 
from the TSS was divided in two sequences, having 16 CpG dinucleotides each (upper panel). 
Within the 16 CpGs located further from the TSS, a significant demethylation effect was 
observed 24 and 48 hours post treatment, which then vanished at 72 hours. Remarkably, the 
wave of demethylation transferred to the second 16 CpGs, located closer to the TSS, where a 
statistical significant demethylation effect was observed 48 and 72 hours post treatment. 
Altogether, these data demonstrated that saRNAs, besides inducing re-activation of gene 
expression, can also induce demethylation within the CEBPA promoter in cell lines displaying 





Figure 3 CEBPA-saRNA treatment induces, to different extent, demethylation of the CEBPA gene 
in A549 and K562 cell lines. a, Schematic profile of the CpG island (green rectangle) extending within 
the promoter and the coding region of the CEBPA gene. b, Combined Bisulfite Restriction Analysis 
(COBRA) on bisulfite-converted genomic DNA from A549 and K562 cells. Solid black arrows indicate 
the analyzed sequences localized at -1.4 and -0.8 kb from the TSS of CEBPA and containing 36 and 29 
CpG dinucleotides (CpGs), respectively. Stars show position of the BstUI recognition site: black stars 
indicate one site, white stars indicate two adjacent sites. c, Bisulfite Sequencing PCR (BSP) on CEBPA-
saRNA-treated samples from A549 cells. The sequence within the CEBPA’s promoter and located 
between -1.4 and -0.8 kb from the TSS is evaluated (upper panel). Middle panel shows relative ratio of 
methylated (M) to unmethylated (UM) CpGs: dark color indicates high DNA methylation level whereas 
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light grey color indicates lower DNA methylation level. Lollipop representation (bottom panel) shows 
methylated (black dot) and unmethylated (white dot) CpGs upon CEBPA-saRNA treatment 24, 48 and 
72 hours post transfection (n ≥ 13 clones). d, BSP on CEBPA-saRNA-treated K562. Methylation profile 
of sequence located between -0.8 and -0.55 Kb from the TSS of the gene is evaluated (upper panel). 
Red rectangles show the CpGs analyzed within the sequence. DNA methylation changes are shown 
either as the relative ratio of methylated (M) to unmethylated (UM) CpGs in all clones analyzed per 
each sample (middle panel) and as lollipop representation (bottom panel). Color scale in middle panels 
can be interpreted as in c. (n = 14 clones ). All bisulfite sequenced clones were analyzed by Fisher’s 
exact test. UD: undigested; D: digested; NC: negative control; x: single nucleotide polymorphism 
(SNP); **** : P < 0.0001; * P < 0.05. 
 
Characterization of the P15 locus in various cell lines 
In order to choose the appropriate cell models for testing P15-saRNAs, characterization of the 
P15 locus (Fig.4a) was performed in K562, KG1a, Raji and HEK293 cell lines. Standard PCR 
analysis (data not shown) on wild type cells demonstrated the presence or otherwise of the P15 
locus among the mentioned cell lines. Interestingly, only the K562 cell line did not show any 
amplification, indicating absence of the analyzed sequence. DNA FISH (Fig.4b) on KG1a and 
K562 cell lines confirmed the results previously obtained, suggesting that K562 cells, lacking 
the entire P15 locus, could be considered a natural P15-knockout cell model and a negative 
control in the study. Since regulatory mechanisms, as DNA methylation, can influence gene 
expression, levels of the P15 mRNA were also evaluated (Fig.4c). By means of ssqRT-PCR, 
the P15 transcript was measured in K562, KG1a, Raji and HEK293 cell lines. Intriguingly, the 
KG1a cells, despite having an intact P15 locus, showed low-to-undetectable levels of the P15 
mRNA, expressed as input of copy number. On the contrary, the Raji and HEK293 cell lines 
showed medium-to-high expression of the P15 mRNA. RNA FISH analysis on K562, KG1a 
and HEK293 validated the results showed by means of ssqRT-PCR, indicating HEK293 as a 
P15-high expressing cell line whereas KG1a as a P15-non expressing cell line (Fig.4d). 
Therefore, except for K562, the other cell lines had an intact P15 locus but different levels of 
P15 expression. According to the results, we decided to test the P15-saRNAs in KG1a and Raji 
cell lines, and used HEK293 as positive control.  
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Different levels of P15 mRNA measured in KG1a and Raji might account for different DNA 
methylation profiles. Early studies on methylation-dependent P15 silencing in AML 
demonstrated that P15 promoter is fully methylated in KG1a whereas is partially methylated 
in Raji cell line [150, 151]. Li et al, while testing saRNAs targeting the CDH1 gene, realized 
that epigenetically silenced genes, as CDH1 in HeLa cells, could not be re-activate by saRNAs 
alone. Therefore, prior to saRNAs treatment, low doses of 5AC (between 1 to 10 μM) were 
used to partially demethylate the locus and allow gene re-activation upon saRNAs [86]. 
However, since even low doses of demethylating agent can induce minimal demethylation and 
gene upregulation throughout the genome [152], we did not treat KG1a cells with 5AC before 
saRNAs transfection, in order to avoid additional off-targets and unspecific demethylating 
effects. However, as we did in K562 and A549 prior to CEBPA-saRNA treatment, we 
synchronized KG1a and Raji cell lines in G1/early S phase as to obtain a homogeneous cell 






Figure 4 P15 locus characterization. a, Schematic of the 9p21 locus and corresponding transcripts. b, 
DNA fluorescent in situ hybridization (FISH) to detect the 9p21 locus on KG1a and K562 cell lines. 
The BAC probe RP11-149I2 has coordinates on chr9:21909258-22010413 (hg19); the BAC probe 
RP11-454D15 has coordinates on chr9: 21819270-21971266 (hg18) (www.empiregenomics.com). c, 
Strand-specific qRT-PCR (ss qRT-PCR) from total RNA to measure copy number of P15 mRNA in 
KG1a, Raji, HEK293 and K562 cell lines, expressed as input of copy number. d, Detection of P15 
mRNA by RNA FISH on HEK293, KG1a and K562. Black stars indicate position of Stellaris FISH 
probes in P15 transcript. In the picture, white dots indicate P15 mRNA.  
 
The P15-saRNAs induced upregulation of the aberrantly methylated P15 locus in 
KG1a and Raji cell lines 
Three saRNAs targeting the P15 locus were designed and tested in KG1a and Raji cell lines: 
PR313 (at -375 bp from the TSS, targeting the promoter), PR11 (at +624 bp from the TSS, 
targeting the first exon) and PR56 (at +1241 bp from the TSS, targeting the intron) (Fig.5a). A 
negative control, the saRNA-FLUC was also used. 50 nM of each saRNA, both as single 
saRNA and as mix of all three RNA molecules, were delivered into KG1a and Raji cells 
64 
 
(Fig.5b). Before nucleofection, cells were synchronized by double thymidine block in G1/early 
S phase. Samples were collected from 24 to 96 hours post nucleofection. Since P15 is a cell 
cycle regulator and its activation is able to arrest cell cycle progression, cell growth was 
monitored upon treatment from 24 to 72 hours post nucleofection. Cells growth was not 
evaluated 96 hours post nucleofection because at 72 hours cells were re-plated at a specific 
concentration and then re-transfected with lipofectamine. There was not significant change in 
cell growth upon saRNA treatment, compared to the scramble control FLUC, in KG1a cells. 
On the contrary, in Raji cell line, treatment with mix of all three saRNAs partially reduced cell 
growth compared to other treatments and FLUC (Fig.5b).  
To address whether P15-saRNAs were efficiently delivered into cells, tagged-saRNAs were 
designed and tested. As described in Material and Methods, sense and antisense strand of 
double-strand RNAs were labeled with different fluorophores: Alexa488 identified the sense 
strand, whereas the ATTO590 identified the antisense strand. This approach allowed us to 
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evaluated potential differences in transfection efficiency between sense and antisense strand 
(Fig.6a). Cytofluorimetric analysis was performed 24 hours post transfection in live cells from 
KG1a and Raji. Only live cells were gated and considered for further analysis. FLUC-treated 
samples did not show any fluorescence in either cell lines, thus excluding mechanism of 
autofluorescence due to transfection. In KG1a cells the efficiency of transfection was greater 
than 50% in each samples, reaching almost 100% in the Mix (Fig.6a, middle panel). In Raji, 
the efficiency of transfection was about 100% in each sample. Differences in fluorescence from 
sense and antisense strand could also be observed. In KG1a, except for PR313 and Mix, green 
fluorescence associated with sense strand was more intense than red fluorescence associated 
with antisense strand. This phenomenon could depend on processing on the double-stranded 
RNA and degradation of the fluorophore inside the cells. As in KG1a, in Raji green 
fluorescence was more intense than red fluorescence, which is barely detectable. Interestingly, 
cell population showing either sense and antisense fluorescence (yellow color in the graph) 
reached 60% in PR313 and almost 100% in Mix. On the contrary, PR11 and PR56 showed a 
higher green fluorescence. Yellow fluorescence identified double positive events (cells), 
having either green and red fluorescence. However, whether sense (green) and antisense (red) 
strand were still annealed and yet to be processed or whether, after processing, they were still 
labeled and fluorescent could not be addressed by standard cytofluorimetric analysis. Overall, 
these results demonstrated that P15-saRNAs were efficiently transfected in either cell lines. 
We further examined P15 RNA activation by means of ssqRT-PCR. KG1a and Raji cells were 
transfected with 50 nM P15-saRNAs, as single saRNAs (PR313, PR11 and PR56) and as mix 
of all three, and mRNA level was measured 48, 72 and 96 hours after transfection. In KG1a, 
re-expression of the transcript was observed at each time point; the highest increased in P15 
mRNA was detected upon mix treatment, with peak of expression at 96 hours (4.5-fold 
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increase) (Fig.6b, left panels). On the contrary, in Raji, P15 mRNA re-expression was observed 
only at 48 hours upon PR56 treatment, with a 2-fold increase compared to scramble control 
(Fig.6b, right panels). Altogether, these results indicate P15-saRNAs as innovative and 
potential tool to re-activate the aberrantly methylated P15 gene. 
 
Figure 5 Schematic of P15-saRNA delivery a, Schematic of saRNAs’ hotspots targeting the P15 
locus; from left to right: saP15-PR56 targets the intron, saP15-PR11 targets the first exon, saP15-PR313 
targets the promoter. b, Schematic of saRNAs’ delivery. KG1a and Raji cell lines are first synchronized 
in G1 phase by double thymidine block (2.5 and 3 mM, respectively); synchronized cells are then 
electroporated by nucleofection with 50 nM saRNA, as single saRNAs (PR313, PR11 and PR56) or as 
mix of all three RNAs. DNA and RNA are collected from 24 to 72 hours post nucleofection. 72 hours 
post-nucleofection cells are transfected with lipofectamine 2000 and 50 nM saRNAs. Samples are 







Figure 6 P15 mRNA reactivation upon saRNAs treatment a, saRNAs’ transfection efficiency is 
evaluated by means of labeled saRNAs in both KG1a and Raji cell lines. Sense and antisense strands 
are labeled at 3’ end with Alexa488 (green) and ATTO590 (red), respectively (left panel). Fifty nM of 
labeled and double stranded RNAs are delivered into cells by nucleofection and fluorescence is 
measured by standard cytofluorimetric analysis in live cells (right panel). Yellow color identifies double 
positive cells, whereas striped pattern double negative cells. b, Top left and right, diagram of P15 locus 
with corresponding qRT-PCR primers (black arrows). Bottom left and right, P15 copy number from 
total RNA upon saRNAs’ treatment 48, 72 and 96 hours post nucleofection (n=2). 
 
P15-saRNAs induce demethylation, to different extent, in KG1a and Raji cell 
lines, respectively 
To examine demethylation effects upon P15-saRNA treatment, we performed bisulfite 
sequencing analysis on KG1a and Raji cell lines. The P15 locus has promoter-associated CGI 
that undergoes aberrant methylation in myeloid malignancies and sporadic parathyroid 
adenomas [118, 123, 153]. As mentioned before, KG1a cell line is heavily methylated whereas 
Raji is hemi-methylated within the promoter-associated CGI. Additionally, hypermethylation 
of the P15 3’UTR region is frequently observed in tumors with loss of heterozygosity but 
without methylation of the promoter-associated CGI, as in primary lymphomas [154]. 
Therefore, we decided to analyze 16 CpG dinucleotides, flanking the promoter and 5’UTR of 
the locus. In more details, 13 CpGs out of 17 localize within the P15 promoter, the remaining 
4 CpGs localize within the 5’UTR of the gene. Since we observed re-activation of the locus at 
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72/96 hours and 48 hours after transfection in KG1a and Raji, respectively, promoter DNA 
methylation was evaluated at 48 and 72 hours in either cell lines (Fig.7a and b). In KG1a, a 
decrease in DNA methylation level was observed 48 hours after transfection upon mix 
treatment (Fig.7a, right panel), consistent with data of expression. However, the same result 
was not observed 72 hours after treatment, when also re-expression of the transcripts was 
detected. This result might be explained with a different DNA modification associated with 
RNAa, the 5-hydroxymethylcytosine (5hmC), produced by the ten-eleven translocation (TET) 
family of dioxygenases during active DNA demethylation. Besides being a chemical 
intermediate, 5hmC is a stable DNA modification that binds to specific regulatory proteins and 
is mainly found within actively transcribed genes. 5hmC marks decline in cancer tissue, 
suggesting its potential regulatory role in the mammalian genome [155]. Therefore, to 
overcome the limitations associated with bisulfite-based approaches, which do not segregate 
5mC and 5hmC marks, new bisulfite-free techniques [156], as well as other strategies, have 
been developed that preserve the genomic DNA integrity [157, 158]. Hence, a different 
approach able to evaluate 5hmC mark should be considered for evaluating DNA methylation 
changes in KG1a upon saRNA treatment. 
On the contrary, bisulfite sequencing analysis on DNA from PR56-saRNA-treated Raji cells 
demonstrated a statistical significant demethylation both 48 and 72 hours after treatment 
(Fig.7b), which, however, did not correspond to an equal gene re-activation. In this regard, Raji 
cells were derived from B-lymphocytes of a Burkitt's lymphoma and comprise structural 
aberrations as the t(8;14) translocation, resulting in the juxtaposition of the MYC gene to the 
IGH enhancers, which leads to its activation and oncogenic transformation [134, 135]. MYC 
negatively regulates P15 expression by inhibiting the P15 gene’s activator MIZ-1, resulting in 
P15 transcriptional repression [159]. Therefore, even though we observed demethylation 72 
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hours post treatment at the P15 promoter, P15 mRNA transcription could be inhibited by the 
activity of MYC, resulting in inconsistent changes in P15 expression. 
Overall these data demonstrated that saRNAs can induce demethylation of targeted genes and, 
in the presence of heavily methylated loci, other epigenetic modifications, as 5hmC could be 
evaluated.  
 
Figure 7 saRNAs mediated demethylation of the P15 promoter. a, Bisulfite sequencing analysis on 
KG1a DNA upon Mix treatment 48 and 72 hours after transfection. Upper panel shows schematic of 
the P15 locus and the P15 promoter-associated CGI. DNA methylation profile of FLUC and Mix 
samples is shown as lollipop representation, where black dots indicate methylated CpG dinucleotides 
whereas white dots unmethylated CpGs (bottom panel). Histogram shows percentage of demethylation 
48 hours post treatment, expressed as ratio of methylated (M) to unmethylated (UM) normalized to 
scramble control (FLUC). b, Bisulfite sequencing analysis on Raji DNA upon PR56-saRNA treatment, 
48 and 72 hours after transfection. Upper panel shows schematic of the P15 locus and the P15 promoter-
associated CGI. DNA methylation profile of FLUC and PR56 samples is shown as lollipop 
representation and can be interpreted as in b (bottom panel) (n  ≥ 13 clones). All bisulfite sequenced 












This study explores the role of a recent class of noncoding RNAs, the short activating RNAs 
(saRNAs) [86, 89, 93]. Using CEBPA and P15 as gene models, we want to investigate whether 
saRNAs, while re-activating gene transcription, are also able to induce DNA methylation 
changes thus acting as DNMT1-interacting RNAs mimicking molecules. To increase the 
chance of interaction between the saRNAs and DNMT1 enzyme, we synchronize all cell lines 
in G1/early S phase (Fig.1b and d, Fig.5b), when DNMT1’s activity peaks. 
 We show that the CEBPA-saRNA AW1-51 promotes CEBPA re-expression in A549 and K562 
cell lines (Fig.2a and b, left panels), suggesting its potential therapeutic role in lung cancer and 
leukemia, respectively. Importantly, we also show that CEBPA-saRNA induces transcription 
of the extra coding CEBPA (ecCEBPA), whose expression negatively correlates with 
methylation of the CEBPA promoter and, hence, positively associates with expression of the 
corresponding coding gene (Fig.2a and b, right panels) [54]. We also investigate DNA 
methylation profile of either cell lines upon saRNA treatment and we demonstrate that RNA 
activation (RNAa) induces changes in DNA methylation (Fig.3c and d). Though, in A549, 
where re-expression of coding and noncoding transcript significantly increases upon treatment, 
we do not observe an equal significant demethylation within the CEBPA promoter. This result 
can be explained by considering the basal methylation level of the CEBPA upstream promoter 
in A549 and the method we use to analyze DNA methylation profile.  
Promoter hypermethylation has been recognized as a hallmark of cancer and frequently marks 
promoter-associated CGIs of tumor suppressor genes [160, 161]. DNA methylation is an 
epigenetic feature of heterochromatinic structures, which, together with other regulatory 
mechanisms [162], contributes in determining genes transcription [163]. As a result, the higher 
is the methylation level within a promoter-associated CGI, the lower is the accessibility of the 
locus [164]. CEBPA upstream promoter is heavily methylated in A549, therefore longer 
treatment with saRNA might be necessary in order to observe a more significant demethylation. 
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DNA methylation shows heterogeneity across clones, either in A549 and K562, ranging from 
20 to 80% of demethylation compared to control (Fig.3c and d). In K562 the demethylating 
effect is also dependent on the CpGs’ location, closer to or further from the TSS of the locus 
(Fig.3d). It is therefore difficult to predict an accurate demethylating effect if saRNAs would 
be used in treatment of patients. However, in addition to longer treatment to potentiate the 
saRNA effect on DNA demethylation, it would be of great help the use of a single cell approach 
to analyze DNA methylation profile and evaluate clones distribution. Moreover, Li et al 
suggest that, in the presence of highly methylated loci as CDH1 in HeLa cells, the use of low 
doses of demethylating agents prior to saRNAs treatment will promote RNAa thus resulting in 
a more accessible locus and initial demethylation that might be maintained by saRNAs [86]. A 
similar trend is observed in KG1a cell line, where re-activation of the P15 mRNA is detected 
upon treatment with mix of all three saRNAs at 48, 72 and 96 hours post transfection (Fig.6b, 
left panel), but demethylation is observed only at 48 hours (Fig.7a). Indeed, as for CEBPA in 
A549, P15 promoter is highly methylated in KG1a cell line thus resulting in a very close gene 
locus and low-to-undetectable mRNA levels. Besides DNA methylation, more recent studies 
have highlighted DNA hydroxymethylation as epigenetic modification produced during active 
DNA demethylation and involved in transcriptional activation. As previously mentioned, 5-
hydroxymethylcytosine (5hmC), besides being a chemical intermediate, is also a stable DNA 
modification that is mainly found within actively transcribed genes. Indeed, 5hmC marks 
decrease in cancer cells thus suggesting its potential regulatory role [155]. Bisulfite sequencing 
PCR (BSP) is not able to discriminate between 5-methylcytosine (5mC) and 5hmC, therefore, 
by detecting only 5mC we might ignore essential information regarding DNA epigenetic 
modifications upon saRNAs treatment. To overcome limitations associated with bisulfite-
based methods, e.g. BSP, bisulfite-free techniques, able to distinguish 5mC and 5hmC, should 
be used [156-158].  
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Single-cell analysis is a powerful approach that allows detection of new and potentially 
unsurprising biological discoveries relative to traditional techniques based on bulk population. 
Tumor cells comprise heterogeneous populations showing distinct morphology, expression and 
epigenetic signatures [165, 166]. Some characteristics confer a selective advantage to the cell, 
such as more rapid growth, and the descendants of a cell bearing such a mutation will 
consequently become dominant within the tumor population. This phenomenon occurs also 
upon specific treatments as, for examples, saRNAs. saRNA-mediated re-activation of tumor 
suppressor genes, as P15, or transcription factors regulating terminal differentiation and cell 
cycle arrest, as CEBPA, represents a disadvantage for a cell. DNA methylation analysis on bulk 
population might overestimate methylated clones relative to demethylated ones, thus resulting 
in unmodified DNA methylation profile. In view of that, results shown in Fig.3c (A549) and 
in Fig.7a (KG1a) might represent methylated clones with selective advantage over 
unmethylated ones. Therefore, single clone selection will help to elucidate percentage of 
partially or fully unmethylated clones within the analyzed population.  
Strikingly, DNA methylation analysis in Raji cell line upon PR56-saRNA treatment 
demonstrates a significant decrease in DNA methylation level at 48 and 72 hours post 
transfection (Fig.7b), supporting our hypothesis that saRNAs affect, besides gene expression, 
also DNA methylation. However, we do not observe increase in P15 transcript expression at 
72 hours, as methylation data would suggest. Gene expression, other than by epigenetic marks, 
is regulated by transcription factors. Raji cell line contains the t(8;14) translocation, which 
leads to aberrant activation of the MYC oncogene [134, 167]. MYC negatively regulates P15 
expression by interacting with MIZ-1, whose activity is essential for transcriptional activation 
of the P15 locus [159]. Therefore, even though PR56-saRNA exerts a significant demethylating 
effect within the P15 promoter, transcriptional reactivation is antagonized by MYC, that limits 
P15 re-expression. Cells doubling time may also be considered in order to interpret the results. 
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Raji cells have a doubling time of about 18 hours, therefore, if DNMT1’s activity is impaired 
upon saRNA treatment, a demethylating effect might be detected by 48 hours post transfection, 
as we observed (Fig.7b). Besides DNA methylation profile, cell-cycle too regulates gene 
expression. A comprehensive study has systematically investigated the transcriptional 
landscape across cell-cycle, identifying different cell-cycle regulated genes and suggesting a 
lag between transcription and steady-state expression during the cycle of cells [168]. Ross et 
al, by exploring the expression of 8000 unique genes in 60 cell lines, concluded that gene 
expression pattern is related to physiological features of the cells, as their doubling time in 
culture [169]. Therefore, the discrepancy between gene re-expression and DNA demethylation 
in Raji can be attributed to the characteristics, as transcription factors accessibility and doubling 
time, of the cell line analyzed. 
The causal relationship between DNA methylation pattern and gene expression is not always 
obvious. While, in some contexts, DNA methylation and transcription are inversely related, in 
others they might have a direct correlation. In this regard, as already stated in the Introduction, 
DNA methylation has to be framed in the context of genomic location, resulting in a more 
complex scenario than expected [8]. Moreover, regulatory elements are tissue-specific, even 
within a promoter [170]. Therefore, considering the P15 locus and its complexity, DNA  
demethylation may occur in regions other than those analyzed in the study and might also be 
tissue-specific. Indeed, a comprehensive study has shown that differential methylation often 
occurred in regions surrounding the TSS of tissue-specific loci, as first exon [171].          
Besides direct and indirect correlation between DNA methylation and gene expression, even 
temporal relationship between the two events should be investigated. Pacis and colleagues 
demonstrate that, during infection with Mycobacterium tuberculosis, re-expression of specific 
genes in dendritic cells precedes active demethylation of regulatory elements [172], hence 
indicating that transcriptional activation itself contributes to DNA demethylation. Therefore, 
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longer treatment with saRNAs accompanied with longer time points would help unveiling 
mechanisms of demethylation that are difficult to observe otherwise.  
In cancer, either hyper- and hypomethylation play a role in silencing of tumor suppressor genes 
and in activating genes required for metastasis and invasion, respectively [173]. Therefore, the 
use of specific agent affecting DNA methylation profile is necessary in order to prevent off-
target effects. In this regard, current hypomethylating agents, as 5AC and DAC, regardless 
their efficacy, demonstrate significant unspecific and toxic effects which limit their clinical use 
[128-130]. Hence, saRNAs might represent a new therapeutic tool able to modify local DNA 
methylation profile of target genes. Aiming at evaluating genome-wide methylation effects 
upon saRNAs, we are currently analyzing data from Infinium MethylationEPIC arrays and 
RNA sequencing that will reveal unspecific demethylation and activation of pathways 
correlated to CEBPA and P15 expression, respectively.  
Besides gene expression, DNA methylation is essential in controlling mechanisms of splicing. 
[7]. Small nuclear RNA (snRNA) species play an important role in the splicing process and 
recognize the sequence, within the nascent RNA, constituting splice and branch site [174]. 
Therefore, in view of that, saRNAs, by interacting with DNMT1 and affecting DNA 
methylation, might prevent and/or repair wrongly spliced genes.  
Taken together, these data support the hypothesis that short activating RNAs participate in 
mechanisms of demethylation and pave the way for site-specific adjustments of aberrantly 





1. Deichmann, U., Epigenetics : The origins and evolution of a fashionable topic. Dev. 
Biol., 2016, 416, 249-254. 
2. Nicoglou, A. and F. Merlin, Epigenetics : A way to bridge the gap between biological 
fi elds. Stud. Hist. Philos. Biol. Biomed. Sci., 2017, 66, 73-82. 
3. Goldberg, A.D., C.D. Allis, and E. Bernstein, Epigenetics : A Landscape Takes 
Shape. Cell, 2007, 128, 635-638. 
4. Moris, N., C. Pina, and A.M. Arias, Transition states and cell fate decisions in 
epigenetic landscapes. Nat. Rev. Genet., 2016, 17, 693-703. 
5. Russo, V.E.A., R.A. Martienssen, and A.D. Riggs, in Epigenetic Mechanisms of Gene 
Regulation. 1996, CSHL Press. 
6. Bird, A., Perceptions of epigenetics. Nature, 2007, 447, 396-398. 
7. Tirado-Magallanes, R., et al., Whole genome DNA methylation: beyond genes 
silencing. Oncotarget, 2016, 8, 5629-5637. 
8. Jones, P.A. and D. Takai, The Role of DNA Methylation in Mammalian Epigenetics. 
Science, 2001, 293, 1068-1071. 
9. Illingworth, R.S. and A.P. Bird, CpG islands - 'A rough guide'. FEBS Lett., 2009, 583, 
1713-1720. 
10. Fazzari, M.J. and J.M. Greally, Epigenomics: beyond CpG islands. Nat Rev Genet, 
2004, 5, 446-455. 
11. Saxonov, S., P. Berg, and D.L. Brutlag, A genome-wide analysis of CpG 
dinucleotides in the human genome distinguishes two distinct classes of promoters. 
PNAS, 2006, 103, 1412-1417. 
12. Klose, R.J. and A.P. Bird, Genomic DNA methylation : the mark and its mediators. 
Trends Biochem. Sci., 2006, 31. 
13. Jones, P.A. and G. Liang, Rethinking how DNA methylation patterns are maintained. 
Nat Rev Genet, 2009, 10, 805-811. 
14. Jeltsch, A., et al., Mechanism and biological role of Dnmt2 in Nucleic Acid 
Methylation. RNA Biol., 2017, 14, 1108-1123. 
15. Goll, M.G., et al., Methylation of tRNAAsp by the DNA methyltransferase homolog 
Dnmt2. Science, 2006, 311, 395-398. 
16. Santi, Y.L.a.D.V., m5C RNA and m5C DNA methyl transferases use different 
cysteine residues as catalysts. PNAS, 2000, 97, 8263–8265. 
17. Chedin, F., M.R. Lieber, and C.L. Hsieh, The DNA methyltransferase-like protein 
DNMT3L stimulates de novo methylation by Dnmt3a. PNAS, 2002, 99, 16916-16921. 
18. Neri, F., et al., Dnmt3L antagonizes DNA methylation at bivalent promoters and 
favors DNA methylation at gene bodies in ESCs. Cell, 2013, 155, 121-134. 
19. Robertson, K.D., DNA methylation and chromatin – unraveling the tangled web. 
Oncogene, 2002, 21, 5361-5379. 
20. Yarychkivska, O., et al., BAH domains and a histone-like motif in DNA 
methyltransferase 1 (DNMT1) regulate de novo and maintenance methylation in vivo. 
J. Biol. Chem., 2018, 293, 19466-19475. 
21. Elliott, E.N., K.L. Sheaffer, and K.H. Kaestner, The 'de novo' DNA methyltransferase 
Dnmt3b compensates the Dnmt1-deficient intestinal epithelium. Elife, 2016, 5. 
22. Song, Y., et al., Dynamic Enhancer DNA Methylation as Basis for Transcriptional 
and Cellular Heterogeneity of ESCs. Mol. Cell, 2019, 75, 905-920.e906. 
77 
 
23. Liebl, K. and M. Zacharias, How methyl-sugar interactions determine DNA structure 
and flexibility. NAR, 2019, 47, 1132-1140. 
24. Skvortsova, K., et al., DNA Hypermethylation Encroachment at CpG Island Borders 
in Cancer Is Predisposed by H3K4 Monomethylation Patterns. Cancer Cell, 2019, 35, 
297-314.e298. 
25. Ollikainen, M., et al., Genome-wide blood DNA methylation alterations at regulatory 
elements and heterochromatic regions in monozygotic twins discordant for obesity 
and liver fat. Clin Epigenetics, 2015, 7, 39. 
26. Visone, R., et al., DNA methylation of shelf, shore and open sea CpG positions 
distinguish high microsatellite instability from low or stable microsatellite status 
colon cancer stem cells. Epigenomics, 2019, 11, 587-604. 
27. Irizarry, R.A., et al., The human colon cancer methylome shows similar hypo- and 
hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet., 2009, 
41, 178-186. 
28. Hellman, A. and A. Chess, Gene body-specific methylation on the active X 
chromosome. Science, 2007, 315, 1141-1143. 
29. Teissandier, A. and D. Bourc'his, Gene body DNA methylation conspires with 
H3K36me3 to preclude aberrant transcription. EMBO J., 2017, 36, 1471-1473. 
30. Arechederra, M., et al., Hypermethylation of gene body CpG islands predicts high 
dosage of functional oncogenes in liver cancer. Nat. Commun., 2018, 9, 3164. 
31. Sartor, R.C., et al., Identification of the expressome by machine learning on omics 
data. PNAS, 2019, 116, 18119-18125. 
32. Sleutels, F. and D.P. Barlow, The Origins of Genomic. Adv. Genet., 2002, 46, 119-
163. 
33. Gaszner, M. and G. Felsenfeld, Insulators: exploiting transcriptional and epigenetic 
mechanisms. Nat Rev Genet, 2006, 7, 703-713. 
34. Alasoo, K., et al., Shared genetic effects on chromatin and gene expression indicate a 
role for enhancer priming in immune response. Nat. Genet., 2018, 50, 424-431. 
35. Aran, D. and A. Hellman, DNA Methylation of Transcriptional Enhancers and Cancer 
Predisposition. Cell, 2013, 11-13. 
36. Tatetsu, H., et al., Down-regulation of PU.1 by methylation of distal regulatory 
elements and the promoter is required for myeloma cell growth. Cancer Res., 2007, 
67, 5328-5336. 
37. West, A.G., M. Gaszner, and G. Felsenfeld, Insulators : many functions , many 
mechanisms. Genes Dev., 2002, 16, 271-288. 
38. Wang, H., et al., Widespread plasticity in CTCF occupancy linked to DNA 
methylation. Genome Res., 2012, 22, 1680-1688. 
39. Bell, A.C. and G. Felsenfeld, Methylation of a CTCF-dependent boundary controls 
imprinted expression of the Igf2 gene. Nature, 2000, 405, 2-5. 
40. Rao, X., et al., CpG island shore methylation regulates caveolin-1 expression in breast 
cancer. Oncogene, 2013, 4519-4528. 
41. Mattick, J.S., Non-coding RNAs: the architects of eukaryotic complexity. EMBO 
reports, 2001, 2, 986–991. 
42. Goff, L.A. and J.L. Rinn, Linking RNA biology to lncRNAs. Genome Res, 2015, 25, 
1456-1465. 
43. Mattick, J.S. and J.L. Rinn, Discovery and annotation of long noncoding RNAs. Nat 
Struct Mol Biol, 2015, 22, 5-7. 
44. Ma, L., V.B. Bajic, and Z. Zhang, On the classification of long non-coding RNAs. 
RNA Biol, 2013, 10, 925-933. 
78 
 
45. Ulitsky, I. and D.P. Bartel, lincRNAs: genomics, evolution, and mechanisms. Cell, 
2013, 154, 26-46. 
46. Kopp, F. and J.T. Mendell, Functional Classification and Experimental Dissection of 
Long Noncoding RNAs. Cell, 2018, 172, 393-407. 
47. Da Rocha, S.T. and E. Heard, Novel players in X inactivation: insights into Xist-
mediated gene silencing and chromosome conformation. Nat Struct Mol Biol, 2017, 
24, 197-204. 
48. Chu, C., et al., Systematic discovery of Xist RNA binding proteins. Cell, 2015, 161, 
404-416. 
49. Chen, C.K., et al., Xist recruits the X chromosome to the nuclear lamina to enable 
chromosome-wide silencing. Science, 2016, 354, 468-472. 
50. Engreitz, J.M., et al., Local regulation of gene expression by lncRNA promoters, 
transcription and splicing. Nature, 2016, 539, 452-455. 
51. Groff, A.F., et al., In Vivo Characterization of Linc-p21 Reveals Functional cis-
Regulatory DNA Elements. Cell Rep, 2016, 16, 2178-2186. 
52. Guttman, J.R.a.M., RNA and dynamic nuclear organization. Science, 2014, 345. 
53. Fang, H., et al., Trans- and cis-acting effects of the lncRNA Firre on epigenetic and 
structural features of the inactive X chromosome. bioRxiv, 2019, 687236. 
54. Di Ruscio, A., et al., DNMT1-interacting RNAs block gene-specific DNA 
methylation. Nature, 2013, 503, 371-376. 
55. Kim, V.N., J. Han, and M.C. Siomi, Biogenesis of small RNAs in animals. Nat. Rev. 
Mol. Cell Biol., 2009, 10, 126-139. 
56. Romano, G., et al., Small non-coding RNA and cancer. Carcinogenesis, 2017, 38, 
485-491. 
57. Borchert, G.M., W. Lanier, and B.L. Davidson, RNA polymerase III transcribes 
human microRNAs. Nat Struct Mol Biol, 2006, 13, 1097-1101. 
58. Bartel, D.P., MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell, 
2004, 116, 281-297. 
59. Tuschl, G.M.a.T., Mechanisms of gene silencing by double-stranded RNA. Nature, 
2004, 431, 343-349. 
60. Chi, S.W., G.J. Hannon, and R.B. Darnell, An alternative mode of microRNA target 
recognition. Nat Struct Mol Biol, 2012, 19, 321-327. 
61. Carthew, R.W. and E.J. Sontheimer, Origins and Mechanisms of miRNAs and 
siRNAs. Cell, 2009, 136, 642-655. 
62. Lee, R.C., R.L. Feinbaum, and V. Ambros, The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75, 843-
854. 
63. Hwang, H.W., E.A. Wentzel, and J.T. Mendell, A hexanucleotide element directs 
microRNA nuclear import. Science, 2007, 315, 97-100. 
64. Catalanotto, C., C. Cogoni, and G. Zardo, MicroRNA in Control of Gene Expression: 
An Overview of Nuclear Functions. Int J Mol Sci, 2016, 17. 
65. Turunen, T.A., et al., Changes in nuclear and cytoplasmic microRNA distribution in 
response to hypoxic stress. Sci Rep, 2019, 9, 10332. 
66. Liu, H., et al., Nuclear functions of mammalian MicroRNAs in gene regulation, 
immunity and cancer. Mol Cancer, 2018, 17, 64. 
67. Morris, K.V., et al., Small Interfering RNA–Induced Transcriptional Gene Silencing 
in Human Cells. Science, 2004, 305, 1289-1291. 
68. Ting, A.H., et al., Short double-stranded RNA induces transcriptional gene silencing 




69. Karunanithi, S., et al., Exogenous RNAi mechanisms contribute to transcriptome 
adaptation by phased siRNA clusters in Paramecium. NAR, 2019, 47, 8036-8049. 
70. Watanabe, T., et al., Endogenous siRNAs from naturally formed dsRNAs regulate 
transcripts in mouse oocytes. Nature, 2008, 453, 539-543. 
71. Tam, O.H., et al., Pseudogene-derived small interfering RNAs regulate gene 
expression in mouse oocytes. Nature, 2008, 453, 534-538. 
72. Lai, K.O.a.E.C., Endogenous small interfering RNAs in animals. Nat. Rev. Mol. Cell 
Biol., 2008, 9, 673-678. 
73. Castanotto, D., et al., Short hairpin RNA-directed cytosine (CpG) methylation of the 
RASSF1A gene promoter in HeLa cells. Mol Ther, 2005, 12, 179-183. 
74. Sørensen, D.R., M. Leirdal, and M. Sioud, Gene Silencing by Systemic Delivery of 
Synthetic siRNAs in Adult Mice. Journal of Molecular Biology, 2003, 327, 761-766. 
75. Lam, J.K., et al., siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol 
Ther Nucleic Acids, 2015, 4, e252. 
76. Sui, H., et al., siRNA containing a unique 5-nucleotide motif acts as a quencher of 
IFI16-mediated innate immune response. Mol Immunol, 2019, 114, 330-340. 
77. Maillard, P.V., et al., Inactivation of the type I interferon pathway reveals long 
double-stranded RNA-mediated RNA interference in mammalian cells. EMBO J., 
2016, 35, 2505-2518. 
78. Luteijn, M.J. and R.F. Ketting, PIWI-interacting RNAs: from generation to 
transgenerational epigenetics. Nat Rev Genet, 2013, 14, 523-534. 
79. Kalmykova, A.I., M.S. Klenov, and V.A. Gvozdev, Argonaute protein PIWI controls 
mobilization of retrotransposons in the Drosophila male germline. NAR, 2005, 33, 
2052-2059. 
80. Khurana, J.S. and W. Theurkauf, piRNAs, transposon silencing, and Drosophila 
germline development. J Cell Biol, 2010, 191, 905-913. 
81. Castel, S.E. and R.A. Martienssen, RNA interference in the nucleus: roles for small 
RNAs in transcription, epigenetics and beyond. Nat Rev Genet, 2013, 14, 100-112. 
82. Ozata, D.M., et al., PIWI-interacting RNAs: small RNAs with big functions. Nat Rev 
Genet, 2019, 20, 89-108. 
83. Tan, L., et al., PIWI-interacting RNA-36712 restrains breast cancer progression and 
chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol 
Cancer, 2019, 18, 9. 
84. Fu, A., D.I. Jacobs, and Y. Zhu, Epigenome-wide analysis of piRNAs in gene-specific 
DNA methylation. RNA Biol, 2014, 11, 1301-1312. 
85. Portnoy, V., et al., Small RNA and transcriptional upregulation. Wiley Interdiscip Rev 
RNA, 2011, 2, 748-760. 
86. Li, L.-C., et al., Small dsRNAs induce transcriptional activation in human cells. 
PNAS, 2006, 103, 17337–17342. 
87. Wang, J., et al., Inducing gene expression by targeting promoter sequences using 
small activating RNAs. J Biol Methods, 2015, 2. 
88. Voutila, J., et al., Development and Mechanism of Small Activating RNA Targeting 
CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. Molecular Therapy, 
2017, 25, 2705-2714. 
89. Kuwabara, T., et al., A Small Modulatory dsRNA Specifies the Fate of Adult Neural 
Stem Cells. Cell, 2004, 116, 779–793. 
90. Jopling, C.L., et al., Modulation of hepatitis C virus RNA abundance by a liver-
specific MicroRNA. Science (New York, N.Y.), 2005, 309, 1577-1581. 
91. Place, F.R., et al., Defining Features and Exploring Chemical Modifications to 
Manipulate RNAa Activity. Curr Pharm Biotechnol, 2010, 11, 518-526. 
80 
 
92. Yi, R., et al., Exportin-5 mediates the nuclear export of pre-microRNAs and short 
hairpin RNAs. Genes Dev., 2003, 17, 3011-3016. 
93. Yoon, S. and J.J. Rossi, Therapeutic Potential of Small Activating RNAs (saRNAs) in 
Human Cancers. Curr Pharm Biotechnol, 2018, 19, 604-610. 
94. Porse, B.T., et al., Loss of C/EBP alpha cell cycle control increases myeloid 
progenitor proliferation and transforms the neutrophil granulocyte lineage. J Exp Med, 
2005, 202, 85-96. 
95. Smith, M.L., et al., Mutation of CEBPA in Familial Acute Myeloid Leukemia. The 
New England Journal of Medicine, 2004, 351, 2403–2407. 
96. Koschmieder, S., et al., Dysregulation of the C/EBPalpha differentiation pathway in 
human cancer. J Clin Oncol, 2009, 27, 619-628. 
97. Hughes, J.M., et al., C/EBPα-p30 protein induces expression of the oncogenic long 
non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget, 2015, 6. 
98. Muller, C., et al., Nucleolar retention of a translational C/EBPalpha isoform 
stimulates rDNA transcription and cell size. EMBO J., 2010, 29, 897-909. 
99. Gorgens, A., et al., Revision of the human hematopoietic tree: granulocyte subtypes 
derive from distinct hematopoietic lineages. Cell Rep, 2013, 3, 1539-1552. 
100. Paul, F., et al., Transcriptional Heterogeneity and Lineage Commitment in Myeloid 
Progenitors. Cell, 2015, 163, 1663-1677. 
101. Imperato, M.R., et al., The RUNX1-PU.1 axis in the control of hematopoiesis. Int J 
Hematol, 2015, 101, 319-329. 
102. Friedman, A.D., C/EBPalpha in normal and malignant myelopoiesis. Int J Hematol, 
2015, 101, 330-341. 
103. Ma, O., et al., Granulopoiesis requires increased C/EBPalpha compared to 
monopoiesis, correlated with elevated Cebpa in immature G-CSF receptor versus M-
CSF receptor expressing cells. PLoS One, 2014, 9, e95784. 
104. Zhang, D.-E., et al., Absence of granulocyte colony-stimulating factor signaling 
andneutrophil development in CCAAT enhancer binding protein a-deficient mice. 
PNAS, 1997, 94, 569–574,. 
105. Chim, C.S., A.S.Y. Wong, and Y.L. Kwong, Infrequent hypermethylation of CEBPA 
promotor in acute myeloid leukaemia. Br. J. Haematol., 2002, , 119 988–990. 
106. Hackanson, B., et al., Epigenetic modification of CCAAT/enhancer binding protein 
alpha expression in acute myeloid leukemia. Cancer Res., 2008, 68, 3142-3151. 
107. Poetsch, A.R. and C. Plass, Transcriptional regulation by DNA methylation. Cancer 
Treat Rev, 2011, 37 Suppl 1, S8-12. 
108. Lourenco, A.R. and P.J. Coffer, A tumor suppressor role for C/EBPalpha in solid 
tumors: more than fat and blood. Oncogene, 2017, 36, 5221-5230. 
109. LI, F., et al., Correlation of expression of transcription factor C/EBPa and surfactant 
protein genes in lung cells American Journal of Physiology, 1995, 269, 241-247. 
110. Halmos, B., et al., Down-Regulation and Antiproliferative Role of C/EBPa in Lung 
Cancer. Cancer Res., 2002, 62, 528–534. 
111. Tada, Y., et al., Epigenetic modulation of tumor suppressor CCAAT/enhancer binding 
protein alpha activity in lung cancer. J Natl Cancer Inst, 2006, 98, 396-406. 
112. Brown, V.L., et al., p16INK4a and p14ARF Tumor Suppressor Genes Are Commonly 
Inactivated in Cutaneous Squamous Cell Carcinoma. Journal of Investigative 
Dermatology, 2004, 122, 1284-1292. 
113. Holdt, L.M. and D. Teupser, Long Noncoding RNA ANRIL: Lnc-ing Genetic 
Variation at the Chromosome 9p21 Locus to Molecular Mechanisms of 
Atherosclerosis. Front Cardiovasc Med, 2018, 5, 145. 
81 
 
114. Pasmant, E., et al., Characterization of a germ-line deletion, including the entire 
INK4/ARF locus, in a melanoma-neural system tumor family: identification of 
ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer 
Res., 2007, 67, 3963-3969. 
115. Fuxe, J., E. Raschperger, and R.F. Pettersson, Translation of p15.5INK4B, an N-
terminally extended and fully active form of p15INK4B, is initiated from an upstream 
GUG codon. Oncogene 2000 19, 1724-1728. 
116. Tien, H.-F., et al., Methylation of the p15INK4B gene in myelodysplastic syndrome: 
it can be detected early at diagnosis or during disease progression and is highly 
associated with leukaemic transformation. Br. J. Haematol., 2001, 112, 148-154. 
117. Pavletich, N.P., Mechanisms of Cyclin-dependent Kinase Regulation: Structures of 
Cdks, their Cyclin Activators, and Cip and INK4 Inhibitors. Journal of Molecular 
Biology, 1999, 287, 821-828. 
118. Wolff, L. and J. Bies, p15Ink4b Functions in determining hematopoietic cell fates: 
implications for its role as a tumor suppressor. Blood Cells Mol Dis, 2013, 50, 227-
231. 
119. Teofili, L., et al., Expression of p15ink4b gene during megakaryocytic differentiation 
of normal and myelodysplastic hematopoietic progenitors. Blood, 2001, 98, 495-497. 
120. Kusy, S., C.J. Larsen, and J. Roche, p14ARF, p15INK4b and p16INK4a methylation 
status in chronic myelogenous leukemia. Leuk Lymphoma, 2004, 45, 1989-1994. 
121. Teofili, L., et al., Expression of cyclin-dependent kinase inhibitor p15INK4B during 
normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 
519–526. 
122. Figueroa, M.E., et al., MDS and secondary AML display unique patterns and 
abundance of aberrant DNA methylation. Blood, 2009, 114, 3448-3458. 
123. Fares, J., L. Wolff, and J. Bies, CDKN2B (cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 
2012. 
124. Latres, E., et al., Limited overlapping roles of P15INK4b and P18INK4c cell cycle 
inhibitors in proliferation and tumorigenesis. The EMBO Journal, 2000, 19, 3496-
3506. 
125. Rosu-Myles, M., B.J. Taylor, and L. Wolff, Loss of the tumor suppressor p15Ink4b 
enhances myeloid progenitor formation from common myeloid progenitors. Exp 
Hematol, 2007, 35, 394-406. 
126. Bies, J., et al., Myeloid-specific inactivation of p15Ink4b results in monocytosis and 
predisposition to myeloid leukemia. Blood, 2010, 116, 979-987. 
127. Mehdipour, P., T. Murphy, and D.D. De Carvalho, The role of DNA-demethylating 
agents in cancer therapy. Pharmacol Ther, 2019, 107416. 
128. Diesch, J., et al., A clinical-molecular update on azanucleoside-based therapy for the 
treatment of hematologic cancers. Clin Epigenetics, 2016, 8, 71. 
129. Shen, H. and P.W. Laird, In epigenetic therapy, less is more. Cell Stem Cell, 2012, 10, 
353-354. 
130. Kelly, T.K., D.D. De Carvalho, and P.A. Jones, Epigenetic modifications as 
therapeutic targets. Nat Biotechnol, 2010, 28, 1069-1078. 
131. Reebye, V., et al., Gene activation of CEBPA using saRNA: preclinical studies of the 
first in human saRNA drug candidate for liver cancer. Oncogene, 2018, 37, 3216-
3228. 
132. Voutila, J., et al., Gene Expression Profile Changes After Short-activating RNA-
mediated Induction of Endogenous Pluripotency Factors in Human Mesenchymal 
Stem Cells. Mol Ther Nucleic Acids, 2012, 1, e35. 
82 
 
133. Perrotti, D., et al., BCR-ABL suppresses C/EBPalpha expression through inhibitory 
action of hnRNP E2. Nat. Genet., 2002, 30, 48-58. 
134. Masauzi, N., et al., A translocation t(8;14) and c-myc gene rearrangement associated 
with the histological transformation of B-cell acute lymphocytic leukemia (FAB-L2) 
into Burkitt's type (FAB-L3) leukemia. Leuk Lymphoma, 1997, 27, 357-363. 
135. Karpova, M.B., et al., Raji revisited: cytogenetics of the original Burkitt's lymphoma 
cell line. Leukemia, 2005, 19, 159-161. 
136. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001, 25, 402-
408. 
137. Frommer, M., et al., A genomic sequencing protocol that yields a positive display of 
5-methylcytosine residues in individual DNA strands. PNAS, 1992, 89, 1827-1831. 
138. Li, Y. and T.O. Tollefsbol, DNA methylation detection: bisulfite genomic sequencing 
analysis. Methods Mol. Biol., 2011, 791, 11-21. 
139. Xiong, Z. and P.W. Laird, COBRA : a sensitive and quantitative DNA methylation 
assay. NAR, 1997, 25, 2532-2534. 
140. Banfalvi, G., Overview of cell synchronization. Methods Mol. Biol., 2011, 761, 1-23. 
141. Ma, H.T. and R.Y. Poon, Synchronization of HeLa cells. Methods Mol. Biol., 2011, 
761, 151-161. 
142. Xeros, N., Deoxyriboside Control and Synchronization of Mitosis. Nature, 1962, 194, 
682-683. 
143. Bjursell, G.a.R., P., Effects of Thymidine on Deoxyribonucleoside Triphosphate 
Pools and Deoxyribonucleic Acid Synthesis in Chinese Hamster Ovary Cells. Journal 
of Biological Chemistry, 1973, 248, 3904-3909. 
144. Reebye, V., et al., Novel RNA oligonucleotide improves liver function and inhibits 
liver carcinogenesis in vivo. Hepatology, 2014, 59, 216-227. 
145. Koschmieder, S., et al., CDDO induces granulocytic differentiation of myeloid 
leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding 
protein alpha. Blood, 2007, 110, 3695-3705. 
146. Radomska, H.S., et al., CAAT/Enhancer Binding Protein Alpha Is a Regulatory 
Switch Sufficient for Induction of Granulocytic Development from Bipotential 
Myeloid Progenitors. MOLECULAR AND CELLULAR BIOLOGY, 1998, 4301-4314. 
147. Leonhardt, H., et al., A targeting sequence directs DNA methyltransferase to sites of 
DNA replication in mammalian nuclei. Cell, 1992, 71, 865-873. 
148. Preker, P., et al., RNA Exosome Depletion Reveals Transcription Upstream of Active 
Human Promoters. Science, 2008, 322, 1851-1854. 
149. Ebisuya, M., et al., Ripples from neighbouring transcription. Nat Cell Biol, 2008, 10, 
1106-1113. 
150. Herman, J.G., et al., Hypermethylation-associated Inactivation Indicates a Tumor 
Suppressor Role for p15INK4B1. Cancer Res., 1996, 56, 722-727. 
151. Martel, V., et al., De novo methylation of tumour suppressor genes CDKN2A and 
CDKN2B is a rare finding in B-cell chronic lymphocytic leukaemia. British Journal 
of Haematology, , 1997, 99, 320–324. 
152. Cameron, E.E., et al., Synergy of demethylation and histone deacetylase inhibition in 
the re-expression of genes silenced in cancer. Nat. Genet., 1999, 21, 103-107. 
153. Arya, A.K., et al., Promoter hypermethylation inactivates CDKN2A, CDKN2B and 
RASSF1A genes in sporadic parathyroid adenomas. Sci Rep, 2017, 7, 3123. 
154. Malumbres, M., et al., Hypermethylation of the cell cycle inhibitor p15INK4b 3'-
untranslated regioninterferes with its transcriptional regulation in primary 
lymphomas. Oncogene, 1999, 18, 385-396. 
83 
 
155. Bachman, M., et al., 5-Hydroxymethylcytosine is a predominantly stable DNA 
modification. Nat. Chem., 2014, 6, 1049-1055. 
156. Liu, Y., et al., Bisulfite-free direct detection of 5-methylcytosine and 5-
hydroxymethylcytosine at base resolution. Nat. Biotechnol., 2019, 37. 
157. Skvortsova, K., et al., Comprehensive evaluation of genome ‑ wide 5 ‑ 
hydroxymethylcytosine profiling approaches in human DNA. Epigenetics Chromatin, 
2017, 10:16, 1-20. 
158. Song, C.-X., et al., Simultaneous single-molecule epigenetic imaging of DNA 
methylation and hydroxymethylation. PNAS, 2016, 3-8. 
159. Staller, P., et al., Repression of p15INK4b expression by Myc through association 
with Miz-1. Cell Bio., 2001, 3. 
160. Esteller, M., CANCER EPIGENETICS: DNA METHYLATION AND CHROMATIN 
ALTERATIONS IN HUMAN CANCER, in New Trends in Cancer for the 2/" Century, 
L.-B.a. Felipo, Editor. 2003, Kluwer Academic/Plenum Publishers. p. 39-49. 
161. Watanabe, Y. and M. Maekawa, Methylation of DNA in Cancer. 2010. p. 145-167. 
162. Baylin, S.B., DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol., 
2005, 2, 4-11. 
163. Vignaux, P.A., C. Bregio, and N.A. Hathaway, Contribution of promoter DNA 
sequence to heterochromatin formation velocity and memory of gene repression in 
mouse embryo fibroblasts. PLoS One, 2019, 14, e0217699. 
164. Liu, G., et al., Inherited DNA methylation primes the establishment of accessible 
chromatin during genome activation. Genome Res, 2018, 28, 998-1007. 
165. Hwang, B., J.H. Lee, and D. Bang, Single-cell RNA sequencing technologies and 
bioinformatics pipelines. Exp Mol Med, 2018, 50, 96. 
166. Gross, A., et al., Technologies for Single-Cell Isolation. Int J Mol Sci, 2015, 16, 
16897-16919. 
167. Haluska, F.G., et al., The t(8;14) chromosomal translocation occurring in B-cell 
malignancies results from mistakes in V-D-J joining. Nature, 1986, 324, 158-161. 
168. Liu, Y., et al., Transcriptional landscape of the human cell cycle. PNAS, 2017, 114, 
3473-3478. 
169. Douglas T. Ross, U.S., Michael B. Eisen, Charles M. Perou, Christian Rees, Paul 
Spellman, Vishwanath Iyer, Stefanie S. Jeffrey, Matt Van de Rijn, Mark Waltham, 
Alexander Pergamenschikov, Jeffrey C.F. Lee, Deval Lashkari, Dari Shalon, Timothy 
G. Myers, John N. Weinstein, David Botstein &Patrick O. Brown, Systematic 
variation in gene expression patterns in human cancer cell lines. Nat. Genet., 2000, 
24. 
170. Suh, H.C., et al., LPS independent activation of the pro-inflammatory receptor Trem1 
by C/EBPepsilon in granulocytes. Sci Rep, 2017, 7, 46440. 
171. Hodges, E., et al., Directional DNA methylation changes and complex intermediate 
states accompany lineage specificity in the adult hematopoietic compartment. Mol. 
Cell, 2011, 44, 17-28. 
172. Pacis, A., et al., Gene activation precedes DNA demethylation in response to infection 
in human dendritic cells. PNAS, 2019, 116, 6938-6943. 
173. Szyf, M., P. Pakneshan, and S.A. Rabbani, DNA demethylation and cancer: 
therapeutic implications. Cancer Lett, 2004, 211, 133-143. 






The Bright and Dark Side of DNA Methylation:
A Matter of Balance
Marta Borchiellini 1,2, Simone Ummarino 3,* and Annalisa Di Ruscio 2,3,*
1 Department of Health Sciences, University of Eastern Piedmont, 28100 Novara, Italy;
marta.borchiellini@uniupo.it
2 Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy
3 Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA
* Correspondence: summarin@bidmc.harvard.edu (S.U.); adirusci@bidmc.harvard.edu (A.D.R.);
Tel.: +1-617-735-2228 (S.U.); +1-617-735-2218 (A.D.R.)
Received: 20 September 2019; Accepted: 10 October 2019; Published: 12 October 2019


Abstract: DNA methylation controls several cellular processes, from early development to old age,
including biological responses to endogenous or exogenous stimuli contributing to disease transition.
As a result, minimal DNA methylation changes during developmental stages drive severe phenotypes,
as observed in germ-line imprinting disorders, while genome-wide alterations occurring in somatic
cells are linked to cancer onset and progression. By summarizing the molecular events governing
DNA methylation, we focus on the methods that have facilitated mapping and understanding of this
epigenetic mark in healthy conditions and diseases. Overall, we review the bright (health-related)
and dark (disease-related) side of DNA methylation changes, outlining how bulk and single-cell
genomic analyses are moving toward the identification of new molecular targets and driving the
development of more specific and less toxic demethylating agents.
Keywords: epigenetics; DNA methylation; DNMTs; imprinting; cancer
1. DNA Methylation: More than One Purpose
DNA methylation is a key epigenetic signature (Box 1, Figure 1) implicated in regulation of
gene expression that occurs predominantly within CpG dinucleotides [1–6]. CpG dinucleotides are
under-represented in the mammalian genome (1%), but tend to cluster in CpG-rich regions called
CpG islands (CGIs), located in the proximity of the transcription start sites (TSSs) of the majority
(70%) of human protein-coding genes [7,8]. CGIs are stretches of DNA sequences of 200 nucleotides or
greater [9], with the GC ratio observed/expected to be greater than 0.6. Although the bulk of genome is
methylated at 70–80% of its CpGs, CGIs are mostly unmethylated in somatic cells [9,10].
DNA methylation is mediated by members of the DNA methyltransferase (DNMT) family that
can covalently transfer a methyl group (CH3) from the universal donor S-adenosyl-L-methionine
(SAM) to the carbon 5-position of the cytosine ring. Conventionally, DNMTs are classified as de novo
(DNMT3a and DNMT3b) or maintenance (DNMT1) enzymes [11]. Of note, DNMT2, a member of
the methyltransferase family, catalyzes methylation of RNA at position 38 in tRNAAsp GUC [12–14]
(Figure 2). DNMT3-like (DNMT3L) is a DNMT3-associated protein lacking an enzymatic domain and
interacting with DNMT3a/3b to modulate its activity [15,16]. In mice, Dnmt1 and Dnmt3b are essential
for embryonic development, as DNA methylation changes dramatically. An overall demethylation
after fertilization is followed by de novo methylation of discrete regions upon implantation [17].
Dnmt1 knockout mice show early lethality at embryonic day (E) 9.5, whereas Dnmt3b depletion induces
death at E 14.5–18.5, due to developmental impairment. On the contrary, Dnmt3a knockout mice do
not display defects in embryonic development, but they do die at 4 weeks of age. Although this binary
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classification is convenient, the function of the de novo and maintenance DNMTs overlaps in many
instances [18–20].
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Figure 2. Schematic representation of the methylation reaction catalyzed by the DNA methyltransferases
(DNMTs) (adapted from [14]). Shown are the mechanisms proposed for methylation of cytosine by
DNMT1, 3a and 3b on DNA (upper left panel) or by DNMT2 on RNA (lower left panel). Briefly, a thiol
group (SH) from the binding site of the enzyme provides the nucleophilic attack to position 6 of the
cytosine heterocycle, to activate position 5 towards one-carbon transfer (I). The methyl group on position
5 is donated by the coenzyme AdoMet (II). A proton in position 5 of the 5,6-dihydropyrimidine is then
removed (II–III), and a consequent β-elimination generate 5-methylcitosyne and free enzyme (IV).
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Box 1. History of epigenetics.
The term epigenetics was originally coined in the 17th century by the physician and physiologist William
Harvey to indicate the gradual development of the embryo from a homogeneous to a heterogeneous material,
referred to as “epigenesis” [1]. Later on, in the 1940s, Conrad Waddington used the term “epigenetics” to explain
the relationship between the genotype, defined as the whole genetic system of an organism, and the phenotype,
indicating the entire set of characteristics that an organism develops over time [2]. Waddington established
the first causal relationship between genes and their outcomes by introducing the concept of the “epigenetic
landscape” as “the various developmental pathways that undifferentiated cells (sharing identical genotype)
might take toward differentiation” (Figure 1) [3]. In other words, he described how the static information written
in the form of nucleotide sequences is dynamically translated into tissues and organs, thus driving cell fate
decisions [4]. In the last two decades, the definition of epigenetics has evolved from “the study of mitotically
and/or meiotically heritable changes in gene function that cannot be explained by changes in DNA sequence” [5]
to “the structural adaptation of chromosomal regions so as to register, signal or perpetuate altered activity states”,
which is inclusive of all the stable or transient chromosomal markers arising in response to different stimuli [6].
A number of studies have shown that DNA methylation is not randomly distributed across the
genome, but displays regional specificity [21]. Methyl groups promote conformational changes in
the major groove of DNA, thus altering protein-DNA binding [22] and, as a result, gene expression.
Most studies have initially focused on the effect of CGI methylation within the promoter and TSS of
protein-coding genes. Recently [23], however, more comprehensive genome-wide methylation analyses
have started elucidating the role of DNA methylation at CpG clusters within exons, introns, and
intergenic sequences, expanding on the previous knowledge of CGIs and leading to the identification
of CG shores (regions up to 2 kb from CGI), shelves (regions from 2 to 4 kb from CGI), and open sea
(the rest of the genome) regions [24–26].
Hence, DNA methylation needs to be framed in the context of the genomic location. As a
proof of concept, methylation of TSS-associated CGIs negatively correlates with gene expression,
leading to long-term gene silencing [7], whilst gene-body methylation positively correlates to gene
expression [27–30]. Another interesting finding emerging from bulk methylome studies is that
non-CGI-CpGs are mostly methylated and therefore less stable than CGIs, due to the tendency of
5-methylcytosine (5mC) to undergo spontaneous or enzymatic deamination to T [31]. The C-to-T
transition causes germ-line or somatic mutations, resulting in the depletion of CpGs dinucleotides in
the human genome. Methylation at other genomic regions, such as enhancers and insulators, does not
follow a specific pattern and may vary in different settings. Enhancers and insulators are long-range
regulatory elements able to alter gene expression or protect gene promoters from inappropriate
signals, respectively [32,33]. Aran et al. have shown that distal methylation sites in estrogen receptor
(ER)-positive breast tumors associates with breast cancer-related gene expression better than promoter
methylation [34]. Moreover, Tatetsu et al. demonstrated that aberrant methylation of the 17-kb 5′
upstream enhancer of PU.1 is required for myeloma cell growth [35]. Insulators are bifunctional instead,
acting either as a blocking enhancer, by preventing enhancer-mediated transcription, or as barriers,
by limiting the advance of nearby heterochromatin that would otherwise silence expression [36].
CCCTC-binding factor (CTCF), an enhancer-blocking protein, does not bind to its DNA consensus
sequence if methylated, as demonstrated for the imprinted IGF2-H19 locus and the CD45 gene [37].
It follows that DNA methylation can regulate gene expression indirectly by controlling access of
enhancers to gene promoters [38]. Finally, CGI shores, with a lower CpG density, have recently
emerged as critical regulatory elements affecting gene expression depending on their DNA methylation
profile [39].
This review will address the impact of cutting-edge next-generation sequencing technologies on
our perception and interpretation of DNA methylation in health conditions and diseases.
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2. DNA Methylation Analysis: Think Globally, Act Locally
DNA methylation has a crucial role in various biological processes, such as development,
differentiation, and gene expression [40–42]. Thus, comprehensive mapping becomes critical for
addressing the functional role of this modification [43]. Various strategies have been developed
to differentiate methylated and non-methylated C residues [44]. The initial lack of genome-wide
approaches has restricted DNA methylation profiling to gene-specific evaluation using polymerase chain
reaction (PCR) amplification of the target sequence. As DNA polymerases do not discriminate between
C and 5mC, all potential differences in methylation are lost during classical PCR amplification [44,45].
To overcome this challenge, Frommer et al. developed a locus-specific method based on DNA treatment
with sodium-bisulfite (SB) that leads to the conversion of all unmodified cytosine to uracil [45].
5mC are resistant to deamination induced by SB, and are preserved during the PCR amplification
by primers designed on the converted DNA. The resulting product is then analyzed by Sanger
sequencing. Although very laborious, bisulfite sequencing PCR (BSP) is considered the gold standard
to quantitatively study gene-locus specific DNA methylation [46].
The possibility to interrogate the entire genome using next generation sequencing technologies
has expanded DNA methylation analyses [47]. The application of massive parallel sequencing
to bisulfite-treated DNA has resulted in new genome-scale and -wide protocols, such as reduced
representation bisulfite sequencing (RRBS) and whole genome bisulfite sequencing (WGBS), respectively.
RRBS uses MspI, a methylation insensitive enzyme, to produce small fragments with CpG dinucleotides
at both ends. Digested products are bisulfite converted and then sequenced [48]. Even though RRBS
is more capable of covering a higher number of CpG loci within a given region than array-based
techniques [47,49], the coverage across corresponding CpG-rich sequences might change among the
samples tested, therefore introducing higher inter-sample variability and altering reproducibility [50].
As RRBS is biased for CpG-rich regions, such as CGIs, the coverage drops for CG shores, shelves, and
open sea regions [50].
WGBS couples bisulfite-conversion of genomic DNA with high-throughput sequencing [51]
and therefore provides a comprehensive and quantitative analysis of DNA methylome at single
nucleotide resolution, without relying on restriction enzyme enrichment. Until few years ago, the high
amount of DNA required as input, as well as the cost, limited its use. The recent advancement in
sequencing platforms and sample preparation have now made WGBS more accessible and feasible,
especially cost-wise, to allow projects with large sample sizes [52].
Likewise, non-bisulfite-based methods have also benefited from the introduction of
high-throughput sequencing platforms. For example, immunoprecipitation of methylated DNA with an
antibody recognizing 5mC residues coupled with sequencing (methylated DNA immunoprecipitation
sequencing [MeDIP-Seq]) [47], is commonly used as an alternative approach to RRBS (Box 2).
MeDIP-Seq covers a higher number of regions than those normally screened by RRBS, but its
efficiency is based on the specificity of the antibody, which can be biased toward hypermethylated
sequences. Yet, neither RRBS nor MeDIP-Seq can determine the profile of virtually all CpG dinucleotides
throughout the genome. Therefore, WGBS is considered the gold standard for full methylome
analysis. More recently, the establishment of enzymatic methyl-Seq (EM-Seq), has added another
free-bisulfite-based method to profile the entire methylome in instances when BS treatment is not
suitable (i.e., fragmented DNA) or the DNA input is too low. EM-Seq relies on two sequential enzymatic
reactions protecting 5mC and 5hmC from downstream deamination. The enzymatically converted
DNA can then be processed for sequencing similar to WGBS [53].
Despite their sensitivity, all bulk sequencing methods are unable to dissect intra-cellular and
intra-tumoral epigenetic heterogeneity within a specific cell population [54]. Single-cell technology
has emerged as an invaluable tool to ascertain this heterogeneity [55]. WGBS and RRBS protocols
have been optimized to carry out single-cell bisulfite sequencing (scBS) and single-cell RRBS (scRRBS),
respectively [56]. While scBS is able to cover a higher number of CpG sites than scRRBS, the latter
enables a better coverage of CGIs [57] (Figure 3).























































































Figure 3. Workflows of bisulfite and non-bisulfite-based methods applied to either bulk- or single—cell
population for DNA methylation analyses. On the left hand-side, bulk-bisulfite-based methods:
bisulfite sequencing PCR (BSP), reduced representation bisulfite sequencing (RRBS), and whole
genome bisulfite sequencing (WGBS). Following bulk-non-bisulfite-based methods: methylated DNA
immunoprecipitation sequencing (MeDIP-Seq) and enzymatic methyl sequencing (EM-Seq), in which
an enzymatic reaction protects [
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Notably, these new approaches are shedding light on the impact of epigenetic alterations in
specific cellular subsets with respect to developmental processes and cancer, filling the gaps arising
from bulk studies [58].
Box 2. More about sodium bisulfite treatment.
Although bisulfite sequencing approaches are considered the gold standard for DNA methylation analysis,
all bisulfite-based methods share common limitations. Sodium bisulfite is a harsh chemical treatment that
degrades template DNA, thus producing a poor quality product. An incomplete conversion of cytosine to
uracil may also introduce artifacts into the analysis [59]. In addition, bisulfite-based methods are not able to
discriminate between 5-methylcitocine (5mC) and its oxidative derivative 5-hydroxymethylcytosine (5hmC),
produced by the ten-eleven translocation (TET) family of dioxygenases during active DNA demethylation.
Other than being a chemical intermediate, 5hmC is a stable DNA modification that binds to specific regulatory
proteins and is mainly found within actively transcribed genes. 5hmC marks a decrease in cancer tissues,
suggesting its potential regulatory role in the mammalian genome [60]. To overcome the limitations associated
with bisulfite-based approaches, new bisulfite-free techniques [47,59] have been developed that preserve genomic
DNA integrity, as well as other strategies able to distinguish 5mC and 5hmC marks [61,62].
3. DNA Methylation in Health: A Matter of Location and Timing
DNA methylation plays a critical role in the regulation of early development in humans and
other mammals. In contrast to DNA sequences, DNA methylation is not inherited from gametes,
as the parental DNA methylation pattern is erased at an early embryo stage [63]. During implantation,
the DNA methylation profile is re-established, and the entire genome undergoes de novo methylation
with the exclusion of CpG island-like regions, which elude this epigenetic modification due to the
presence of RNA polymerase complexes that prevent access of de novo methylation machinery to the
DNA. The resulting bimodal pattern is conserved throughout development and preserved for the
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whole lifespan of the organism unless unexpected alterations [64,65]. Yet, a group of genes, so-called
“imprinted” genes, can escape this extensive reprogramming process occurring during embryonic
development. Genomic imprinting is defined as the monoallelic, parental-specific expression of a
gene in diploid cells, and as such, it is considered a form of gene regulation. Imprinted genes are
epigenetically marked, i.e., “imprinted”, within differentially methylated regions (DMRs) in gametes,
and such imprints are conserved after fertilization [66]. As a result, only one parental copy of the
imprinted gene will be expressed, whereas the other copy will be silenced by DNA methylation [67–69].
The human insulin-like growth factor II (IGF-II)/H19 region is an example of paternally imprinted gene,
in which methylation of the imprinting control sequence (ICR) regulates binding of the CTCF [70,71].
In mammals, the majority of imprinted genes affects growth of the embryo, placenta, and neonate.
In that regard, paternally imprinted genes function as growth enhancers, whereas maternally imprinted
genes function as growth repressors [72]. The loss of maternal DNA methyltransferases results in
post-implantation lethality [16,72], suggesting the essential role of genomic imprinting in embryonic
development and differentiation. Another category of imprinted genes include those involved in
neurologic and behavioral regulation [73].
DNA methylation also partakes in protecting the structural integrity of the genome. It has been
proposed that methylation of CpGs within parasitic DNA elements and retrotransposons, which account
for 40% of the entire genome, operates as a genome defense system, in order to prevent the expression
of these elements and preserve genomic stability [74].
Another puzzling and intriguing matter is whether the dynamic changes observed in response to
biological and non-biological stimuli are paralleled by DNA methylation changes during the different
phases of the cell cycle in physiological conditions. Substantial data with respect to this question are
still lacking, and the few reported studies do not seem to agree with one another. Single-cell RNA
sequencing results from murine embryonic stem cells (mESCs) point to a higher methylation rate
in G1/S compared to other phases of the cycle, in line with previous observations in HeLa cells and
human primary foreskin fibroblasts [75,76]. Similarly, Desjorbet et al. have demonstrated that the
inheritance of DNA methylation marks efficiently occurs in late S phase, and cytosine methylation is
completed in G2/M phase [77]. However, a different study analyzing DNA methylation levels in G0,
G1, and G2 phases in low passage primary dermal fibroblasts did not confirm these cell cycle changes
in DNA methylation patterns [78]. The specific cell type interrogated, along with not including the S
phase in the analysis, could possibly account for these contrasting results, since hemi-methylated DNA
sequences are challenging to evaluate with low coverage sequencing. Further analyses will need to
delve into this question.
4. DNA Methylation and Disease: Too Little, too Much, or Both?
Given its critical role in many biological processes, it is not surprising that dysregulation of
DNA methylation is frequently linked to either germ-line or somatic diseases [79,80]. The study of
monozygotic (MZ) twins has offered an exceptional tool to investigate the contribution of the epigenetic
load to phenotypic variations, including predisposition to pathological conditions, in individuals with
identical genetic background [81–84]. MZ twin studies have shown in many instances that phenotypic
variations can be ascribed to differences in DNA methylation [84]. Following up, studies from the
recent NASA research on MZ twins demonstrated that global DNA methylation was altered in response
to different environmental stimuli, namely the absence of gravity for the one subject who was sent
into space, versus the gravity the sibling who remained on earth was exposed to, affecting specific
pathways transiently or permanently [85] (Box 3).
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Box 3. Environmental factors “another variation on the theme”.
Major clues have been brought about by the evidence that the environment and environmental factors can
profoundly affect DNA methylation. To list few examples, prenatal or chronic exposure to chemicals, including
air pollution and tobacco smoke, or drugs associated with either global or site-specific DNA methylation
alterations [86,87]. Nutritional elements, also considered under environmental factors, can impact developmental
programming and result in later-life health outcomes [86,87]. Furthermore, prenatal and early life social
conditions might lead to DNA methylation alterations involving immune functions and inflammatory pathways.
Maternal depression in the prenatal period can affect DNA methylation of the brain-derived neurotrophic factor
(BDNF) and maternal anxiety can induce loss of methylation in the IGF2/H19 locus [71].
4.1. Germ-Line Associated Diseases
Epimutations within DMRs of imprinting genes are responsible for up to 50% of imprinting
diseases (IDs), leading to alteration in the imprinted gene dosage. Defects in DNA methylation, as
hyper- or hypomethylation, mainly localize within specific DMRs of the imprinted gene, and epigenetic
mutations at further DMRs can account for the severity and outcome of the pathology [88]. Examples of
IDs are Silver-Russell syndrome, displaying hypomethylation of the paternally imprinted locus
H19/IGF2 in the 11p15 region, together with other alterations at chromosome 7 and 11 [89–92], Fragile X
syndrome, most commonly caused by a trinucleotide repeat expansion “CGG”, within the promoter of
the fragile X mental retardation 1 protein (FMR1), which leads to aberrant DNA methylation and gene
silencing [93–95], and Angelman syndrome, with a frequency of 2–3%, caused by an imprinting defect
in the expression of maternally expressed 15q11-q13 genes. Additional examples of IDs are listed in
Table 1.
Table 1. List of the best-known imprinting diseases and associated epigenetic lesions.
Imprinting Diseases Epigenetic Lesions Reference
Transient Neonatal Diabetes
Mellitus Type 1 (TNDM1)
Hypomethylation of the maternally imprinted genes
PLAGL1 and HYMAI [96,97]
Silver-Russell Syndrome Hypomethylation of the paternally imprinted locusH19/IGF2 and promoter hypomethylation of HOXA4 [91,92]
Beckwith-Wiedemann Imprinting defects within two imprinted domains,IGF2/H19 and CDKN1C/KCNQ1OT1 [98,99]
Fragile X Syndrome De novo methylation of the FMR1 gene [93,95]
Angelman Syndrome Imprinting defects within chromosome 15q11-q13 thatalter the expression of the maternally inherited UBE3A [100,101]
Prader-Willi Syndrome Loss of expression of the paternally inheritedchromosome 15q11.2-q13 due to imprinting defects [102,103]
Pseudohypoparathyroidism Epigenetic defects in the imprinted GNAS cluster onchromosome 20q13.3 [104,105]
4.2. Somatic Diseases
According to the “two-hits” model of cancer proposed by Knudson in 1971, a dominantly inherited
germ-line mutation (first hit) and a second somatic mutation (second hit) predisposes and causes
tumorigenesis, respectively [106]. However, evidence later proved that methylation-associated gene
silencing can act as cancer-predisposing event (first hit) as effectively as genetic mutation [107–109].
Two distinct alterations of normal DNA methylation patterns occur in cancer: global hypo-methylation
and gene-specific hypermethylation [110–113]. Genome-wide analyses evidenced that only 40 to 60% of
a cancer cell genome is methylated, versus 80% of methylated genome in healthy controls. This global
demethylation in cancer cells contributes to genomic instability, aneuploidy, an increased mutation rate,
and could result from deregulation of passive and active demethylation processes mediated by DNMTs
and TET family proteins, respectively [114–116]. Conversely, aberrant methylation of CGIs within
5′ regions of cancer-related genes is a hallmark of nearly all tumors and correlates with changes of
chromatin structure that lead to silencing of tumor suppressor genes (TSGs) [117,118]. Colorectal cancer
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(CRC) and myelodysplastic syndrome (MDS) offer two good examples for understanding how
aberrant loss or gain of DNA methylation may contribute to tumorigenesis, but they are not the only
ones [119,120].
4.2.1. Colorectal Cancer
CRC results from the accumulation of genetic and epigenetic alterations, both leading to genomic
instability. Aberrant DNA methylation is considered a potential driver in CRC and understanding
its establishment might contribute to developing new therapeutic strategies in the treatment of
the tumor [121–123]. At the genome level, CRC is characterized by loss in DNA methylation
(10–40% lower levels of absolute methylation than normal colonic tissue), mainly occurring within
repetitive sequences and resulting in genomic instability and potential initiation of CRC [124,125].
In contrast, hypermethylation has been observed in regions corresponding to CGIs, histone H3
trimethylated on lysin 4 (H3K4me3), and open chromatin in normal controls [126]. A subgroup of
CRCs, termed CpG-island methylator phenotype (CIMP), is characterized by aberrant promoter DNA
methylation of critical genes involved in the WNT, P53, and RAS signaling pathways, although the
role of component of these pathways, as initiators or drivers in the progression of the disease remains
elusive [124,125].
4.2.2. Myelodysplastic Syndrome
MDS is a clonal hematologic disorder often leading to acute myeloid leukemia (AML) in
approximately 30% of cases. In contrast, with the common finding of global hypomethylation in
cancer, MDS is characterized by a global hypermethylation associated with poor prognosis [127,128].
Aberrant promoter methylation of transcription factors, such as the CCAAT/enhancer-binding protein
alpha (CEBPA), or TSG as CDKN2B (P15) and CDKN2A (P16), the adhesion molecule e-cadherin
(CDH1) and the estrogen receptor (ER) [129] have been reported in either MDS and/or AML [129–131].
MDS displays extensive epigenetic reprogramming that explains why the number of hypermethylated
genes is greater than in de novo AML or normal CD34+ cells. Hence, DNA methylation aberrations are
linked to MDS progression, along with epigenetic regulators including TET2, DNMT3a, IDH1, ASXL1,
and EZH2 which are among the group of genes most frequently mutated in MDS [132,133]. In summary,
genetic and epigenetic alterations often coexist, leading to distinct DNA methylation signatures in
cancer cell genomes [134]. In terms of MDS treatment, the heterogenous nature of the disease warrants
a complex combined therapy. Thus far, the DNMT inhibitors (DNMTi) 5-azacytidine (AZA) and
decitabine (DAC), are the most successful epigenetic drugs approved for MDS and AML treatment.
DNMTi modulate the epigenome of cancer cells by reversing aberrant DNA methylation patterns and
re-establishing transcription of epigenetically silenced genes [135,136]. Additionally, a recent study
performed in different AML cell lines has demonstrated that AZA is able to induce down-regulation of
cell metabolism and up-regulation of immune defense-related genes. However, despite their efficacy,
the severe side-effects of DNMTi, together with no or partial responses to treatment, do limit their
clinical application [137].
5. Conclusions: The Best Is yet to Come
Epigenetics, defined as the interplay of DNA methylation, histone modifications, and expression
of non-coding RNAs, govern numerous biological mechanisms from early development to old
age, including biological response to endogenous or exogenous stimuli contributing to disease
transition. In this review, we focused on DNA methylation, as alterations of this epigenetic mark are
considered a triggering event in the pathogenesis of several human diseases affecting either germ-line
imprinting disorders or somatic malignant transformation. The identification and characterization
of different DNMT family members has led to a better understanding of mechanisms behind the
establishment of DNA methylation in health and disease, and to the discovery of new therapeutic
targets. DNMTs inhibitors have indeed been approved for the treatment of MDS and AML, while they
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are being tested in combination with other anticancer drugs, as a therapeutic approach for multiple
solid cancers such as colon, ovarian, and lung cancer [138]. Unfortunately, the lack of specificity and
the high cytotoxicity of the currently approved demethylating drugs hamper their clinical application.
The study of DNA methylation at single-cell level resolution is providing deeper insights into the
epigenetic events driving disease onset and progression, and will likely shed light on other unknown
features of DNA methylation. By means of new advanced technologies, such as WGBS and scBS,
novel molecular targets will be identified and, more specific and less toxic therapeutic molecules
might be developed with the ultimate goal of overcoming the downside effects of conventional
hypomethylating protocols.
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One Sentence Summary: Expression of E-cadherin on mouse hematopoietic progenitors marks 
their commitment to the basophil and mast cell fates from an early stage, downstream of the 
expression of the GATA-2 transcription factor. 
  
Abstract: E-cadherin is a calcium-dependent cell-cell adhesion molecule extensively studied for 
its involvement in tissue formation, epithelial cell behavior and suppression of cancer. However, 
E-cadherin expression in the hematopoietic system has not been fully elucidated. Combining 
single-cell RNA sequencing analyses and immunophenotyping, we revealed that granulocyte-
monocyte progenitors (GMPs) expressing high levels of E-cadherin have an enriched capacity to 
differentiate into basophils and mast cells. Importantly, we detected E-cadherin expression on 
committed progenitors prior to the expression of other reported markers of these lineages. We 
named such progenitors pro-BMPs (pro-basophil and mast cell progenitors). Using 
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RNA-sequencing, we observed transcriptional priming of pro-BMPs to the basophil and mast 
cell lineages. We also showed that GATA-2 directly regulates E-cadherin expression in the 
basophil and mast cell lineages, thus providing a mechanistic connection between the expression 




Basophils and mast cells (MCs) are functionally related cells of the innate immune 
system, playing critical roles in allergic diseases and responses to multicellular pathogens, 
including helminths. Both cell types express the high affinity receptor for IgE (FcεRIα), 
responsible for their activation upon the binding of allergen to cell-bound IgE(1).  
 
Several progenitor populations have been reported to differentiate into basophils and/or 
MCs. However, the heterogeneity of these populations, and the controversies regarding the 
existence of bipotent progenitors giving rise to basophils and MCs, have hampered development 
of a clear model of their ontogeny. Mast cell progenitors (MCPs, Lin- c-Kit+ Sca-1- Ly6c- 
FcεRIα- CD27- integrin β7(β7)+  T1/ST2+) with exclusive MC potential were identified in the 
bone marrow (BM)(2).  In the spleen, basophil-mast cell progenitors (BMCPs), identified as Lin- 
c-Kit+ FcγRII/IIhi β7hi cells, were initially described as bipotential basophil and MC 
progenitors(3). However, two subsequent reports suggested that splenic BMCPs only have MC 
potential(4, 5). Multipotential development of erythroid, megakaryocyte, and MC lineages was 
observed in a progenitor fraction called SN-β7(6), defined as Lin- (including FcεRIα-) c-Kit+ 
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Sca-1- Flk-2- CD150- β7+, which contains the previously described MCPs(2). A small fraction of 
GMPs with low levels of β7 reportedly generates MCs and basophils while still preserving 
granulocyte and monocyte potential(3). And yet another small fraction of GMPs, with expression 
of FcεRIα and designated pre-basophil and mast cell progenitors (pre-BMPs), displays enriched 
capacity to differentiate into basophils and MCs(4). Adding more complexity, a recent study 
identified bone marrow BMCPs, a population phenotypically identical to splenic BMCPs, which 
can differentiate toward basophil and MC lineages but falls outside of the GMP definition due to 
low expression of CD34(7).  
 
In this study, we demonstrate that E-cadherin, a calcium-dependent cell-cell adhesion 
molecule involved in adherens junctions, and extensively studied for its involvement in epithelial 
cell behavior(8), comprehensively marks the mouse basophil and MC lineages. We show that 
E-cadherin is expressed by mature basophils and splenic MCs, and that expression of E-cadherin 
in progenitor cells correlates with their ability to differentiate into basophils and MCs.  We also 
identified a new "pro-basophil and mast cell progenitor" (pro-BMP) stage, contained within the 
GMP fraction and lacking other reported markers of basophils and MCs, which displays a strong 
commitment to the basophil and MC fates. Finally, we showed that E-cadherin expression is 
regulated downstream of the GATA-2 transcription factor in these lineages, thus demonstrating a 
direct connection between the expression of this surface marker with the transcriptional program 
regulating their fate. 
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Results  
 
E-cadherin is expressed in the basophil and MC lineages 
 
Analysis of mouse hematopoietic stem and progenitor cells (HSPCs)(9) using the Gene 
Expression Commons(10), the Immunological Genome Project(11), and public dataset(12) 
indicated a moderate, yet higher, expression of E-cadherin in GMPs compared with other 
progenitors (Fig. 1A-B). We next exploited a public single cell RNA sequencing (scRNA-seq) 
dataset(7) to query E-cadherin expression in the bone marrow lineage- c-Kit+ compartment 
containing HSPCs. We found a fraction of HSPCs expressed E-cadherin (gene symbol: cdh1) 
(Fig. 1C). To gain more insight into the identity of these E-cadherin-expressing progenitors, we 
performed differential gene expression (DGE) analysis and found 1113 differentially expressed 
genes (false discovery rate under 0.001). Among the top 20 most upregulated genes (Fig. 1D), 
we identified multiple basophil and MC markers, including prss34(13) (mast cell protease 11), 
gzmb (granzyme B)(14), mcpt8(15) (mast cell protease 8), ms4a2 (high affinity IgE receptor 
subunit β)(16), fcer1a(16), and cma1 (chymase 1)(17), whose expression profiles overlapped 
with that of E-cadherin (Fig. 1E). Next, we exploited the scRNA-seq dataset from the Tabula 
Muris consortium(18). This dataset was established from unfractionated bone marrow cells. 
Thirteen different clusters were identified (Fig. S1A-B), among which two (clusters 4 and 13) 
expressed E-cadherin (Fig. 1F). DGE analysis identified multiple basophil specific genes among 
the top upregulated genes of E-cadherin-expressing cells from cluster 4 (Fig. 1G), including 
prss34(13), mcpt8(15), fcer1a(16), cpa3 (carboxypeptidase A3)(19, 20), cd200r3(21), and 
ms4a2(16). Conversely, by computing a cell probability score based on the simultaneous 
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expression of multiple markers of the basophil and MC lineages, we found an overlap between 
E-cadherin expressing cells and the basophil and MC shared gene expression signatures, as well 
as with the basophil-specific gene expression signature (Fig. 1H). Similar analyses performed on 
E-cadherin expressing cells from cluster 13 identified them as plasmacytoid dendritic cells 
(pDCs) (Fig.  S1C-D), a cell type recently reported to also express E-cadherin(22). 
 
To confirm the scRNA-seq data, we quantified E-cadherin mRNA in multiple 
fluorescence activated cell sorting (FACS)-purified populations corresponding to hematopoietic 
progenitors, pre-BMPs, basophil progenitors (baPs), basophils, and splenic MCs (Fig. 2A). pDCs 
were used as positive controls. GMPs and pre-BMPs displayed a higher expression of E-cadherin 
compared with other multipotent progenitors, while the highest levels were observed in 
basophils, baPs, and MCs. Next, we quantified the frequency of E-cadherin expression by flow 
cytometry across multiple populations (Fig. 2B-C). E-cadherin expression was detected on 
31.1% (± 1.8 % (SD)) of GMPs, and on virtually all pre-BMPs, baPs, basophils, BMCPs, and 
splenic MCs.  
 
Importantly, all CD49b+ E-cadherin+ cells were positive for FcεRIα (Fig. 2D). Therefore, 
E-cadherin staining can replace FcεRIα staining (together with CD49b) for the identification of 
mature basophils. Similar observations were performed for peripheral blood and spleen basophils 
(Fig. S2). Focusing on the progenitor compartment (Lin- c-Kit+ Sca-1-), we found that E-cadherin 
expression mostly overlapped with the GMP compartment based on CD34 and CD16/32 
expression (Fig. 2E). A minor fraction of cells with lower CD34 expression corresponded to the 
recently described BM-BMCPs(7).  
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GMPs expressing high levels of E-cadherin are committed to a basophil and MC fate 
 
As E-cadherin was expressed in some GMPs and was uniformly expressed in basophils, 
MCs, and their reported progenitors, we hypothesized that E-cadherin expression on GMPs 
might correlate with their differentiation fate. Using FACS sorting and differentiation in culture 
in a medium supportive of multiple myeloid lineages, we compared the differentiation potential 
of GMPs with high (E-cadhigh), intermediate (E-cadint) or no E-cadherin (E-cadneg) expression 
(Fig. 3A). Strikingly, most of the cells differentiated from E-cadhigh GMP showed commitment to 
the basophil or MC lineages, while E-cadneg and E-cadint fractions essentially differentiated into 
neutrophils and monocytes (Fig. 3B). We then plotted the number of each differentiated cell type 
generated by 1,000 GMPs over time (Fig. 3C). E-cadhigh GMPs generated significantly higher 
numbers of basophils and MCs, and significantly lower numbers of neutrophils and monocytes, 
compared to E-cadint/neg GMPs. E-cadint GMPs generated a significantly higher number of 
eosinophils compared with E-cadhigh/neg GMPs. Stainings confirmed the immature morphology of 
E-cadhigh GMPs, indistinguishable from E-cadneg GMPs (Fig. 3D). Cytospins from day 5 and 7 
cultures also confirmed the major prevalence of basophils and MC-committed cells from the 
E-cadhigh GMP fraction and of neutrophils from E-cadneg GMPs. 
 
E-cadherin expression defines a new pro–BMP stage in the basophil/MC lineages 
 
We next further investigated the expression of E-cadherin on progenitor cells as an early 
marker of the basophil and MC lineages. Pre-BMPs are a fraction of GMPs that express FcεRIα 
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and which have been shown to have an enriched capacity to generate basophils and MCs(4). We 
therefore tested whether E-cadherin expression in GMPs would be restricted to pre-BMPs or 
would define a new population of progenitors. We found that only half of the E-cadhigh GMPs 
also expressed FcεRIα (Fig. 4A). We thus defined a new subpopulation of GMPs characterized 
by a high expression of E-cadherin (at the same intensity as in pre-BMPs) and no expression of 
FcεRIα, that we designated "pro-basophil and mast cell progenitors" (pro-BMPs).  
 
We first compared phenotypically the pro-BMP population with pre-BMPs, baPs, bone 
marrow basophils and splenic BMCPs and MCs (Fig. 4B). Pro-BMPs and pre-BMPs expressed 
similar levels of the progenitor markers c-Kit and CD34 and both lacked the mature basophil 
marker CD49b. Most pro-BMPs lacked expression of integrin β7, which was expressed in 
pre-BMPs and baPs albeit at a lower level than in BMCPs and MCs. By definition, pro-BMPs 
displayed no expression of FcεRIα, which was expressed in all the other populations of the 
basophil/MC lineages. 
 
We next investigated the fate of pro-BMPs, pre-BMPs, E-cadint GMPs or double-negative 
(E-cadneg FcεRIαneg) GMPs (DN-GMPs) at the single-cell level. After 4 days of differentiation, 
colonies were analyzed by flow cytometry (FC) (Fig. 4C). Colonies were detected for >65% of 
single-sorted cells from all populations. DN-GMPs generated no basophils and MCs, and mostly 
generated cells of other myeloid lineages (primarily neutrophils and monocytes). A small 
fraction of E-cadint GMPs demonstrated basophil potential, but most clones differentiated into 
eosinophils, neutrophils, and monocytes. Pro-BMPs generated mostly cells in the basophil and 
MC lineages. Pre-BMPs almost exclusively gave rise to basophils and MCs. Retrospective 
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analysis (Fig. 4D) of the index-sorted cells showed that GMPs that exhibited multipotential 
ability to generate basophils and other myeloid lineages were mostly contained within the 
E-cadint and pro-BMP fractions. However, MC potential and basophil/MC bipotential cells were 
found mostly in pro-BMP and pre-BMP fractions. Interestingly, bipotent progenitors for the 
basophil/MC lineages were found almost as frequently as unipotent MC progenitors, confirming 
the existence of a common progenitor for these lineages (Fig. 4E). Time course analyses showed 
that pro-BMPs and pre-BMPs differentiated into baPs, basophils, and MCs with similar kinetics 
(Fig. 4F).  
 
In order to determine the hierarchical relationship between pro-BMPs and pre-BMPs, we 
performed short-term adoptive transfer experiments with analyses at 42h post-transplantation, a 
time-point at which transplanted cells retained high CD34 expression (Fig. 4G), consistent with 
an immature, progenitor state. We found that the majority of pro-BMPs generated FcεRIα-
expressing cells in vivo, consistent with a pre-BMP stage (Fig. 4H). A smaller fraction of 
pro-BMPs-derived cells remained E-cadherin+ and FcεRIα-, while a small percentage lost 
E-cadherin expression, consistent with their commitment to other myeloid lineages (as observed 
during ex vivo culture). Pre-BMPs however, essentially generated double-positive (E-cadherin+ 
FcεRIα+) cells, suggesting that they cannot generate pro-BMPs. These data support a hierarchical 
relationship between pro-BMPs and pre-BMPs, according to which a large fraction of pro-BMPs 
transition through a pre-BMP stage during their commitment toward the basophil and MC 
lineages. 
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Pro-BMPs show transcriptional commitment to the basophil lineage and the capacity to express 
type 2 cytokines despite lacking FcεRIα expression 
 
To pursue further the potential commitment of pro-BMPs to the basophil and MC 
lineages, we performed bulk RNA-seq on FACS-purified DN-GMPs, pro-BMPs, pre-BMPs, and 
basophils. Multidimensional scaling plots confirmed that the 4 populations were distinct (Fig. 
S3A). To understand the dynamics of basophil commitment, we generated a heatmap based on 
the top 50 most variable genes across all samples (Fig. 5A). Strikingly, the heatmap revealed in 
pro-BMPs a transcriptomic profile intermediate between DN-GMPs and pre-BMPs. Four major 
trends were observed: genes that were progressively upregulated from pro-BMPs to basophils; 
genes that were increased from pre-BMPs to basophils; genes that were specific for basophils; 
and genes that were expressed in DN-GMPs and pro-BMPs, and repressed in pre-BMPs and 
basophils. Among the genes that showed gradual upregulation from pro-BMPs to basophils, we 
identified basophil and/or MC markers, including the G-protein coupled receptor 34 (gpr34)(23), 
the interleukin (il)-33 receptor il1rl1 (also known as ST2)(24), and prss34(13).  
 
To better unveil differences between pro-BMPs and DN-GMPs, we performed DGE 
analysis. Only 262 genes were differentially expressed between pro-BMPs and DN-GMPs, 
confirming their transcriptional proximity (versus 3336 between pre-BMPs and DN-GMPs and 
6507 between basophils and DN-GMPs, using a false discovery rate cutoff of 0.05) (Tables 
S1-3). Importantly, we identified multiple genes with reported basophil and/or MC functions 
among the upregulated genes (Fig. 5B).  These genes were further increased in pre-BMPs and 
basophils with the exception of gzmb, which is downregulated in basophils, in agreement with its 
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specific expression in MCs(7, 25) (Fig. 5C). By contrast, downregulated DEGs included genes 
expressed by other myeloid cell types, such as neuropilin 1 (nrp1) and triggering receptor 
expressed on myeloid cells 2 (trem2) (Table S1), both expressed in macrophages and dendritic 
cells(26-29). To look for a broader basophil and MC signature in pro-BMPs, we generated a 
heatmap of genes that were significantly upregulated in pro-BMPs, pre-BMPs, and basophils in 
comparison with DN-GMPs. Using this approach, 118 significantly upregulated genes were 
identified (Fig. S3C). Importantly, many of these genes were also found specifically expressed in 
basophils, MCs, and/or their progenitors in other studies(4, 7, 17), confirming the existence of a 
broad basophil/MC signature in pro-BMPs. 
 
As basophils and MCs are robust producers of type 2 cytokines, we next compared the 
ability of the different populations to express IL-4 and IL-13(30). IL-4 and IL-13 mRNAs were 
expressed at very low to undetectable levels in DN-GMPs (Fig. 5D). Pro-BMPs expressed IL-4 
and IL-13, albeit at lower levels than in more differentiated cells. Importantly, pro-BMPs, 
pre-BMPs, baPs, and basophils all displayed the ability to significantly induce IL-4 mRNA upon 
PMA and ionomycin stimulation (Fig. 5E). As expected, pro-BMPs, which lacked FcεRIα 
expression, did not induce IL-4 expression upon IgE crosslinking, as was observed in pre-BMPs, 
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E-cadherin marks the commitment toward the basophil and MC lineages downstream of GATA-2 
expression 
 
To better understand how pro-BMPs are primed to the basophil and mast cell lineages, 
we  compared the expression of transcription factors involved in basophil and MC specification, 
including the zinc finger transcription factors GATA-1(31, 32) and GATA-2(33, 34), runt-related 
transcription factor 1 (Runx1)(5), and CCAAT/enhancer-binding protein alpha (C/EBPα)(4). 
GATA-1 and GATA-2 were significantly upregulated in pro-BMPs compared with DN-GMPs 
(Fig. 6A, Table S1, and Fig. S4A), which confirmed their transcriptional priming to the 
basophil/MC lineage. Runx1 and C/EBPα, however, were only upregulated at later stages, 
supporting the immature state of these progenitors. 
 
We next used the upstream regulator analysis tool of the Ingenuity Pathway Analysis 
software to identify upstream regulators responsible for gene expression changes between 
pro-BMPs and DN-GMPs (Table S4). This analysis identified GATA-2 and Zinc Finger 
Protein, FOG Family Member 1 (zfpm1, also known as Friend Of GATA-1 (FOG-1)) as the two 
regulators with the most significant overlap with the differentially expressed genes. GATA-2 
was in addition predicted to be activated (Z-score 1.39) and differentially expressed in pro-BMPs 
vs DN-GMPs (Table S1). These two regulators were, according to the IPA database, predicted to 
regulate multiple basophil and MC-specific genes increased in pro-BMPs vs DN-GMPs, such as 
cpa3, gzmb, itga2b and ms4a2 (Table S4).  
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Interestingly, in MCF7 breast cancer cells, GATA-3 induces E-cadherin expression by 
binding GATA-like motifs located in its promoter(35). Further, GATA and its coregulator, 
U-shaped, regulate E-cadherin expression in Drosophila hematopoietic progenitors(36). We thus 
hypothesized that E-cadherin expression in the basophil and MC lineages may depend on the 
expression of GATA-1 and/or -2, thus providing a mechanistic connection between the 
expression of this surface marker and the commitment of pro-BMPs to the basophil and MC 
lineages. 
 
Using a GATA-1 protein reporter mouse (37), we found that most GATA-1-positive 
GMPs expressed E-cadherin, whereas only a minor fraction expressed FcεRIα (Fig. 6B). 
Therefore, E-cadherin expression in GMPs correlates better with GATA-1 expression than does 
FcεRIα. Consistently, the majority of pro-BMPs and pre-BMPs expressed GATA-1 at the protein 
level, whereas E-cadint GMPs and DN-GMPs did not (Fig. 6C). We next investigated whether 
GATA-1 directly regulates E-cadherin expression. We found a significant increase in the number 
of basophils in the GATA-1low mutant mice(38) compared with WT controls, although these 
were less mature based on their reduced expression of CD49b (Fig.6D, Fig. S4B). These 
basophils expressed higher levels of GATA-2 and E-cadherin mRNA compared with WT 
controls (Fig. 6E), suggesting that GATA-2, rather than GATA-1, regulates E-cadherin 
expression. Supporting this hypothesis, analysis of public GATA-2 ChIP-sequencing datasets 
(Fig. 6F) showed a strong enrichment of GATA-2 in the promoter region and in the intron 2 of 
E-cadherin in BMDMCs(39), a region previously demonstrated to be essential to initiate and 
maintain E-cadherin expression in different tissues(40). These peaks were also enriched in bone 
marrow hematopoietic progenitor cells (lineage-negative)(41) and in the multipotent 
 Wanet et al., E-cadherin marks the mouse basophil/MC lineages 14 
FDCPmixed (factor-dependent cells Paterson) cell line(42). Using a GATA-2 transcriptional 
reporter mouse(43), we found that most GMPs expressing high levels of GATA-2-Venus also 
expressed E-cadherin, whereas only a fraction expressed FcεRIα (Fig. 6G). Consistently, the 
majority of pro-BMPs and all pre-BMPs expressed GATA-2 Venus, while E-cadint GMPs and 
DN-GMPs did not (Fig. 6H). Therefore, GATA-2 and E-cadherin are co-expressed in myeloid 
progenitors committed to the basophil/MC lineages.  
 
To demonstrate that GATA-2 regulates E-cadherin expression, we transfected baPs with 
siRNA against GATA-2 and found that the knockdown of GATA-2 resulted in the decreased 
expression of E-cadherin mRNA (Fig. 6I). To confirm these findings, we deleted GATA-2 in 
FACS-sorted pre-BMPs from an inducible GATA-2 knockout mouse(33) (Fig. 6J). Accordingly, 
GATA-2 deletion resulted in a loss of E-cadherin expression at the mRNA and protein levels 
(Fig. 6J-K).  
 
Discussion  
We have demonstrated that mouse basophils express E-cadherin and can be identified 
using CD49b in conjunction with E-cadherin instead of FcεRIα. This opens the possibility of 
marking and sorting mature basophils while leaving the FcεRI untouched, which could be of 
great utility for functional studies involving IgE ligation. The expression of E-cadherin has been 
reported in mouse BMCMCs and peritoneal MCs(44). In agreement with these observations, we 
found expression of E-cadherin in splenic MCs. Surprisingly, E-cadherin mRNA is 
downregulated in connective tissue MCs when compared with basophils(17), suggesting that 
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E-cadherin expression in mature MCs may be heterogeneous depending on their anatomic 
location. 
 
We also demonstrated that, in the bone marrow, E-cadherin comprehensively marks the 
basophil and MC lineages early in their specification. We identified a new progenitor population, 
"pro-BMPs", which displays an enriched capacity to differentiate into basophils and MCs and 
expresses high levels of E-cadherin, yet lacks other reported markers of the basophil and MC 
lineages. Pro-BMPs are phenotypically different from the previously described pre-BMPs(4), 
which express FcεRIα, and from MCPs(2), which express β7 and have no potential to 
differentiate into basophils. Pro-BMPs also differ from bone marrow BMCPs(7), which 
constitute a much rarer subset, expressing β7 but not CD34. Finally, pro-BMPs differ from the 
SN-β7 progenitors, which also express β7 and display multipotential development of erythroid, 
megakaryocyte and MC lineages(6). Although we did not analyze the erythroid and 
megakaryocyte potential of pro-BMPs, a small fraction of progenitors expressing E-cadherin 
overlaps with the CMP definition (due to lower CD16/32 expression) (Fig. 2E). Therefore, it 
remains possible that progenitors expressing E-cadherin have multipotential to differentiate 
toward the erythroid, megakaryocyte and MC lineages.  
 
Using bulk RNA-seq, we demonstrated that pro-BMPs display a transcriptional profile 
consistent with their priming to the basophil/MC lineages. We identified a broad transcriptional 
signature in pro-BMPs that is enriched for genes specifically expressed in basophils, MCs, and 
their progenitors. We also found that the transcription factors GATA-1 and -2, involved in 
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basophil and MC differentiation and functions(31, 32, 34), were upregulated in pro-BMPs, 
pre-BMPs and basophils when compared with DN-GMPs. We demonstrated that E-cadherin 
expression was regulated by the transcription factor GATA-2, thus explaining a mechanistic 
connection between the expression of E-cadherin and the commitment of early hematopoietic 
progenitors to the basophil and MC lineages. 
 
Differentiation assays at the single cell level demonstrated that pro-BMPs had a strong 
capacity to differentiate into basophils and MCs. The existence of bipotent progenitors of both 
the basophil and MC lineages has been controversial. Because basophil/MC bipotential was 
found almost as frequently as MC unipotential (Fig. 4E), the probability that the observed 
basophil/MC bipotential results from the sorting of cell doublets is extremely unlikely. Our data 
support the conclusion that a small fraction of progenitors displays both basophil and MC 
potential, at least in the culture conditions tested. We also observed that a fraction of pro-BMPs 
and GMPs with intermediate levels of E-cadherin expression displayed multipotential toward the 
basophil and other myeloid lineages (including neutrophils). Our data are therefore in contrast 
with the observation that human CD34+ CD38+ progenitors have either neutrophil/monocyte or 
eosinophil/basophil/MC potential(45). These differences are likely related to species-specific 
differences and/or culture conditions. Accordingly, mouse GATA-1-expressing pre-GMs can 
generate MC, neutrophils and eosinophils(46). Unlike previously reported observations(4), we 
found that the ability for bi/multipotential differentiation to basophil and other myeloid fates was 
restricted to cells lacking FcεRIα expression. These differences are likely due to the different 
culture conditions and sorting stringencies employed (we used single cell assays). Our 
observations support the conclusion that high levels of FcεRIα expression is acquired once cells 
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are strictly committed to the basophil or MC fate and have essentially lost the potential to 
generate other myeloid lineages.  
 
Interestingly, a number of ligands for E-cadherin have been described, including 
E-cadherin itself, but also the integrinα2β1(47), integrinαEβ7(48), and the Killer Cell Lectin 
Like Receptor G1(49). These ligands are expressed by multiple immune and non-immune cell 
subsets, suggesting that E-cadherin expression on basophils and MCs might be important for 
their ability to signal to multiple other cell types. Further studies are now required to identify the 
cell interactions mediated by E-cadherin in basophils, MCs, and their progenitors, and to 
understand how E-cadherin may modulate their signaling in health and disease. 
 
Materials and Methods 
 
Study design 
The aim of this study was to investigate the expression of E-cadherin in the mouse hematopoietic 
system. We used public microarrays and single-cell RNA-sequencing datasets to query 
E-cadherin expression in the hematopoietic system and identified expression in the mouse 
basophil lineage. We used flow cytometry and RNA-sequencing analyses to characterize a new 
progenitor population characterized by a high commitment towards the basophil and MC 
lineages that we named “pro-BMPs”. Using genetic approaches, we demonstrated a role for 
GATA-2 in the regulation of E-cadherin expression in the mouse basophil and MC lineages. All 
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data were collected from independent age and gender-matched biological replicates, i.e., from 
different mice or cells isolated from different mice.  
 
Mice 
Wild-type (WT) C57BL/6 mice and B6.SJL-Ptprca Pepcb/BoyJ were purchased from The 
Charles River Laboratory. Experiment were performed with 8-12 weeks-old mice. Short-term 
adoptive transfer experiments were performed by injecting in the tail vein 12,000 pro-BMPs or 
pre-BMPs FACS-sorted from C57BL/6 donor mice into B6.SJL-Ptprca Pepcb/BoyJ recipients, 
pre-conditioned by a sublethal irradiation at 450 rads 6h before transplantation. Mice were 
housed in a sterile barrier facility and procedures were approved by the Institutional Animal Care 
and Use Committee at the Beth Israel Deaconess Medical Center. Bone marrow cells from 
GATA-1low mice(38) and from GATA-2 inducible KO mice (Gata2f/f RosaYfp/Yfp 
TgCreErt2hemi and its control Gata2+/+ RosaYfp/Yfp TgCreErt2hemi)(33) were provided by 
Stuart Orkin and Hua Huang, respectively. The GATA-1-mCherry knock-in mice(37) were 
housed and analyzed in Schroeder’s laboratory at ETH Zurich and animal experiments were 
approved according to Institutional guidelines of ETH Zurich and Swiss Federal Law by 
veterinary office of Canton Basel-Stadt, Switzerland (approval number 2655). GATA-2 Venus 
mice(43) were housed and bred by Dzierzak’s laboratory, in animal facilities at the University of 
Edinburgh, in compliance with the Home Office regulations. All procedures with animals were 
conducted by a Home Office UK Project License and approved by the University of Edinburgh 
Ethical Review Committee. 
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Flow cytometry (FC) 
Single-cell suspensions from various organs were analyzed with an LSRII flow cytometer (BD 
Biosciences) and sorted using a FACSAria II (BD Biosciences). Phosphate buffered saline with 
2% fetal bovine serum was used as a buffer at all times as the use of 2 mM EDTA interfered with 
the binding of the anti-E-cadherin antibody. Detailed procedures, antibodies and gating strategies 
are described in the Supplementary Material and Methods and Fig. S5-6. 
 
qRT-PCR 
RNA was extracted using TRIzol reagent (Thermo Fisher Scientific), reverse transcribed using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche), and quantitatively assessed using 
Taq™ universal SYBR® Green (Bio-Rad) and a Rotor-Gene 6000 Real-time PCR machine 
(Corbett). For each sample, transcript levels of tested genes were normalized to RPL13A. 
Primers are listed in Supplementary Material and Methods. 
 
Cell culture 
Sorted cells were differentiated in StemSPAN SFEM (STEMCELL Technologies) supplemented 
with 10 ng/ml mIL-3, 10 ng/ml hIL-6, 10 ng/ml mM-CSF, 10 ng/ml mGM-CSF, 20 ng/ml 
mSCF, 50 ng/ml mFLT3 (all cytokines from Peprotech), and Pen-Strep (Gibco) (100U/mL). 
When indicated, sorted cells were stimulated for 4h with 50 ng/ml phorbol 12-myristate 13-
acetate (PMA) and 1 µM ionomycin (P&I) and the corresponding vehicles, crosslinked (CL) 
with 1 µg/ml IgE (D8406, Sigma) and 1 µg/ml anti-IgE (Clone R35-72, BD) or not crosslinked 
(NCL). Nucleofection was performed 2 days post-plating using Amaxa Nucleofector kit L using 
Amaxa Nucleofector II program X-001 and 1 µM of siRNA against mouse GATA-2 
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(Dharmacon E-062114-00- 0005) or non-targeting control (Dharmacon D-001910-01-05). 
Following nucleofection, 900 ul of complete medium was added to cells, which were cultured for 
an additional 48h before analysis. For the induction of GATA-2 KO, sorted pre-BMPs were 
treated with 50 nM 4-hydroxytamoxifen (Sigma-Aldrich) for 5 days before analysis. 
 
RNA-sequencing (RNA-seq) 
The indicated FACS-sorted populations from 10-12-week-old C57BL/6 mice were lysed in 
TRIzol and RNA was isolated. Biological triplicates were prepared. RNA quality was assessed 
using Agilent 2100 Bioanalyzer (RIN ≥ 8.4 for all samples). Libraries were prepared using 
SmartSeq v4 (Takara) and Nextera XT DNA library kits (Illumina) and sequenced on a NextSeq 
500 (Illumina) High flowcell (2x75). Data were deposited on Gene Expression Omnibus(50) 
under accession number GSE132122. 
 
Bioinformatics analyses 
Expression of E-cadherin was accessed via the Gene Expression Commons(10) 
(https://gexc.riken.jp/models/1038/genes/Cdh1?q=CDH1) and via the Immunological Genome 
Project(11) website for GSE15907 and GSE60101. For the Dahlin et al. (7) dataset, normalized 
counts for the Lin- c-Kit+ fraction were sourced from https://gottgens-
lab.stemcells.cam.ac.uk/adultHSPC10X/. For the Tabula Muris Consortium(18), raw droplet 
counts were sourced from the mouse bone marrow compartment (GSM3040900 and 
GSM3040901). Detailed pipeline processing for scRNA-seq and bulk RNA-seq are described in 
Supplementary Material and Methods. Public GATA-2 ChIP-sequencing datasets were accessed 
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Statistical analyses were performed using the Prism 7 Software. Depending on the data being 
compared, we used t-tests, one-way or two-way ANOVAs followed by multiple comparisons 
using the Tukey's test or Dunnetts’test as indicated in the Table S6. To ensure variance 
homogeneity, data presented in Fig. 5D-E were log10 transformed. 
 
Supplementary Materials 
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Figures:  
 
Fig. 1. Transcriptomic analyses uncover expression of E-cadherin in GMPs and in the 
basophil/MC lineage. (A) Graphical representation of the probeset meta profile for 
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(https://gexc.riken.jp/models/1038/genes/Cdh1?q=CDH1). The axis represents expression 
intensity in log2 scale. The distribution of expression levels in the database is displayed 
by the histogram on the left side of the axis. (B) E-cadherin expression in progenitor 
populations from ImmGen GSE15907 (microarray) and GSE60101 (RNA-seq). (C-E) 
Analysis of a public dataset on BM Lin- c-Kit+ HSPCs. (C, E) Expression pattern of the 
selected genes was accessed at https://gottgens-lab.stemcells.cam.ac.uk/adultHSPC10X/ 
and is visualized in the force-directed graph layout of the single-cell profiles (ms4a2, 
basophil/MC-specific gene; prss34, basophil-specific gene; gzmb, MC-specific gene). 
(D) Top 20 most upregulated genes in E-cadherin-expressing BM Lin- c-Kit+ HSPCs 
versus non-E-cadherin-expressing cells. (F-H) Analysis of the Tabula Muris dataset on 
unfractionated BM. (F) Springplot showing E-cadherin expression. (G) Top 20 most 
upregulated genes in E-cadherin-expressing cells from cluster 4 versus all non-
E-cadherin-expressing cells. (H) Cell probability scores were calculated for the Tabula 
Muris Dataset on the basis of previously published gene expression signatures shared by 
basophils and MCs or specific for basophils(17).  Abbreviations: LT-HSC (long term 
hematopoietic stem cell), ST-HSC (short term HSC), MPP (multipotent progenitor), MLP 
(multilymphoid progenitor), CLP (common lymphocyte progenitor), CMP (common 
myeloid progenitor), MEP (megakaryocyte erythrocyte progenitor), MDP (monocyte 
dendritic cell progenitor), CDP (common dendritic cell progenitor). 
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Fig. 2. E-cadherin is expressed in the mouse basophil and MC lineages. (A) RNA was isolated 
from the indicated populations (sorted from the bone marrow, unless otherwise 
indicated); E-cadherin mRNA abundance was determined by RT-qPCR and is expressed 
relative to RPL13A levels. (B) Frequency of E-cadherin expression for each 
hematopoietic cell as determined by FC. (C) Representative contour plots showing 















































































E-cad+: 69.6 ± 3.7%
Lin- c-Kit+ Sca1-: 22.2 ± 2.0%
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E-cadherin+ cells identifies basophils as efficiently as gating of Lin- Sca-1- c-Kit- CD49b+ 
FcεRIα+ cells. (E) Dot plots showing expression of E-cadherin on Lin- Sca-1- c-Kit+ cells 
and the overlap with the GMP gate. Dots on the left of the GMP gate, with reduced CD34 
expression, correspond to BM-BMCPs. (A-E) Data are the mean ± SEM of 3 C57BL/6 
mice. Abbreviations: LSKs (Lin- Sca-1+ c-Kit+), CLPs (common lymphocyte 
progenitors), CMPs (common myeloid progenitors), MEP (megakaryocyte erythrocyte 
progenitors), NK (natural killer), Fr. F (Hardy's fraction F). 
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Fig. 3. E-cadherin-expressing GMPs generate more basophils and MCs in culture. (A) 
Representative dot plot for the sorting of GMPs expressing different levels of E-cadherin. 
(B-D) GMPs were differentiated in liquid culture for 7 days. (B) Differentiation was 
assessed by FC and the frequency of each cell type is expressed as percentage of live 
cells. (C) Total number of differentiated cells obtained when plating 1,000 GMPs. 
Statistics were calculated using two-ways ANOVA followed by Tukey’s multiple 
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differentiation in culture. Magnification: 600x. Data are the mean ± SEM of 3 
experiments.  
 
Fig. 4. E-cadherin marks the commitment to the basophil and MC lineages at the pro-BMP stage. 
(A) Dot plot showing distribution and frequency of E-cadherin and FcεRIα on GMPs 
(mean ± SEM of n=6). (B) Histograms comparing the expression of the indicated markers 
on the different populations. (C-E) Single GMPs were index-sorted based on the 
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assessed by FC. Data are the mean ± SEM of cells sorted from 3 different mice and are 
representative of 2 independent experiments. (C) Frequency of each colony type on day 
4. (D) Dot plots from day 0 showing the expression of E-cadherin and FcεRIα of single 
cells that generated the indicated type of colony (listed on top) on day 4. (E) Frequency 
of each colony type obtained on day 4 after pooling the data from all single progenitors 
analyzed (2 independent experiments, for a total of progenitors sorted from 6 mice). (F) 
Pro-BMPs, pre-BMPs, baPs and BMCPs (depicted by lines of different colors) were 
FACS-sorted from the BM (pro-BMPs, pre-BMPs and baPs) or spleen (BMCPs) and 
differentiated in liquid culture for 7 days. Their differentiation into baPs, basophils and 
MC was assessed by FC until day 7. The number of differentiated cells was calculated 
based on the plating of 1,000 cells/well (mean ± SEM of n=3). (G-H) Pro-BMPs and 
pre-BMPs were FACS-sorted from donor mice (expressing CD45.2) and transplanted 
into recipients (expressing CD45.1). Expression of the indicated cell surface markers on 
the transplanted cells (CD45.2+) were analyzed 42h later by FACS. Data are 
representative of 2 independent experiments. 
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Fig. 5. Pro-BMPs are transcriptionally primed toward a basophil/MC fate and express Th2 
cytokines but are not responsive to IgE stimulation. (A-C) RNA-seq was performed on 
FACS-sorted DN-GMPs, pro-BMPs, pre-BMPs, and mature basophils. (A) Heatmap 
showing the top 50 most variable genes between the compared populations. (B) Volcano 
plot showing differential gene expression between pro-BMPs and DN-GMPs. Selected 
basophil and MC markers are highlighted in red. (C) Expression profile of selected genes 



















































































































































































































 Wanet et al., E-cadherin marks the mouse basophil/MC lineages 34 
populations were FACS-sorted. (D) mRNA abundance of the indicated cytokines was 
determined by RT-qPCR. Statistics were calculated using one-way ANOVA followed by 
multiple comparisons using Dunnett’s tests. (E) Cells were stimulated for 4 h with PMA 
and ionomycin (P&I) (or vehicle) or with IgE crosslinking (or not crosslinked (NCL)) 
and IL-4 mRNA abundance was measured (mean ± SEM of n=3-5). Statistics were 
calculated using t-tests for the P&I vs vehicle and CL vs NCL comparisons.  
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Fig. 6. E-cadherin is induced in the basophil and MC lineages downstream of the GATA-2 
transcription factor. (A) Expression profile of selected transcription factors involved in 
basophil and MC differentiation (RNA-seq). (B) Flow cytometry analysis of 
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reporter mouse. (C) Expression intensity of GATA-1mCherry in the indicated 
populations. (D) Representative dot plots showing the bone marrow basophil populations 
from wild-type and GATA-1low mutant mice (numbers are the average of n=3, SEM). (E) 
Relative mRNA abundance of GATA-1, GATA-2 and E-cadherin from FACS-sorted 
basophils from wild-type and GATA-1low mutant mice (n=3, SEM). (F) GATA-2 
ChIP-seq profiles at the E-cadherin locus. (G) Flow cytometry analysis of 
GATA-2Venus, E-cadherin and FcεRIα on gated GMPs from a GATA-2Venus reporter 
mouse. (H) Expression intensity of GATA-2Venus in the indicated populations. (I) BaPs 
were FACS-sorted and nucleofected with non-targeting siRNA (siNT) or siRNA against 
GATA-2 (siGATA-2). Relative mRNA abundance of GATA-2 and E-cadherin was 
analyzed 48h post-nucleofection (n=4, SEM). (J-K) Pre-BMPs were FACS-sorted from 
the bone marrow of GATA-2+/+ TgCreErt2hemi and GATA-2fl/fl TgCreErt2hemi mice 
and GATA-2 deletion was induced by the addition of 50 nM 4-hydroxytamoxifen 
(4-OHT) for 5 days before analysis of (J) GATA-2 and E-cadherin mRNA abundance 
and (K) E-cadherin protein expression by FACS. Statistics were calculated using t-tests. 
 
